List of Diagnostics Companies in United States - 643

At 100XBIO we strive to deliver 100x more data on antigen specificity of the T cells in the limited sample volume (blood, tumor, lymph nodes), and as the downstream -- confirming the cells' phenotype and cytokine expression. Looking for (1) early investments, (2) R&D partners, and (3) early academia, biotech and pharma clients. We are raising $500K of pre-seed investment, and raised over $200K.

20/20 GeneSystems (‘20/20’) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. Our headquarters are in the heart of the biotechnology corridor in Rockville, Maryland in close proximity to the National Institutes of Health with which we have extensive collaborations. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic. Biological Detection: 20/20 is on the leading edge of developing technologies to help in the detection of biological toxins.

3CPM Corporation is a Medical Technology company that offers a non-invasive 45-minute test using AI-derived patented technology to accurately characterize gastrointestinal motility disorders such as gastroparesis and functional dyspepsia.

Abaxis develops and commercializes medical device and innovative technology and services that support best medical practices, enabling practitioners to respond to the health needs of their patients, while operating point of care, onsite diagnostics for human and animal health.Abaxis is now part of Zoetis.

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.htm

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL acquired all the patents and IP rights from TherapyEdge, Inc. in 2005 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. COVID-19: CE mark (07/2020)

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

Access Genetics, LLC is a privately held Minnesota-based company founded in 2001 by Dr. Ronald McGlennen, an internationally recognized molecular diagnostics expert with over a decade of experience in implementing and developing molecular genetic laboratories. As a medical technology service company, we offer turnkey solutions to assist laboratories in the implementation of molecular genetic testing by recommending a tailored, cost-effective and state-of-the-art suite of hardware, software, prepackaged materials and supplies, process guides, custom tools, staff training, technical support, telemedicine interpretations, and other optional consultative services. This comprehensive service package makes Access Genetics unlike other companies in the genetic testing market that may only provide a piece of the testing puzzle. Our Mission is to improve the availability and utility of diagnostic genetic testing through a base of laboratory providers using our Web-Enabled DNA Testing Model. We partner with qualified clinical labs to enable them to build a quality in-house molecular genetics program that is simple, fast, economical and complete.

AccuGenomics is a biotechnology company that specializes in a unique spike-in control technology to enhance the accuracy of clinical sequencing tests for low abundance biomarkers and infectious pathogens.

Since its inception in 2013, AccuraGen has pioneered the development of liquid biopsy technology to facilitate more personalized cancer treatment. Our international team of scientists brings together the best of industry with the best of academia. We currently operate from two locations: Menlo Park, California and Shanghai, China.

Accu Reference Medical Lab is a state-of-the-art medical testing laboratory service that provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions. We are certified under the federal government’s Clinical Laboratory Improvement Amendments (CLIA) and operate in compliance with all governmental regulations. We use the latest diagnostic technology. As new medical tests become available, we update our list of services. Our laboratory technicians are well trained and have many years of experience, providing the most accurate and precise testing results. We also continuously strive to improve the quality of our testing, data handling and reporting through integrating robust technique and technological advancements. Accu Reference Medical Lab is an equal opportunity employer.

We are a clinical stage diagnostics company committed to developing and commercializing novel products for the treatment and management of all cancers.

ACON Laboratories is an international diagnostic and medical device company with our corporate headquarters in San Diego, California USA. For more than 15 years, ACON has led the way in making high quality diagnostic and medical devices more affordable to people all around the world. The ACON name is well known in over 130 countries. Headquartered in San Diego, California, the US office is the center of strategic management, administration, business development, innovative research and development. Our state of the art manufacturing facility is ISO 13485:2003 certified, FDA registered and has been inspected by US FDA. Our current product lines include Diabetes Care, Clinical Chemistry (including Urinalysis and Point of Care Tests) and Immunoassay EIA/ELISA. We also have a number of new products in the pipeline for introduction in the future.

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Acutus Medical is a dynamic arrhythmia care company focused on developing distinct, innovative technologies that provide physicians and patients with improved results. AcQMap, AcQRef and AcQGuide devices are CE Marked and FDA cleared. Please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

Develops a rapid leukocyte differential instrument is used to screen for infections, allergies, and blood-related cancers including leukemia.

Aditxt is a social innovation platform. Every year, billions of individuals face health challenges such as autoimmune diseases, misdiagnosis, infectious diseases, organ failure, reproductive health issues, malnutrition, cancer, as well as barriers to accessing healthcare. Innovations with immense potential to address critical healthcare challenges are all around us. Untapped innovations hold the key to transformative solutions. Socially owned and capitalized as  a Nasdaq listed company with a mission of discovering, developing and deploying promising health innovations. Now is the time to inspire and mobilize the social capital inherent in a global community of stakeholders to actively participate in the discovery, development, and implementation of health solutions that could benefit humanity.

AdvanBio Inc., www.Advabio.com, a subsidiary of Autobio Diagnostics in the U.S is a fast-growing biotechnological company based in Irvine, CA. Established in 2021. We specialize in providing cutting-edge IVD Quality Control products & Reagents designed for a diverse range of analytes. In addition, we are committed to providing global partners with high-performance IVD Critical Raw Materials and services such as: • FDA Submission • Assay Development • Product Sales • New Technology/Biomarker Development We are committed to the advancement of medical laboratory technology and dedicated to the promotion of human health. We empower medical providers in making pivotal biomarker & diagnostic decisions with our portfolio of innovative technologies. #Advanbio#ADLM

Over the past decade, Advanced Brain Monitoring has developed and implemented mobile, user-friendly platforms for acquiring, integrating, analyzing and reporting multi-sensor data in real-world applications. Our strong and growing technical team includes PhD- and masters-level hardware engineers, biostatisticians, software engineers and experts in signal processing, experimental design and clinical trials. ABM seeks to build on existing collaborations within the academic community and develop strategic partnerships across industry with like-minded professionals.

Founded by Dr. Elizabeth Ruzzo, adyn is helping people find birth control without side effects based on a person's genetic risk and hormone profile. Despite the 47M birth control users in the US, virtually no studies examine the biological factors that explain why individuals respond differently to a given contraceptive method. Launched in May 2022, The Birth Control Test is the first test designed to prevent birth control side effects. While we are improving the birth control experience, we are also committed to closing the gender health gap. By partnering with individuals, adyn leverages personal preference, medical history, and biological data to proactively help every (unique) body select the most desirable birth control option – with the least dangerous side effects. Our vision is to be earth's most inclusive and patient-centric personalized medicine company. When a person uses The Birth Control Test, they can opt in as an anonymous research participant to help close these research gaps. This means you can simultaneously find the right birth control for your body, while helping others do the same.

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

In 1976 Alister Voller, Mike Clark, and associates reported the successful and sensitive detection of plant viruses by ELISA. Two years earlier, Voller, Engvall, Bidwell and Huldt developed the microwell ELISA plate. This technology arrived just in time to test and select plants grown by tissue culture and to assist clean plant programs using one-way pass-through propagation methods. The rapid exploration and acceptance of ELISA created an immediate need for optimized, validated tests, for kits, for quality controlled antibodies, enzyme conjugates and accessories. Agdia, Inc. was formed to meet this need. Agdia's first tests were developed for common potato pathogens, i.e., the viruses, PVX, PVY, PLRV, PVS, PVM, PVA and the bacteria, ringrot [Cms] and blackleg [Eca]. Next, a Testing Service was developed to help those who needed testing results but did not want to perform the tests themselves. The products and services were an instant hit. Agdia grew quickly as its products and services became known worldwide. In rapid succession many tests were developed for fruit, ornamental and field crops. And, significant advances were made in test formats and test type, including, the PathoScreen® test format, the potyvirus group test, membrane assays for viroids, nested PCR for phytoplasma, PCR virus group tests and ImmunoStrips®. All of this was possible only because a worldwide community of scientists and customers provided technology, biomaterials, plant samples and constant encouragement. Agdia's continuing focus on developing and performing tests for plant pathogens and dedication to confidential customer service and support have earned a special trust and place in the worldwide agricultural community. We value and treasure this trust. And, with each day, we dedicate ourselves anew to providing you with products and service that enable you to grow healthy crops with confidence.

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced platforms deliver timely molecular insights in the areas of mutation profiling, liquid biopsy, pharmacogenetics, and more. Agena offers the MassARRAY® System, an open platform that provides researchers with insights through a highly multiplexed solution. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

A.I. Analysis, Inc. is a medical software company specializing in the application of artificial intelligence (AI) to radiology. A.I. Analysis, Inc.’s first product is the Change Detector for Brain Imaging, a machine-learning based system that compares serial MR imaging studies and presents changes in the form of a color overlay superimposed on the anatomical images. The Change Detector saves radiologists time at the beginning of their reading — perhaps up to 10 minutes for diseases such multiple sclerosis. The Change Detector highlights the locations of changes and degree of those changes, so the radiologist can more quickly reach clinical judgments. Using the Change Detector, it may be possible for radiologists to detect changes months earlier than is possible with manual inspection alone, with greater reproducibility.

Aiberry is an AI-powered multimodal platform that offers providers and care managers rapid, objective, and unbiased behavioral health assessments. Aiberry delivers evidence-based insights virtually (in telehealth scenarios) and at the point of care, offering unique outreach and scale opportunities.

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

Akrivis solutions cool equipment and deliver cleanroom conditions in modular buildings and cabins. Specialist units delivering exceptional performance, outstanding reliability, and ultra-low energy usage.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Alere is now Abbott! Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.

We are the pioneers of allergy solutions. Allergy is the most common chronic disease globally and it has profound impact on people’s lives. More than 500 million people worldwide live with respiratory allergies, more than 200 million people have some sort of food allergy, and more than 100 million children are living with allergic rhinitis. These numbers are only expected to increase, and as a result, the need for allergy solutions is ever-growing. For more than a 100 years, ALK has been at the forefront of long-term allergy treatment. Building on our strong heritage, we are now stepping into the next 100 years with a mission to help even more people, with more solutions, more efficiently. We call it Allergy+. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

Allele Diagnostics, Inc., located in Spokane, WA, was established in 2014 to offer superior genetic testing services. We feel that high-quality testing, reporting, and services can be offered to you with quick results. We pride ourselves in being a laboratory that offers the genetic counseling services clinicians need in a genetic testing company. We combine this service with reliable, fast, accurate test results provided to you via user-friendly and conveniently accessible reports. At Allele Diagnostics, we are passionate about providing reliable answers as quickly and accurately as possible. We continuously strive to improve the efficiency of our workflow and improve the quality of our test results. We encourage feedback from our clients on how we can improve or assist in bringing your ideas into a clinical testing environment. Utilizing our extensive experience in genetic testing, we can work with you to develop solutions to the challenges you have previously experienced in receiving fast, accurate results. Additionally, we are always looking for new and better ways to provide answers to genetic questions and are continuously evaluating novel technologies to see how they can fit into our laboratory given the rapidly evolving clinical genetic testing space. Allele Diagnostics is a CLIA and CAP certified clinical laboratory committed to providing superior testing services for the best patient care possible. We are currently licensed in California, Florida, and Pennsylvania and are pursuing various other state specific licenses.

We are a leading global developer and provider of innovative molecular and immunodiagnostic products focused on Infectious and Gastroenterological Diseases. We are a trusted partner creating value for research and clinical laboratories with high-quality, user-friendly, reliable and accurate solutions. We achieve this through a culture of respect, dedication, empowerment and creativity.

Alpha-1 Biologics is a biotherapeutics company developing innovative treatments for cancers and immune deficiencies. The company is dedicated to their mission to develop patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of α1PI, and in the most prevalent cause of immune deficiency, malnutrition. Alpha-1 Biologics is currently testing their orally-available, small molecules in studies to determine their ability to increase the number of tumor infiltrating CD4+ T cells and coordinate with immune checkpoint inhibitors to eliminate tumors. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

AlphaDERA Labs, LLC. is a full-service medical laboratory providing wellness testing, routine blood chemistry, prescription & illicit drug test including urinary tract testing, respiratory pathogen testing, and COV-19 antigen testing for healthcare facilities, clinics, and PCR Covid-19 testing for patients.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS).

AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). IDgenetix® is AltheaDx’s PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.

Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet. Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI). Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

At Alveo, we're on a mission to use our open, accessible, and actionable molecular detection platform to detect pathogens before they spread. Our portable, handheld, analyzer and cloud-based data analytics brings molecular detection out of the lab and into the field. Alveo's agile platform can be adapted to detect a wide range pathogens including viruses, bacteria, and fungi. Whether testing a patient at a pharmacy at the point-of-care, chickens pen-side at the point-of-need, or farmers testing crops in-the-field, Alveo's technology brings users real time data precisely when and where it matters most. Partner with Alveo today to bring the power of early detection to your industry. Know Sooner, Act Faster™.

Ambay Immune Sensors and Controls (AISC) is working to bring aboutá A revolution in early detection of diseasesá Speeding up the discovery process by developing new research kits and providing technical and professional services

Imagine a world in which devastating disease such as cancer is detected sooner; thus, providing doctors the ability to treat patients earlier with better outcomes. Amplified Sciences is a startup life science diagnostics company focused on accurately detecting and pre-empting the risks of debilitating diseases. The company leverages IP licensed from Purdue University and has developed a platform that can scale to point of care. The lead assay is an ultra-sensitive molecular sensing technology revolutionizing #pancreaticcancer. Enabling early detection of debilitating diseases across oncology and chronic kidney disease.

Amprion pioneers Testing for diseases associated with mis-folded proteins. Our flagship product - SYNTap is the assay used by the Michael J Fox Foundations Parkinson's Progression and Markers Initiative (PPMI) to define PD and DLB and its stages. Early diagnosis of synucleinopathies can help guide management, treatment and prognostic discussions. https://www.ampriondx.com

Amron International is a manufacturing company that specializes in high-quality diving, tactical, hyperbaric, and outdoor equipment with over 30 years of industry experience.

We are experienced scientists, engineers, and business people working together to tackle a global challenge: detecting infection with COVID-19. Together, we are determined to help save lives by delivering rapid, precise, and inexpensive diagnostic tests. Our goal is to enable health care professionals to confidently provide lab-quality results in minutes instead of days so that patients can ​confidently know almost immediately whether they are positive -- or not. Our first product, The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector, is designed to provide a precise diagnosis of COVID-19 in under 30-minutes (on average) instead of the 1-3 days that most testing services and physician offices now require for PCR testing. Using our patent-pending proprietary technologies, the AscencioDx diagnostic test is administered painlessly, in just seconds, with a lower-nasal swab. Our mission is to continue developing and marketing diagnostic test systems for diseases in addition to COVID-19 using our PCR- equivalent point-of-care diagnostic platform without the unnecessary delay, expense, or reliance on less-than-precise antigen testing. This is only the beginning. *The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector have not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

AngioInsight, Inc. is a digital health company based in Ann Arbor, Michigan, specializing in artificial intelligence for cardiovascular diagnostics. Founded in 2018, the company develops AI-driven solutions aimed at improving the accuracy and efficiency of diagnosing and managing coronary artery disease (CAD). The AngioAI+ platform is a key offering, designed for real-time assessment during angiography. It provides actionable insights by detecting microvascular dysfunction and quantifying stenosis severity. Additionally, AngioInsight offers fully automated angiogram analysis, which processes coronary angiogram videos to support clinicians in making informed treatment decisions. The company's technology integrates seamlessly into existing clinical workflows, enhancing resource allocation and patient outcomes. AngioInsight has received significant funding, including grants and investments, to support its innovative approach. The company is actively engaged in clinical studies to validate its platform's efficacy, particularly in addressing diagnostic gaps in cardiovascular care. Its solutions are targeted at cardiologists and healthcare institutions that perform millions of angiograms annually.

BioDynamic Imaging delivers better drug assessment in three-dimensional (3D) living tissue samples, revealing a comprehensive phenotypic response that is more physiologically meaningful than from conventional 2D or monolayer screens. Our technique is label-free and probes up to 1 mm deep in living tissue to study drug response in heterogeneous tissue environments. BioDynamic Imaging converts all forms of functional cellular motions into contrast maps of cellular mechanisms of action.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Antech Diagnostics, Inc., operates a network of veterinary diagnostic laboratories in the United States. It offers veterinary diagnostics services in the areas of chemistry, hematology and coagulation, endocrinology, serology and immunology, urine and fecal, therapeutic drugs, cytology and histology, and microbiology. The company provides laboratory medicine to veterinarians, as well as provides daily services to animal hospitals, zoos, and government agencies. Subject To: https://www.antechdiagnostics.com/privacy-policy , https://www.antechdiagnostics.com/terms-of-use

AOA Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx is developing AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of women's health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization. AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies. Awards & Accelerators: 1. Y Combinator 2. MassChallenge 3. Springboard Enterprises 4. MassMedic Ignite 5. Inc Magazine Top 100 Female Founders 6. Women's Health Innovation Summit Award 7. Massachusetts Life Sciences Center MassNextGen Award 8. The Wave Summit's Emerging Women Founder in Bio Award 9. The Eddies Award 10. Bloomberg New Economy Catalyst www.aoadx.com

Revolutionizing Diabetes Care: No More Needles! At Apollon Inc., we're changing the game for diabetes management. Imagine checking your blood sugar without a single prick - that's what our new continuous glucose monitoring (CGM) system does. Using cutting-edge Raman spectroscopy, we're making glucose monitoring easy, painless, and affordable for everyone. Our device is as small as a smartwatch, needle-free, and designed with your safety in mind. We're currently working with MIT to perfect it, bringing together the best talent from Boston to Seoul. Diabetes affects millions worldwide, and we're here to make their lives better. Our goal? To help more people manage their health easily and comfortably. Join us in this exciting journey. Together, we can improve lives, one simple glucose check at a time. Let's make diabetes management stress-free for everyone!

Aposcience AG aspires to improve the health of patients in need of regenerative medicine by commercially exploiting the therapeutic potential of secretomes derived from white blood cells (PBMCs) isolated from peripheral blood. PBMCs are currently a waste product of all blood transfusion units.

Develops DNA Security Tags, Molecular diagnostics, and vaccines.COVID-19: Applied DNA and Takis Biotech completed the design of a diagnostic kit for SARS-COV-2 (the virus that causes the disease COVID-19) being developed for production via the company’s proprietary PCR-based DNA (LineaRx™) manufacturing process. They also work with Takis on vaccines. EUA (05/2020)

Applied Spectral Imaging (ASI) improves patient care through advanced image analysis. Founded in 1993, ASI is a global leader in the development of imaging and analysis platforms for pathology, cytogenetics, and life science research. ASI's GenASIs™ automated imaging platforms for pathology and genetic analysis provide advanced diagnostic aids for pathologists and cytogeneticists, with reproducible and reliable results. The GenASIs platform can be used with most brightfield or fluorescence microscope systems and supports manual and automatic scanning for a wide range of workflows and applications, to best suit the needs, size and budget of any lab. Our GenASIs HyperSpectral™ and HiSKY® platform created the field of hyperspectral karyotyping (SKY) and is still recognized today as the field's most advanced and productive platform. ASI's applications are US FDA cleared for BandView® (karyotyping), FISHView, SpotScan (for CEP XY, UroVysion®, ALK and HER2/neu FISH), and HiPath (for IHC Family: HER2, ER, PR and Ki67). ASI maintains comprehensive patent portfolios in the US, Europe, Japan and other countries. With thousands of Systems deployed worldwide, offices in the US, Europe and Asia, and a network of over 50 distributors, ASI also takes great pride in our outstanding record of service and support. We stand ready to answer your questions and assist you at all times.

AptaMatrix is a privately held, start-up biotechnology company headquartered in Syracuse, New York. The company's focus is to accelerate the rate of aptamer discovery using its patent pending High Throughput Screening of Aptamers (HTSA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of a) creating rapid diagnostic tools for detection of chemical and biological targets, and b) leveraging this diagnostic platform for drug discovery applications. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. HTSA and AlloSwitch solutions are built on patented biotechnology based on years of leading-edge biological research and industry partnerships at Syracuse University. The HTSA approach leverages the high throughput capabilities of deep-sequencing technology. All sequencing activity is managed by our Genomics Division and conducted on our Illumina GAIIx platforms. Data analysis is supported by our in-house bioinformatics team. In addition to supporting internal research and development, our genomics division actively supports both academic and commercial deep-sequencing projects.

Aqtual, Inc. is a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology. Our mission is to revolutionize the treatment and management of these conditions by bridging the translational gap between groundbreaking research and practical healthcare solutions.

Aranscia unlocks the power of precision medicine by serving the needs of clinical professionals directly within the care workflow.

Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.

Arbor Vita Corporation (AVC) is a privately held company committed to making a difference by enabling early and accurate diagnosis and treatment of disease. The company has products on the market or in clinical studies to address global health challenges in the areas of HPV-induced cancer and infectious disease. AVC also has a pipeline of products in development.

ArcherDX is developing and seeking regulatory clearances for next-generation sequencing (NGS) diagnostics to help solve for the underutilization of targeted cancer therapies.

ARCpoint Labs is a trusted industry leader serving our communities with drug, alcohol, DNA, and clinical testing solutions. With more than 100 independently owned locations, we are committed to providing accurate, cost-effective solutions for consumers, businesses, and physicians nationwide. As one of the fastest growing third-party administrators for testing solutions, ARCpoint Labs continues to innovate and expand its offerings to better meet the needs of our communities. ARCpoint Labs offers businesses a reliable partner for all drug and alcohol testing, policy development, and supervisory training in addition to convenient SARS-CoV-2 testing solutions. Our offerings are built by our dedication to providing safe and drug/alcohol-free workplaces. Many ARCpoint Labs locations offer affordable walk-in wellness solutions and clinical lab screenings to help individuals take control of their overall health and well-being.

ARK Diagnostics Inc. designs, manufactures, and distributes in vitro diagnostic products. ARK's proprietary assays accurately measure drug levels in biological fluids. Clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. By optimizing drug levels, clinicians improve outcomes, reduce toxicity, and lower healthcare costs. ARK is dedicated to improving the quality of patient health through better therapeutic drug management. (ARK Diagnostics, Inc. seeks regulatory clearance in the United States and Internationally.)

For more than 50 years, ARKRAY has been committed to producing safe, reliable, effective products; from developing the world's first HbA1c Analyzer, to the first blood glucose monitoring system for Long-Term Care. Today, ARKRAY manufactures cost-effective diabetes care products and clinical chemistry equipment that are simple, convenient and easy-to-use, and also serves as a private-label blood glucose meter manufacturer for the world's largest retailer. ARKRAY prides itself on putting customer service first, with personalized training, industry expertise and on-going support.

ARL Bio Pharma is a contract laboratory that provides analytical and microbiological testing for the pharmaceutical industry. Since 1998, ARL has supported the industry-wide commitment to deliver high-quality drug products by providing guidance and test services for all phases of the product lifecycle following USP, FDA, and ICH guidelines. Whether you are a raw material supplier, equipment manufacturer, pharmaceutical manufacturer, pharmacy, or health-system we provide the testing needed to get your drug products ready for release. ARL's dedicated team oversees the entire process from understanding your goals to providing results and helping interpret the data. ARL Bio Pharma is an FDA registered and audited analytical laboratory and DEA licensed for Schedules I through V. The laboratory is ISO 17025:2017 accredited as applicable to our scope of accreditation. 17025:2017 accreditation independently demonstrates ARL's ability to not only comply with quality requirements, but to competently perform specified tests and activities.

Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD). Our aim is to provide physicians with an alternative to liver biopsy which detects the disease too late. We are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bring faster, inexpensive and mobile testing for many other applications that require a rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms). Our technology makes it more affordable for smaller healthcare providers such as Physician Office Labs (~100,000 in the U.S.), independent physicians and public health workers to access diagnostics due to our significantly lower cost as well as our portable, small compact size. Finally, we are also working to create a test for COVID-19 as well as other viruses, initially quantifying the virus in wastewater to help public health authorities and later to detect it in biological samples from individuals and patients.

Arthroventions™ is improving the quality of life for patients with joint disease by developing technologies that enable more effective joint care. Over 70 million Americans (1 in 5) have a form of joint disease. It impacts more people than cancer, there is no cure, and the longer and more active a lifestyle, we live the more likely we will experience it. At Arthroventions, we believe the synovial fluid is the key to diagnosing and treating the different types of joint disease, including Osteoarthritis and Rheumatoid Arthritis. Unlike other chronic diseases, such as cancer, there are no diagnostics assays that can differentiate between disease phenotypes or to predict drug responsiveness. This results in patients receiving ineffective treatments based on physician and payer preference. Our first product line is a Class I medical device that facilitates the aspiration/removal of synovial fluid from and the injection of therapeutics into the joint space, which it is estimated that 30% of these procedures miss the joint space. Our new approach reduces patient pain and decreases the probability of missing the joint space, thereby improving the delivery of therapeutics and patient comfort. Using our devices, physicians and providers can realize additional revenue with improved quality of care. Our products support all types of intra-articular injections, including corticosteroids, viscosupplementation, and new regenerative therapy products such as Platelet Rich Plasma (PRP), Bone Marrow Aspirate Concentrate (BMAC), and Adipose derived cells. Join us and take the first step towards more effective joint care.

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests. With more than 3,000 employees, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays. ARUP is an Equal Opportunity Employer M/F/D/V and supports a drug-free environment. Scammers have been posing as ARUP recruiters to target jobseekers using fraudulent email addresses and social media accounts. ARUP recruiters will only contact you with legitimate offers by calling from 800-522-2787 or 801-583-2787 or emailing from an address ending in @aruplab.com. Read our full fraud statement on aruplab.com/careers

Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.

Specialize in molecular and toxicology assays and technology.COVID-19: Molecular test, EUA (05/2020)

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

Astrotech is an innovative science and technology development and commercialization company. We invent, acquire, and commercialize technological innovations sourced from research institutions, laboratories, and internally to maximize shareholder value. Our current subsidiaries consist of: AgLab (Aglab.com) AgLAB Inc. is an advanced mass spectrometry tech company that focuses on distillation for THC and CBD oils based in Austin, Tx. Our products continually test in-process and provide immediate information that maximizes the potency and ending weight yields of every batch. Yield improvements average 34%. 1stDetect (1stDetect.com) 1st Detect's Tracer 1000 is the most accurate Narcotics and Explosives Trace Detector available. Delivering Advanced Lab-Accurate Mass Spectrometry, our solution is already used in 14 countries worldwide and is known for its simple interface, rapid detection cycle, and near zero false positives. With an unlimited threat library, customers can stay up to date with the latest explosive and narcotic profiles. The Tracer 1000 is reliable, rugged, and provides high specificity, all while ensuring maximum uptime and availability. BreathTech (BreathTech.com) BreathTech Corp. is an advanced mass spectrometry tech company that detects diseases through breath analysis based in Austin, Tx. Our first product, BreathTest-1000™ is the first one-minute test for the detection of lung diseases associated with the COVID-19 infection. The machines are currently utilized by major institutions like NASA, U.S. Army, and airport security for the HHS. Astrotech was founded in 1984 in Delaware as a mass spectrometry company that launches, manages, and commercializes scalable companies based on its innovative core technology. You can learn more about our history here: https://www.astrotechcorp.com/about Interested in one of our products? Visit the website and contact us and someone will be in touch with you shortly.

Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.

At Athelas we're bringing simple, life-changing health care products and medical billing services to patients and providers around the globe. Athelas Revenue Cycle Management (RCM): Billing and reimbursement don't have to be painful. Athelas RCM delivers world-class service, maximizes reimbursements, and delivers actionable insights into the financial health of your practice. Athelas prides itself on end-to-end revenue cycle management. This means we cover all aspects of RCM besides simple submission - include denials, working A/R, research, and more as the backbone of your healthcare business. Athelas has powered revenue intelligence for hundreds of healthcare businesses, from small clinics to large health systems. Athelas Remote Patient Monitoring (RPM): We allow healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

Focusing on developing the best nucleic acid amplification and detection technologies for clinical molecular diagnostics - COVID-19 (FDA EUA Approved), Non Invasive Prenatal Test, HPV Detection, STI, NGS Cancer Panel (Lung, Breast, Colorectal), and many more.

Aurita Corp is a synthetic biology startup that creates a platform for 3D bioscience intended to provide personalized medicine and diagnostics, therapeutic solutions, and cell culture tools.

AutoGenomics is a biotechnology company that offers an automated microarray based multiplexing molecular diagnostic platform to assess disease signatures with novel genetic biomarkers in the areas of women’s health, cancer and personalized medicine.

Autonomix (Nasdaq: AMIX) is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.

Autonomous Medical Devices Incorporated (AMDI), with its principal place of business in California, employs a world class team of engineers, scientists, clinicians, and manufacturing experts dedicated to the development and manufacture of point-of-care diagnostic devices using breakthrough microfluidics, protein engineering, and data/cloud connectivity. AMDI will launch its first products from its ISO:13485 certified 110,000 square foot facility in Santa Ana, CA.

Avails Medical, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and health-care associated infections.

Avalon GloboCare Corp. is an intelligent biotech developer and healthcare service provider. The Company engages in the management of stem cell banks and specialty clinical laboratories. It is developing of exosome technology to improve the diagnosis and management of diseases. The Company operates through two platforms, Avalon Cell and Avalon Rehab. Its technology and service ecosystem covers the areas of regenerative medicine, cell-based immunotherapy, exosome technology, as well as rehabilitation medicine. The Company also focused on diagnostic advancements in the fields of oncology, infectious diseases and fibrotic diseases, and the discovery of disease-specific exosomes to provide the disease origin insight necessary to enable.

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

AXIM Biotechnologies is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical, and cosmetic products as well as alternative energy sources. We prioritize the well-being of our customers while embracing a solid fiscal strategy. We believe in setting the green standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living while respecting the environment. Public Relations Contact Andrew Hard Chief Executive Officer CMW Media andrew.hard@cmwmedia.com P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 824-2857 Lucia Domville, Grayling lucia.domville@grayling.com P. +1646 284-9416

Baebies Inc. is a growth-stage medical device company developing innovative products to enable early disease detection and multifunctional diagnostics for syndromic testing for children and adults. Guided by the vision that everyone deserves to be healthy, we aim to deliver ‘Any test. Anywhere. To Everyone.’ We deliver millions of tests globally every year to save lives and make lives better. Baebies is a pioneer in digital microfluidics technology, which maximizes diagnostic yield from low-volume samples. Baebies is headquartered in Durham, North Carolina, and our products are used in central laboratories and point-of-care settings around the world. Over 20 million tests delivered, and counting. Every test is a chance to save a life. Our current pipeline of test panels on the multifunctional FINDER platform include molecular (Respiratory panel - Flu A, Flu B, RSV, and SARS-CoV-2, STI panel - CT/NG/TV), coagulation (anti-factor Xa, aPTT), and chemistry (G6PD).

Bako Diagnostics is a provider of diagnostic and therapeutic services with a unique focus on pathology of the lower extremity. Bako's comprehensive testing menu includes ENFD Analysis, Mass Spectrometry, for rapid identification of bacteria from culture specimens, and Molecular Genetics for the detection of micro-organisms and as a diagnostic aid in certain pathologic diagnoses. Bako's in-network services are available through its more than 200 million covered lives, including all five national health plans and fully compliant patient-friendly billing policies. Over the past nine years, Bako has evolved into one of the podiatric profession's principal sources of educational sponsorship. Bako Diagnostics, your professional partner for disease diagnostics and management! For more information, call us at 855-422-5628 or visit bakodx.com.

BAMF Health is the world's first vertically integrated platform for molecular imaging and radiopharmaceutical therapy. Using the most advanced imaging and therapy technologies, BAMF Health is dedicated to providing comprehensive and intelligent treatment options for patients with serious health issues such as cancer, heart disease, and stroke.

We're a leading global eye health organization that is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, we have a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries.

Baylor Genetics offers a full spectrum of cost-effective, genetics testing and provides clinically relevant solutions. They offer whole exome sequencing, prenatal diagnostics, cytogenetics, molecular diagnostics, oncology, chromosomal microarray analysis, and over 30 enzyme assays. Along with these tests come interpretation services.

BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.

With a relentless mission to empower those seeking answers to life’s important scientific questions, Beckman Coulter Life Sciences is a preferred laboratory partner providing automation and innovation solutions for Centrifugation, Flow Cytometry, Genomics, Particle Analysis, and Liquid Handling workflows. With a legacy dating back to 1935, our technologies reduce manual laboratory processes and can provide greater speed, accuracy, and advanced analytics to accelerate answers with a guiding focus to improve patient care and enable pioneering discoveries. Beckman Coulter Life Sciences is headquartered in Indianapolis, Indiana with 11 operational hubs around the world and employs more than 3,300 associates with more than 300,000 systems installed globally.

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They are focused on moving Prenatal Screening and Liquid Biopsy forward to improve disease detection.

binx health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining "convenient care" for the modern consumer. binx is developing a suite of offerings that service healthcare needs where people live, work and shop. The Company's io® platform is designed to offer rapid PCR-based results, up to 24-plex, from sample-in-to-answer in about 30 minutes, greatly accelerating today's multiple day standard-of-care central lab testing paradigm. binx is driving solutions to take place in retail clinics, supermarkets, primary care offices, and at home. It does it through a suite of mobile and digital offerings. binx health investors includes financial investors, Johnson & Johnson Innovation, Novartis Venture Fund, LSP Venture Capital, BB Biotech, RMI Investments and Technology Venture Partners and strategic investors, Consort Medical (whose wholly owned subsidiary Bespak are the makers of the company's low-cost, proprietary multi-plex cartridges) and China-based Wondfo Biotech. binx health is a global company and has locations in Boston, MA and Bath UK. For further information visit www.mybinxhealth.com.

Addressing a critical need to find cancer early and treat cancer specifically, bioAffinity Technologies, Inc. develops tests and therapies to detect and treat cancer at the cellular level. Our first product, CyPath® Flow Cytometry for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. CyPath® Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.

BioAmp Diagnostics is committed to preventing the misuse and overuse of antibiotics in healthcare through the development of innovative diagnostic tools, that will give medical providers the information they need to correctly treat an infection.

Biocare Medical LLC is an innovator in automated immunohistochemistry (IHC) instrumentation, and the full range of reagents for IHC and in situ hybridization (ISH; RISH) testing. Biocare pioneered multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption and cost by 50% or more. Multiplex IHC allows pathologists to visualize more than one marker on a tissue at a time, allowing higher confidence for critical differentiation. Biocare's intelliPATH FLX is the only completely open, continuous random access IHC instrument available. The company’s customers come from clinical and research environments that do tissue based testing and include histology laboratories, pharmaceutical and biotechnology companies; CROs; and academic, government and military labs. Biocare Medical offers an expanding portfolio of products for the rapidly growing cancer and infectious disease diagnostic and research markets. Biocare medical is headquartered and has manufacturing facilities in Concord, Calif., and has a global distribution network. See biocare.net and slidestainer.com for more information. NOTE: Biocare Medical, the Biocare Medical logo, and intelliPATH are trademarks of Biocare Medical LLC.

We develop novel and sustainable products and technologies in bio-therapeutics, vaccines and personalized diagnostics of cancer and infectious diseases. Most of the company's efforts have been directed toward in-house innovation in drug development and diagnostics; biotechnology consulting to pharmaceutical companies interested in technologies related to biosimilar and biologics development; and specialized contract research services to clinical and academic research institutions in order to design solutions based on novel methods and protocols useful in clinical validation of biopharmaceutical molecules and vaccines.

BioCheck develops and manufactures high-quality immunoassay kits for the worldwide healthcare markets in their cGMP and ISO 13485 certified facility in the San Francisco Bay Area. BioCheck also provides custom immunoassay development and contract manufacturing services to the diagnostic and research industries.

Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world. We have launched our first product, ASPYRE-Lung, in the US and we have an extensive pipeline of novel products. Biofidelity has developed a novel molecular biology technology which enables genomic analysis for cancer diagnosis to be carried out locally, quickly and far more cost-effectively.

With more than 25 years of molecular experience, BioFire Diagnostics, LLC (now bioMérieux) sets the standard for molecular diagnostics through its pioneering advances in syndromic infectious disease testing. As BioMérieux’s Global Center of Excellence for Molecular Diagnostics, no other company has FDA-cleared and CE-IVD marked assays for more pathogens. BioFire Diagnostics has produced the easiest, fastest, and most comprehensive multiplex PCR testing available: the BioFire® FilmArray® System. The FDA-cleared BioFire System panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes. Whether you’re trying to determine optimal therapy for a septic patient or pinpoint which respiratory pathogen is making a young child sick, the BioFire System can provide definitive answers—fast.

The heart of BioFluidica's CTC (Circulating Tumor Cells) system, is a highly efficient CTC capture bed, comprised of 50 to 500 sinusoidally-shaped channels. These channels are coated with antibodies, which isolate specific CTCs from whole blood. The antibodies are chemically immobilized onto the surfaces of the capture bed using BioFluidicas patented technology.

BioGX develops molecular products and provides partner-specified formulation and manufacturing services for molecular reagents on a platform of a partner’s choice. The company applies its proprietary platform-agnostic reagent technology to offer products and contract services across a variety of real-time PCR and Next Generation Sequencing platforms.BioGX SARS-CoV-2 Reagents for the BD MAX System - EUA 4/2020

Biolinq has created a new Biowearable experience by using an array of electrochemical sensors so small you can barely feel them. Our metabolic health sensors work together to provide maximum reliability for continuous sensing applications. With the potential of multiple analytes such as glucose, ketones, and lactate, we provide an entirely new user experience with actionable metabolic health insights. Over the next 10 years we intend to bring Biosensing and Biowearables mainstream. We are dedicated to the personal and professional growth of all our team members and strive to create a positive and creative work environment.

Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company’s products are designed to enhance health and well-being, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing. The Biomerica InFoods® IBS product identifies patient specific foods that when removed may alleviate an individual's IBS symptoms. This patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians'​ offices is available for InFoods® diagnostic products. Since the InFoods® product is a diagnostic guided therapy and not a drug, it has no drug type side effects.

Antibodies, Immunoassays, Small Molecule

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

For over 30 years, Bionique Testing Laboratories has been a trusted partner and global leader of Mycoplasma Testing Services for the life science industry. Bionique offers the full breadth of GMP services from Lot & Final Drug Product Release Testing to Real-Time PCR assays. Our service portfolio and depth of expertise enables us to support our clients’ needs from concept through clinical trials to commercialization for biopharmaceutical and cell therapy products. Our capabilities extend to successful method development and validation inclusive of rapid microbiological methods to generate real time results. Bionique stands ready to provide the highest quality of mycoplasma testing services to ensure the integrity and biosafety of your therapeutic products. Mycoplasma Testing Solutions for: • Cell and Gene Therapy Products • Clinical Trial Materials • Biopharmaceuticals • Master and Working Cell Banks • Raw Materials • Vaccines Bionique is a cGMP compliant, FDA-registered facility.

For over 30 years, Bionique Testing Laboratories has been a trusted partner and global leader of Mycoplasma Testing Services for the life science industry. Bionique offers the full breadth of GMP services from Lot & Final Drug Product Release Testing to Real-Time PCR assays. Our service portfolio and depth of expertise enables us to support our clients' needs from concept through clinical trials to commercialization for biopharmaceutical and cell therapy products. Our capabilities extend to successful method development and validation inclusive of rapid microbiological methods to generate real time results. Bionique stands ready to provide the highest quality of mycoplasma testing services to ensure the integrity and biosafety of your therapeutic products. Mycoplasma Testing Solutions for: • Cell and Gene Therapy Products • Clinical Trial Materials • Biopharmaceuticals • Master and Working Cell Banks • Raw Materials • Vaccines Bionique is a cGMP compliant, FDA-registered facility.

We provide services in genomics, statistics, and information technology. Our services include Bayesian analysis, bioinformatics, biomarker development, biostatistics, data management, data pipelines, data science, epigenomics, genetics, genome-wide association, imputation, microarray analysis, multiomics, next-generation sequencing analysis, pharmacogenomics, polygenic risk scores, predictive modeling, project management, proteomics, reproducibility, software development, statistical computing, statistical genetics, and statistical programming. We also developed the Smokescreen® Genotyping Array, advancing research into addiction and treatment approaches. Our highly-skilled transdisciplinary team of experts, carefully assembled from leading research universities and industry, has been solving our clients' research challenges for almost two decades. Extensive experience with a wide range of cutting-edge methods and technologies means we can help ensure your project's success, and provide high-quality deliverables on time and within budget. Whether you have a critical issue, need help with every aspect of a new project—including coordinating complex projects—or only one part of an ongoing project, we can work with you to develop the optimal solution to meet your goals and objectives. Our team can be an integral part of the collaboration, and provide full-service support for all the stages of your research journey. We follow all U.S. Department of Health & Human Services standards for the security of electronic protected health information (HIPAA-compliant). We believe in reproducible, reusable, transparent, and extensible research, and do everything we can to put those values into practice. We are prepared to use our internal computing environment, cloud-computing environments, or client-provided environments, if preferred.

For more than four decades, BioReference has built a legacy based on scientific excellence, innovation and world-class service in laboratory testing solutions. Amidst a tidal wave of change in healthcare in recent years, BioReference has evolved, adding significant services and solutions aimed at addressing the needs of today’s customers. Laboratory testing remains the cornerstone to the services we provide. As we challenge the limits of specialty diagnostics, we are making strategic investments to continue drive innovation and cultivate a unique customer experience, as well as expanding our reach to match the dynamic needs of an ever-changing healthcare system. BioReference offers scientific expertise and laboratory innovation in oncology, urology, and women’s health. Our organization provides credible and tailored solutions for a wide spectrum of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, sport leagues, travel and leisure industries, and retail markets. In addition to an extensive test menu with 99% of tests performed in-house, BioReference’s differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory testing and management. BioReference is part of OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Headquartered in Elmwood Park, New Jersey, BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States, and serves over 19 million patients annually.

Biotia is a health tech company launched from Jacobs Technion-Cornell Institute at Cornell Tech in association with Weill Cornell Medicine, located in New York, NY, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Biotia is developing a next-generation sequencing-based test for COVID-19 that characterizes genetic variance across the whole viral genome.

Specializing in Creating and Improving Biosensors with Synthetic Biology. Winner of LymeX Diagnostics Prize

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient product for triage and monitoring of disease progression.

Boundless Bio is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive. Our Culture: At Boundless, you’ll experience what it means to be out in front of the wave. Our unprecedented science takes us to new shores, and our team navigates the best breaks. We’re leaders in our field, and we’re dedicated to the cause of understanding and treating intractable cancers. Every employee at Boundless makes an unbridled impact on our capabilities and our culture. We’ll help you expand your abilities and defy your bounds by providing meaningful work and unbounded opportunities. Career development is essential at Boundless. We’re all in on this fight against cancer– collaboration is requisite to our success. We have a team of people who ask, offer, and accept help without regard for ego. We know that receiving support is energizing, and giving help is fulfilling. We are inspired by the patients who are reliant upon our success. At Boundless, we’re all in. We are unbound by convention, bound to save lives. Career Inquiries careers@boundlessbio.com General Information Inquiries info@boundlessbio.com

We have developed a patented technology that will determine if a patient has lung cancer by analyzing a patient's breath with parts per billion accuracy, allowing very early detection. We have studied over 800 patients. This has the potential to save a significant number of lives and save the healthcare industry significant dollars.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

Bright Uro is an early-stage medical technology company headquartered in Irvine, CA. They are building the next generation of diagnostic devices for Urology.

Market opportunities created by evolving legislation legalizing recreational use of cannabis is generating a significant need for advances in rapid and accurate drug testing technology. Buzzkill Labs is developing next generation technology that will combine patented noninvasive sample collection methodology with scientifically validated laboratory detection and quantitation technology. Buzzkill Labs products will address the growing need for:SAFETY IN THE WORKPLACESUSPECTED IMPAIRED DRIVING BY LAW ENFORCEMENTFAST AND ACCURATE TESTING BY MEDICAL AND DRUG TREATMENT CENTERS

C2N Diagnostics is a molecular diagnostics company aiming to transform the early diagnosis and early treatment of Alzheimer's disease and related forms of dementia. They are developing and accelerating novel diagnostics and therapies for Alzheimer's disease, including the new PrecivityAD™ blood test for Alzheimer's disease.

C4 Imaging develops innovative medical devices that enable clinicians to personalize patient treatment through accurate image-guided procedures. The company's core proprietary technology, C4, is a unique magnetic resonance imaging (MRI) agent that has been encapsulated within an implantable, biocompatible shell. C4 Imaging's first product is the Sirius™ MRI Marker, which will be used to facilitate seed localization during the treatment of prostate cancer. The Sirius™ MRI Marker will allow physicians to accurately locate seeds within the complicated anatomy of the prostate and the surrounding critical structures, utilizing a single post-implant MR imaging procedure. C4 Imaging's goal is to improve quality assurance by allowing post-implant seed localization to be performed with MRI alone, eliminating the need for computed tomography in assessment of prostate brachytherapy.

Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with cutting-edge technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws. Alibrex is a blood-based assay, developed to help physicians identify patients who are not responding to drug therapy. The test is optimized to maximize NPV, that is, minimize the number of false non-responders.

The California Animal Health and Food Safety Laboratory System (CAHFS) is the backbone of California's warning system that helps to protect the health of California's livestock and poultry. CAHFS serves the people of California by safeguarding the public health with rapid and reliable diagnoses for animal diseases including those affecting humans. CAHFS operates in partnership with the California Department of Food and Agriculture, UC Davis, veterinarians, and livestock and poultry producers. CAHFS provides quality services that protect animal health and performance, public health and the food supply.Located on the University of California, Davis campus, the Davis laboratory provides livestock, equine and avian necropsy, histopathology, immunohistochemistry, electron microscopy, toxicology, serology, microbiology and virology testing on site. Specialty services for equine performance chemistryand pharmacology are also located at the Davis facility.CAHFS Davis offers:American College of Veterinary Pathologists board certified diagnosticiansAmerican College of Veterinary Microbiologists board certified microbiologistAmerican Board of Veterinary Toxicology board certified toxicologistExperts in poultry/avian, horse, cattle, pig, llama, alpaca, sheep, goat, exotics and wildlife diseasesForeign animal disease trained diagnosticians on siteComprehensive reports which include gross examination, histopathology and testing in other disciplines as neededNational Poultry Improvement Plan approved site for Salmonella, Mycoplasma and Avian Influenza testing

Calviri’s mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine. For more information, please visit www.calviri.com.

CancerTargetedTechnology develops innovative agents for cancer that accurately detect early and advanced disease, monitor treatment efficacy

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic EngineTM ("Core Technology") for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease.

CardioWise's non-invasive Cardiac Computed Tomography (cCT) analysis software produces an easy-to-understand 3D image model of the human heart.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, mental health and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. IDgenetix is Castle's pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient’s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

Celcuity is a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.

Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging diseases. We are a recognized leader with a rich stable of discoveries, developed in concert with premiere research institutions in the US, EU, and beyond. We secure lasting partnerships with inventors and their institutions, and provide the developmental, financial, and business acumen to bridge the gaps between discovery and clinical impact. With robust funding options, operations in greater Boston, Washington DC and New York City, growing affiliates in Seattle and Indianapolis, a wealth of opportunities in our pipeline, and partnerships with industry leaders worldwide, Celdara Medical navigates the path from science to medicine, accelerating innovation to improve human health. Celdara Medical - Transforming innovation into medicine.™

Cancer diagnostic

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

CellMax Life is a leading cancer diagnostics company whose mission is to transform how cancer is diagnosed and managed with globally affordable non-invasive tests for early cancer detection and management. CellMax's unique expertise in both Circulating Tumor Cell and Next Generation Sequencing of DNA and circulating tumor DNA (ctDNA) has enabled multiple highly effective precision medicine solutions for healthy people as well as patients diagnosed with cancer.

Celula is a biotechnology company that offers Celula IDA, Integrated Diagnostic Accuracy, providing better solutions for prenatal testing and novel approaches to cancer detection.

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com. Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

At CereHealth, our mission is to revolutionize healthcare through the power of artificial intelligence. We are committed to improving patient outcomes and enhancing the efficiency of clinical practices by providing cutting-edge AI-driven Clinical Decision Support Solutions (CDSS). Our purpose is to bridge the gap between data and insights, enabling healthcare professionals to make informed and precise decisions at every critical juncture. By harnessing the potential of AI, we aim to empower medical experts with real-time, evidence-based recommendations that promote accurate diagnoses, personalized treatment plans, and optimize patient care. Driven by our dedication to innovation and integrity, we envision a future where healthcare providers can seamlessly integrate AI into their workflows. Through continuous research, collaboration, and advancements in AI technology, we strive to be at the forefront of CDSS, setting new standards for excellence in healthcare decision-making. We are unwavering in our commitment to privacy and security, ensuring that patient data is treated with the utmost confidentiality and adhering to the highest standards of compliance. Our solutions are designed not only to support medical professionals but also to engender trust among patients, knowing that their well-being remains at the heart of every AI-driven recommendation. By working hand in hand with the medical community, we aim to foster a healthcare landscape where AI augments human expertise, leading to faster, more accurate diagnoses, reduced medical errors, and ultimately, improved patient outcomes. At CereHealth, we are dedicated to shaping a healthier tomorrow through the synergy of AI and medical wisdom.

Ceretype Neuromedicine offers brain circuit profiles to stakeholders across the healthcare ecosystem. It is a services, platform, and insights company that can provide a groundbreaking biomarker engine for neurologic and psychiatric disease. Ceretype grew out of the desire of its physician-scientist cofounders to translate years of academic research in psychiatric neurobiology and imaging methods. It is a next-generation fMRI brain biomarker platform to improve drug discovery and patient care in neuropsychiatry.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett's esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient's tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett's Esophagus is the world's first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett's esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

Cerora (www.cerora.com) is devoted to alleviating suffering and empowering people by transforming antiquated opinion-based methods into enlightened biosensor-based neurodiagnostics. The company intends to make a major positive impact in brain health assessment globally with an initial focus on concussion. The Company is leading the way in the development and testing of mobile software and hardware technologies required to provide critical, objective, biomarker-based brain function diagnostic information. Located in the high-tech nexus at Ben Franklin Technology Partners of Northeastern Pennsylvania's Tech Ventures on Lehigh University's Mountaintop Campus in Bethlehem, Pennsylvania, Cerora has assembled a team of experienced medical scientists and management professionals.

Our unique platform combines a mobile app with a hypergraph data architecture. Italignsmolecular diagnostics, clinical research, pharmaceutical data and a worldwide community of other patients (and their diagnostic and treatment histories) to givehealth insights.

About Chembio Diagnostics: Chembio is a leading point-of-care diagnostics company focused on creating fast actionable tests to diagnose diseases quickly and accurately, including STIs and COVID-19, enabling expedited treatment. Chembio tests are easy to use and provide results in approximately 15 minutes using some of the smallest sample sizes of fingertip blood, nasal swabs and other sample types. Chembio recently received FDA CLIA Waiver for the first rapid point-of-care combination test for HIV & Syphilis. Coupled with Chembio's extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com. About the DPP Rapid Test Platform: Chembio's proprietary DPP® technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio's easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chemeleon has created a platform technology for the rapid, instrument-free, detection of chemical compounds in the field, obviating the need for slow, complex, and expensive lab analysis. Our sensor materials combine highly selective molecular receptors with colorimetric nanomaterial reporters to provide an autonomous and inert means of optically detecting hazardous chemicals in virtually any environment, from clinical to third-world settings.

Circular Genomicsis abiotechnology and genomics company with a vision to use circular RNAs as novel and improved biomarkers for the diagnosis and better treatment of psychiatric and neurological diseases

CirrusDx, Inc. is an infectious disease company with a CLIA certified lab that offers unique testing solutions for UTI, STI, and Respiratory Infections (among others) that are tailored to Long Term Care, Geriatrics, Urology, Uro-Gynecology, OBGYN and various specialty/general practice clinics. Our UTI test provides complete results in 24-48 hours, identifying uropathogens and offering antibiotic recommendations to aid in individualized patient treatment. CirrusDx is bringing diagnostic tools closer to the patient to counteract the challenge presented by antibiotic stewardship and empirical treatment.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

Cleveland Diagnostics is developing a breakthrough technology to discover a new class of diagnostics tests with high sensitivity and specificity for many cancers – early on, when cancer is still curable.

Clinical Labs of Hawai'i, LLP with Pan Pacific Pathologists, LLC is the leading medical laboratory testing company in the State of Hawaii, offering a full range of anatomical and clinical tests for Hawai'i's medical community. We service 11 hospitals statewide and offer outpatient services at over 50 Patient Service Centers. We strive to give our clients and customers the best care and business in the state by providing services that are close, connected and caring.

CND Life Sciences is dedicated to supporting the care of patients suffering from neurodegenerative diseases and other conditions. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, AZ, CND launched the Syn-One Test® as the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. The test serves as an objective diagnostic tool to aid in the confirmation of a synucleinopathy in patients with suspected Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF). Through analysis of three small in-office skin biopsies provided by a referring physician, CND offers a convenient, accurate, minimally invasive alternative to aid in the diagnosis of neurodegenerative diseases. The company has research collaborations with multiple biopharmaceutical companies and is committed to advancing science in the field.

Cognoa innovates solutions for child developmental health. We build breakthrough products like Canvas Dx, the first and only FDA authorized autism diagnostic for children ages 1.5 to 6 years that uses responsible AI to empower doctors to quickly, accurately, and fairly diagnose developmental risk without bias. Our digital solutions are child centric and designed to find, assess, and treat developmental concerns early, within the time windows that will yield the optimal outcomes. Our proprietary "whole child" approach to AI fuels our pipeline of diagnostic and therapeutic products for autism, speech and language, ADHD, childhood anxiety, and more. For more information, visit www.cognoa.com.

Cognoptix is pioneering a new way to see Alzheimer's disease (AD): a low-cost, practical and non-invasive eye scan that detects beta-amyloid deposits in the lens. Amyloid is the earliest biomarker of AD, and our system can detect it years or decades before amyloid appears in the brain.

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Collagen Medical is a healthcare company that specializes in medical products and services related to collagen.

Founded in 2015 in Salem, Mass., and operating out of its CLIA-certified laboratory and as an FDA-registered, ISO 13485-certified medical device manufacturer, Commonwealth Diagnostics International (CDI) helps providers identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. CDI's expansive portfolio of non-invasive at-home hydrogen and methane breath tests supports the diagnosis and treatment of Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO), as well as fructose malabsorption, lactose malabsorption, and sucrose malabsorption. Focused on patient-centric principles, CDI breath tests are easy-to-use, quick, and safe for patients and support meaningful GI health outcomes by helping steer each practitioner's approach to dietary modification, homeopathic remedies, nutritional supplementation, immune support, high-quality probiotics, and additional testing.

CoraVie Medical's implantable, continuous blood pressure monitor informs treatment decisions to improve lives. The end to end solution improves patient compliance to monitoring and improves blood pressure reliability and actionability. By monitoring trends over day and night, CoraVie enables timely notification of changing health status.

Cordant was founded in 1959 by the Ullmann family. Starting with security services, we soon became experts in the delivery of flexible solutions to meet the changing needs of our clients. The business grew, and we began offering other services such as multi-sector recruitment, healthcare, cleaning and more recently technical facilities management. Sixty years later, and we employ around 125,000 staff each year, most of which undertake work for over 5,000 client organisations. We operate internationally, across a broad and diverse range of specialisms, although we've grown, our strong family foundations mean that we've stayed connected to our employees, clients and suppliers, and to the communities we operate in. As pioneers in the recruitment and facilities space, our industry-leading services allow us to take care of people and property so clients can focus on their core business. We're about more than a service transaction - we're about helping thousands of people to live good lives. We're building a stronger society by welcoming a new era of positive impact, shared values and enhanced cooperation. In 2017, we took the natural next step: we became a social business. We're proud to be the biggest business in the UK using purpose to drive meaningful profit and to be amongst a group of forward-thinking companies who are using business to improve society.

CorDx a multi-national biotech organization focused on pushing the limits of innovation and supply in global health. With over 2,100 employees across the world, serving millions of users in over 100 countries, CorDx delivers rapid testing and point-of-care medical device solutions used in the detection of infectious disease such as COVID-19, pregnancy, drugs of abuse, biomarkers, and more. CorDx is at the cutting edge of technology, artificial intelligence, and data science with the goal of delivering diagnostic solutions to some of the most critical questions in healthcare. #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

Corgenix is part of the SEBIA Group. Located outside of Denver, Colorado, USA, Corgenix is a CAP/CLIA accredited laboratory specializing in clinical studies, clinical trial management and physician-ordered patient testing. Corgenix is also a experienced in CDMO—Contract Development and Manufacturing Organization. Corgenix is a highly capable strategic partner with history of success; our main client groups are Biotech companies, Pharmaceutical industry, Cancer Centers, and Academic laboratories. Strategic collaborations have covered all aspects of the IVD process –development, quality control, regulatory compliance, manufacturing (We are ISO-13485:2016, an FDA registered facility and GMP compliant), warehousing, distribution, product support, and commercialization. . Whether you need support for research, clinical trial testing or contract clinical testing services, we are here to serve. Above all, we believe in clear communication and transparency. We take a cross-functional team approach to our projects, fully engaging with our clients throughout the project. What do you need? Please contact us to see how we can support your business strategy!

CosmosID provides award-winning, end-to-end microbiome solutions. They offer NGS, Metabolomics, Bioinformatics, as well as the world's most advanced microbiome analysis software, CosmosID-HUB: Microbiome. The HUB relies on validated databases and algorithms specifically designed for maximum sensitivity, precision and lowest false positive rates. Unlike other solutions, CosmosID delivers strain-level results – we understand that the biologically informative and actionable unit in microbiology is not a genus or species, but ultimately a strain and its unique genetic and metabolic properties. CosmosID was founded in 2008 by Dr. Rita Colwell, former director of the National Science Foundation and currently Distinguished University Professor at the University of Maryland and Johns Hopkins University Bloomberg School of Public Health. To learn more please visit www.cosmosid.com.

Diagnostics

Creative Diagnostics is a biotechnology company based in Shirley, New York, specializing in diagnostic reagents and contract research services. Established in the early 2000s, the company serves global markets in biopharmaceuticals, diagnostics, and academic research. With a team of 25 to 200 employees, Creative Diagnostics generates an estimated annual revenue of $5 million to $25 million. The company offers a range of products, including research-grade and therapeutic antibodies, viral antigens for vaccine development, customizable ELISA kits, rapid test kits, and specialized reagents for gene therapy and bioanalysis. Creative Diagnostics also provides contract assay development, GMP manufacturing for biologics, and custom antibody development through its proprietary Omni-Hybridoma™ platform. Its technical capabilities support rapid commercialization and are particularly relevant for mRNA vaccine development and therapeutic drug monitoring.

Creatv MicroTech's mission is to dramatically reduce global cancer mortality through early detection. Our innovative blood test can detect cancer in the earliest stages, even before symptoms. It can also confirm whether a patient is responding to treatment and surveil for early signs of recurrence after treatment has finished. Clinical application of this highly sensitive and specific test will improve cancer treatment outcomes. Cancer touches all of us. Almost 40% of Americans are currently expected to receive a diagnosis of cancer in their lifetime. Over half of these diagnoses occur after significant progression, in stages 3 and 4, making it difficult to achieve successful therapeutic outcomes. Early detection with high accuracy is needed for all major cancers. Nearly 14.5 million Americans are living with a history of cancer, many in remission under surveillance for possible recurrence. Early detection of recurrence enables faster response and improved outcomes. Our CellSieve diagnostic platform uncovered a previously unknown cell in the blood of cancer patients, the cancer associated macrophage-like cell (CAML). These cells are very large and distinctly different from normal cells and circulating tumor cells (CTCs). We found these CAMLs in patients with solid tumors, but not in healthy individuals. CAMLs are highly informative, because they contain markers of the cancer type and indicate sensitivity or resistance to particular treatments. Unlike CTCs, CAMLs are found in all stages of cancer, including stage I. Together, CAMLs and CTCs provide a unique capability for early detection of cancer, monitoring treatment, and watching for recurrence. CellSieve is currently in research use at leading cancer clinics in the US and eight foreign countries.

CTK Biotech is a biotechnology company that specializes in medical diagnostics for healthcare applications.

Culmination is changing the world by discovering better health. We provide unparalleled value to health care organizations by unlocking biological data and enriching it with clinical, claims, and genomic data. We are on a journey to radically improve everyone's future health care experience. Culmination Bio will become the trusted source for health care insights and for generating discoveries that improve people’s lives.

Cureline is a global precision and translational medicine CRO located in California (USA). With more than a hundred validated clinical partners in 20 countries, HBS repository in San Francisco Bay area and excellence in laboratory services, Cureline provides a full spectrum of translational research services: global regulatory affairs, custom protocol HBS biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2003 Cureline is a global leader in commercial biobanking and biomedical research services with a focus on targeted drug R&D, biomarker research and companion diagnostics development.

CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient's tumor.

Cytonics is a research and development company dedicated to discovering and developing therapeutics based on the protease inhibitor Alpha2 Macroglobulin (A2M). Theyhave discovered a unique “bio-marker” that can assist physicians in improving patient outcomes by pinpointing the source of orthopedic pain. We are also developing a range of therapeutic products for the treatment of painful osteoarthritis, back, and joint pain.

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

Darwin Biosciences specializes insaliva-based diagnostic tests for infectious disease. We are developing diagnostics that can identify people who are asymptomatic or pre-symptomatic for common infectious diseases, including COVID-19. Some of our products are being designed for clinical use. Others are expected to be hand-held and self-administered, so that people can monitor their own health at home or when reporting for work at venues where vulnerable people (i.e. nursing homes, hospitals) or many people (delivery personnel, airport employees) are being served.

At Dash Bio, we're revolutionizing clinical bioanalysis to expedite drug development. By leveraging AI and robotics, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average for clinical trials and GLP studies. While AI startups have transformed drug discovery, the development phase remains bogged down by manual, labor-intensive processes. We're changing that narrative. Our tech-first products automate critical steps, reducing costs and time to market without compromising on quality. Our initial product line focuses on clinical bioanalysis—the testing of samples from clinical trial subjects. With a fresh perspective, we've built a modern platform where quality, automation, and regulation work seamlessly together. Why settle for traditional methods when you can invest in results? We're obsessed with enhancing customer experience and outcomes, constantly pushing boundaries to make processes better and faster.

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

DC3 Therapeutics is a full service Contract Research Organization (CRO). We offer a full set of services necessary for drug discovery, pre-clinical and IND enabling studies. Our services include histology and in vitro pharmacology as well as molecular, cellular, and micro-biology. We are happy to work with our clients to custom tailor experiments according to their research and development goals. Because we understand that drug development is a fast paced and demanding environment, we guarantee that our services are performed accurately. And to ensure a quick turn-around time, each customer is assigned a secured DC3 account to conveniently download data, schedule pickup, and submit inquiries. Our team, who are committed to superior customer service, has extensive experience in the drug development process and the pharmaceutical industry. You can rely on us to deliver quality data.

DeepHealth is RadNet's AI-powered health informatics subsidiary, created to empower breakthroughs in care delivery. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all data to drive value across the enterprise. DeepHealth aims to elevate the role of the radiologist, beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI technologies in breast, lung, prostate, and brain health, as well as operational efficiencies to create end-to-end efficiency across the enterprise.

DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.

Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.

Detect builds tools that empower people to understand their health and make informed, timely decisions. Led by Founder Dr. Jonathan Rothberg, the Detect team is redesigning the future of healthcare with the power of technology. Detect wants to make fast, accurate diagnostic testing as routine as taking your temperature and as accessible as telemedicine.

Detekt is a life sciences product design and engineering firm. Over the last 15 years, the team has worked alongside both private and public companies to launch products that fulfill each client’s vision and successfully go to market.

DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit http://www.diacarta.com.

Using a proprietary nano-scale biosensor for a COVID-19 breath-based diagnostic.

Founded in 1987, DiagnosTechs™ is a pioneer and leader in saliva-based testing. Our commitment to assisting healthcare professionals in restoring patients'​ health and wellness is unsurpassed with over 1.2 million specimens tested per year. Saliva testing is a powerful tool for evaluating stress, hormone-related disease and health conditions, especially over time. DiagnosTechs continually improves and refines its laboratory testing standards, using cutting-edge technology and methods. Many healthcare providers and their patients have chosen DiagnosTechs as their partner in wellness.

Diagnostic BioSystems is a leading developer of specialty Immunohistochemistry reagents. The company is dedicated to high quality antibody production and development of novel multiplex staining reagents. Building on its strong global presence, Diagnostic BioSystems produces novel, clinically relevant tools for pathology market including: monoclonal and polyclonal antibodies, a wide range of detection systems and ancillary reagents for high quality immunostaining. Custom Monoclonal and Polyclonal Antibody Production Services include peptide synthesis, in vitro and in vivo antibody production, purification and conjugation. Diagnostic BioSystems is an FDA registered medical device manufacturer, operating under FDA 21CFR Part 820 Quality System Regulations and certified under ISO 9001:2008 Quality Management System International standards, manufacturing CE marked medical devices, for use in the European market.

DLS is proud to be Hawaii's largest locally-owned clinical testing laboratory with a team of 800+ dedicated professionals. Our Microbiology Lab is the only clinical laboratory in Hawai'i with the WASPLab, a highly advanced specimen processor. Our Core Lab features a chemistry automation line that is the largest of its kind in the state. It also utilizes mobile robots that efficiently deliver samples between processing stations. We know that when it comes to the wide variety of lab tests we perform, quick, accurate results and analyses improve health and save lives. At DLS, we are committed to excellence in laboratory science and stand by our guiding values, I.C.A.R.E.: I - Innovation C - Care A - Aloha R - Respect E - Excellence We work closely and collaboratively with physicians, medical groups, hospitals and clinics. Our employees are what makes DLS a successful company and we strive to provide an environment of growth and professional development for our versatile and high-performing workforce. Beyond lab results, we build relationships and create collaborative partnerships with the communities we serve. No matter what your position is at DLS—medical technologist, medical laboratory technician, technical laboratory assistant, phlebotomist, systems engineer or patient account representative—your role will impact patient health. When it comes to living in Hawai‘i, we at DLS are committed to making our newest members feel at home with guidance and support. We believe in a healthy work-life balance, and we want our team members to take full advantage of our islands' natural beauty and great year-round weather.

We manufacture Vision electrophysiology testing equipment for detecting eye diseases and sold mainly to hospital and eye doctors. Based in the USA, we create the leading solutions for electrophysiology for all your needs in hospitals, research and drug trials

DiamiR developsand diagnostictechnology based on analysis of brain-enriched microRNA biomarkers in blood plasma.

Diazyme uses its proprietary enzyme technologies to develop diagnostic reagents which can be used on most automated chemistry analyzers in user-friendly formats. Diazyme's products include test kits for diagnosis of cardiovascular disease, liver disease, cancer markers, renal disease, diabetes, and electrolytes.Diazyme DZ-LITE SARS-CoV-2 IgG, IgM CLIA Kits

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

Digital Diagnostics is an Iowa-based AI diagnostic platform that offers solutions such as image analysis and EMR integration for the healthcare industry.

A DK Diagnostics®, fundada em 2004, é fabricante exclusiva do Sistema Parasitológico PARATEST®, reconhecido pela Organização Mundial da Saúde (OMS) como uma das 8 tecnologias mais inovadoras do mundo. Com objetivo de fornecer soluções definitivas para a área diagnóstica, a DK é uma empresa global que possui produtos presentes em mais de 35 países ao redor do mundo e com mais de 45 milhões de testes vendidos.

DNA Diagnostics Center is a biotechnology company that specializes in paternity DNA testing and forensic DNA analysis.

DNA Diagnostics Center is a biotechnology company that specializes in paternity DNA testing and forensic DNA analysis.

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

Domus Diagnostics is working to create infectious disease diagnostic tests that are affordable, user-friendly, accurate, and rapid enough to address the needs raised by current and future public health crises.

DotLab measuresdisease-specific biomarkers and appliesadvanced biostatisticsfor non-invasiveendometriosis​ testing. ​​​​​​

At Drawbridge, we’ve created the OneDraw™ technology to transform the way blood is sampled and shipped. But that’s just the start. Our ultimate goal? To give everyone, everywhere access to the powerful health information within their own bodies.

DRG International, Inc. is a leading specialty medical diagnostics and equipment manufacturer, and distributor with operations in more than 110 countries. As a global innovator of high-quality medical diagnostics and equipment, DRG International, Inc.'s mission is to provide the medical and research community with cutting edge, effective tools to build a healthier future. DRG® offers various laboratory immunodiagnostic products and equipment. In addition, DRG®, in cooperation with major U.S. and foreign suppliers, is a leading distributor for cardiac, electrophysiology, and angiology equipment and supplies in certain markets. DRG® provides a complete range of services including delivery, customs clearance, installation, on-site training and technical support as well as after-warranty service.

We're building scalable low-cost, high-performance diagnostics for infectious disease in communities, starting with Tuberculosis. Our mission is to create large scale diagnostics that can be used to test large samples such as those from food, water, environments and air to prevent infectious disease outbreaks. For all 7 billion of us.

Droplet has pioneered a platform to harvest and profile patient lymph through the routine collection of surgical drain fluid.

Diagnostics

Dynocardia is a biomedical device development company committed to satisfying critical unmet needs to improve healthcare worldwide. ViTrack™, our lead diagnostic device, is powered our proprietary technology making it the only stand-alone, cuff-less device that allows for continuous, non-invasive blood pressure (cNIBP) measurement. Unlike conventional occlusive devices, ViTrack offers direct, beat-to-beat measurement of blood pressure that is wrist-wearable, mobile, and easy to use, with the accuracy of intra-arterial lines. ViTrack, with data-rich capability that includes heart rate, heart rhythm, and respiratory parameters in addition to blood pressure, enables early intervention prior to acute events.

Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by Andreessen Horowitz's Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast’s prime biotech hub in South San Francisco.

Echosens is a healthcare technology company that specializes in non-invasive diagnostic tools for assessing liver health.

Edan is a healthcare company dedicated to improving the human condition around the world by delivering value-driven, innovative and high-quality medical products and services. For over 20 years, Edan has been pioneering a comprehensive line of medical solutions that address a broad range of healthcare practices including Diagnostic ECG, OB/GYN, Ultrasound Imaging, In-Vitro Diagnostics, Patient Monitoring, Point-of-Care Testing, and Veterinary. Healthcare professionals around the world depend on Edan's breakthrough medical technologies and outstanding customer support. Till now, EDAN has reached over 170 countries and areas and 40,000 medical facilities with Industry Leading Healthcare solutions.

EDDA Technology, Inc. is an innovative leader in the rapidly growing field of imaging-guided cancer treatment. By adopting a fully quantitative, real-time interactive approach to imaging analysis, simulation and guidance, our next generation computer-assisted radiology and surgery solutions go well beyond advanced 3D image visualization. The award-winning IQQA® platform supports a patient-specific, disease-targeted, and multi-disciplinary approach to cancer treatment. With exceptional ease-of-use and clinical versatility, it facilitates efficiency and precision in treatment planning, guidance, monitoring, and follow-up. The IQQA® platform provides targeted solutions to assist physicians in advanced clinical applications including: fast 3D quantitative analysis and visualization, highly automated volumetric organ/lesion segmentation & quantification, pre– & post–operative assessment, treatment planning & simulation, procedural guidance and monitoring, and Computer-Aided Detection (CAD).

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

At Elanco, we work to improve the health of animals through innovative products and services for pets and farm animals around the world. As a global animal health company, we provide solutions that empower our customers to advance a vision of Food and Companionship Enriching Life. Since 1954, Elanco has committed to empowering veterinarians, farmers, and all those who care for animals with the tools they need to help animals live healthy lives. Healthier animals are the key to making our lives better - This is the fundamental belief uniting all global Elanco employees. That's why we are committed to the idea that our business can be a unique force for good for all in society. Through our Elanco Healthy Purpose™ framework of Environmental, Social and Governance (ESG) commitments, we focus on delivering sustainable solutions to advance the well-being of animals, people and the planet. This program also enables our employees around the world to take paid time off to make an impact as a volunteer, offering their time or talent to give back to our customers, causes and communities. #ElancoHealthyPurpose #WeAreElanco

Elephas is a biopharmaceutical company focused on developing an oncology imaging diagnostics platform to predict response to immunotherapy using the latest advances in metabolic and ex-vivo technology. The company is also building an instrument platform that will inform how clinicians treat cancer patients by interrogating live human tumors ex vivo.

ELITechGroup MDx, part of Bruker Corporation, is a leading provider of molecular diagnostics solutions, designed to meet the diverse and growing needs of laboratories worldwide. Headquartered in Turin, Italy, at ELITechGroup SpA, it serves as a key center for manufacturing, logistics, and business operations, making it one of the most prominent molecular biology hubs in Europe. Over the years, ELITechGroup MDx has developed a comprehensive suite of PCR technologies, including the revolutionary Minor Groove Binder (MGB). In 2016, ELITechGroup revolutionized molecular diagnostics with the introduction of ELITe InGenius, its first fully automated sample-to-result (S2R) system. Since then, the company has continued to expand the platform's capabilities, offering nearly 60 CE-IVD parameters and validating over 20 different sample matrices. Building on this success, ELITechGroup launched ELITe BeGenius in 2021, its second S2R platform, further solidifying its commitment to delivering superior workflow efficiency and guaranteed performance. With a robust pipeline of assays, instruments, and software, the company ensures that laboratories remain at the cutting edge of molecular diagnostics. All its products meet the highest global quality and regulatory standards and are fully compliant with the latest IVD regulations. ELITechGroup MDx is certified by DEKRA Certification BV and operates under a stringent quality management system in compliance with ISO 9001:2015 and EN ISO 13485:2016 standards according to the Medical Device Single Audit Program (MDSAP). In addition to its extensive product portfolio, ELITechGroup MDx provides expert technical support, including training, on-site assistance, and customized solutions from sample to result, ensuring that laboratories receive the highest level of service and performance.

Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

Emerge Diagnostics is a medical devices company that offers an FDA-registered Electrodiagnostic Functional Assessment (EFA) device for assessing muscle activity and differentiating between acute and chronic injuries.

Empatica is an affective computing company, focused on human data analytics. We develop groundbreaking wearable devices with medical quality sensing. Our technology comprises a set of wristband, software running on smartphone and desktop computing, plus real time syncing with a cloud computing service.

We are a biotechnology company offering end-to-end solutions in molecular diagnostic for oncology and hematology by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with its proprietary software embedded throughout entire workflow, EntroGen solutions are designed to be accurate, economic and scalable. EntroGen sells CRCdx®, a U.S. FDA-approved product.

For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of 20,000 high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company's proprietary products and technologies play central roles in all areas of translational research and drug development, including genomic analysis, protein analysis, cellular analysis, tissue analysis, and small molecule chemistry. Enzo Biochem has a broad and deep intellectual property port-folio, with patent coverage across a number of key enabling technologies.

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices. For more information please contact us at info@epicsciences.com

Epinex Diagnostics is a medical device company that specializes in the development of innovative rapid tests that target major deficiencies in existing healthcare markets. Our proprietary platform for rapid tests uses existing technologies to create unique quantitative diagnostic tests for the point-of-care (POC) and over-the-counter (OTC) markets. The Company’s flagship product is the G1A™ Rapid Diabetes Monitoring Index Test, a patented monthly test for diabetes monitoring. The Test has the potential to improve diabetes care and have a successful impact on the current worldwide diabetes epidemic, the most significant chronic disease affecting the world today. Epinex Diagnostics, Inc. is located in Tustin, California, adjacent to the University of California, Irvine, in the heart of the Southern California biomedical industry.

We are on a mission to build a revolutionary cancer diagnosis platform to solve the challenge of early cancer prognosis and detection, as well as prediction of post-diagnosis cancer drug response.

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection.

Essenlix Corporation is a fast-growing startup company in Princeton that develops a new easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

Ethos Biosciences designs, develops, and manufactures diagnostics that are accurate, repeatable, and easy to use. Ethos Biosciences was formed as a subsidiary of Ott Scientific in 2018 to drive healthcare innovation by providing diagnostic tools for scientists and practitioners. In November 2018, Ethos Biosciences acquired the Exocell diagnostic operation in Philadelphia from Glycadia Pharmaceuticals. Exocell was founded in 1988 by Dr. Margo Cohen, MD/PhD to explore diagnostic and therapeutic solutions for diabetes. Exocell quickly became a leader in nephrology diagnostics with 15 patents and over 2000 research citations. The Exocell brand continues to service the top research, academic, and industrial institutions in the world. Ott Scientific is a family owned and operated group of specialty chemical manufacturing companies with expertise in monomers, polymers, microspheres, and reagents for the pharmaceutical, medical device, and diagnostic industries.

Evergreen Sciences, Inc. is a company that is dedicated to improving public health by developing and marketing accurate molecular and immunological testing systems. Theyoffer analytical testing for safety and quality of food matrices. Their focus is to detect and even quantify the foodborne and waterborne pathogens, monitor and determine nutritional analysis and harmful residues.

Everlywell believes that health tests shouldn't be hard to get – or hard to understand. The Everlywell experience is simple. You order one of our kits online, you collect your sample from home and return it via pre-paid mail to one of our fully-certified partner laboratories. A board-certified physician in your state will review and validate your results before you get them. Everlywell provides a complete, easy-to-read results report online in just a few days. Our comprehensive tests measure key biomarkers through samples that are collected in the comfort of your home. Everlywell empowers individuals by providing easy access to health data. We are proud to offer 30+ consumer-initiated, regulatory-compliant tests…without a lab visit.

Evvy is unlocking precision women's healthcare through novel, overlooked female biomarkers — starting with the vaginal microbiome. Backed by leading healthcare investors such as General Catalyst, Left Lane Capital, and LabCorp, the Evvy team includes leading OB/GYNs and vaginal microbiome researchers with decades of experience at organizations like UCSF, Stanford, Harvard, Cleveland Clinic, and more. Evvy is one of the fastest growing women's health companies in the US — enabling us to deliver innovative, high quality care while scaling novel R&D to unlock a new, data-driven future in women's health. Evvy's Vaginal Health Test is the first at-home vaginal microbiome test to use metagenomic sequencing to tell you what's up down there, why it matters, and what you can do about it. Evvy's larger platform is the first vaginal healthcare service to bring together state-of-the-art testing, precision clinical care, and 1:1 coaching to give women and people with vaginas the care they deserve. Through this platform, Evvy is building real-world datasets that can transform our understanding of complex female health conditions. Imagine a world where female health is finally understood: where risks are detected early and precisely; conditions are defined with specificity and nuance; and diseases are treated with personalization and care. That's the world that Evvy is pioneering.

At Exact Sciences, our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. We're hiring! Our organization offers something for everyone, at all stages of careers and from all backgrounds. Let's take on cancer, together.

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company's proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies. We know that people are our greatest asset and we are rapidly building a rock-star team of talent. Our people are driven by the mission, inspired by the vision of the future, and are committed to living our core values (integrity, openness, teamwork, exploration, and kindness) that connect us to our work and to one another. What We Value Our core values represent what we stand for as a team. This is what we believe in. Everyday, we strive to align our behaviors to these core values in everything we do. Integrity – Our thoughts and actions are true to science and to people. We do the right thing. Openness – We recognize and respect our differences – and embrace learning from them. Teamwork – We are team players who trust and respect each other. Exploration – We are explorers, putting curiosity into action. Kindness – We are kind whenever possible – and we believe it's always possible.

Express Gene Molecular Diagnostics Laboratory is a CLIA CLIA-certified laboratory located in Miami, Florida. Our focus is genetic testing and we offer several important genetic tests, including pharmacogenomics tests. Pharmacogenetic (PGx) testing is a type of genetic test that assesses a patient's risk of an adverse response or likelihood to respond to a given drug. This gives healthcare providers insight into what medications to use for a given condition. The PGx test allows physicians to make informed, science-based drug selections and appropriately adjust the dosing.

Challenges with physical cell isolation limit adoption of single-cell sequencing. So we figured out how to prepare complete libraries within intact cells.

Fibronostics is a healthcare technology company providing algorithm-based solutions in a variety of diagnostic testing areas, focusing on assessing liver disease existence/progression, but also other chronic areas such as coronary heart disease, stroke, diabetes, and obstructive sleep apnea. Fibronostics'​ LIVERFASt products provide early detection and monitoring for patients with NAFLD & NASH when a diagnosis is often missed due to limited screening with low-sensitivity tools. The current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool. Fibronostics'​ HealthFACTR tool employes technology to predict risk, providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease. HealthFACTR enables action-oriented recommendations which allow healthcare professions to determine patients'​ risk levels and drive better patient care.

Welcome to the future of neurological assessments with Firefly Neuroscience’s FDA-cleared Brain Network Analytics (BNA™). Utilizing ADVANCED AI and an extensive proprietary EEG database, BNA™ combines the automatic analysis of Event-Related Potentials (ERPs), spectral EEG, and behavioral performance data for a comprehensive and objective data-driven brain health evaluation.

For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining functional drug testing, genomics, and artificial intelligence to design an individualized treatment plan in a week for each patient. Our technology rapidly grows tumor bulk, more importantly chemo-resistant cells enabling the testing 100s of FDA-approved drugs to measure the cellular response of both cell populations. This is the key dataset for the AI engine, supported by genomics data to identify every cancer weakness and identify which drugs work.

Flagship Biosciences is a leader in spatial biology and biomarker analysis, bringing innovative approaches to clinical research and drug development. The company delivers the most accurate and informative data available in the field of spatial biology and biomarker services.

Fore Genomics, a clinically-focused genetics company, has launched FORESITE 360, a leading-edge product offering clinical-grade, in-depth sequencing for the littlest patients. Focusing on newborns and children, a simple cheek swab sample provides doctors and parents with valuable genetic insight into a child's potential for future diseases based on their DNA. Backed by the reliability of CLIA-certified and CAP-approved labs, FORESITE 360 is designed to offer a complete genetic profile of your child, unlocking a lifetime of health insights. FORESITE 360 incorporates ongoing re-analysis of DNA, allowing doctors to take practical steps toward managing any detected medical conditions. Without adding a single item to their to-do list, clinicians can now add value for their patients with leading-edge sequencing, high-quality genetic counseling, and annually updated analysis.

Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The company has garnered significant partnering interest from multiple pharmaceutical companies in oncology and is poised for rapid growth. Foresight Diagnostics is headquartered in Aurora, Colorado.

Fortis Life Sciences® partners with diagnostics and life sciences companies to design, validate, and manufacture solutions to solve their complex development problems. Fortis’ tailored approach and end-to-end capabilities accelerate the work of its customers as they bring the next generation of medicines and diagnostics to market. Fortis serves a global customer base and has offices across North America including four R&D sites and three GMP and ISO 13485 compliant manufacturing facilities. Fortis offers a world-class portfolio of in-house manufactured and validated reagents and solutions through our industry-leading brands: Abcore, Arista Biologicals, Bethyl, Empirical Bioscience, IPOC, nanoComposix, and Vector Biolabs. We are a single partner with the: - Expertise to solve your most complex development problems. - Flexibility to design and validate solutions. - Scale to meet your manufacturing requirements.

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit us at www.FoundationMedicine.com or follow @FoundationATCG on Twitter. Community Guidelines: bit.ly/FMICommunityGuidelines

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Fry Laboratories, L.L.C. is an independent clinical diagnostic and research laboratory located in Scottsdale, Arizona. We are committed to understanding chronic diseases and contributing to their cure through advancements in diagnostics and basic science research with emphasis on chronic inflammatory diseases, vector-borne diseases, and their intersection. Our clinical diagnostic laboratory offers general and targeted immunology services in conjunction with standard and cutting edge infectious disease detection and identification technologies. Our signature services include microscopy for visual identification and quantification of a wide range of blood-borne pathogens, co-infection serology, biofilm detection, and genus wide molecular detection technology with sequencing for individualized species identification. We participate in both CAP and API quality control programs and provide worldwide testing service.

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT

Products for Third World

We believe in being a catalyst to transform healthcare. We transform healthcare by developing diagnostic solutions that utilize novel insights on disease to innovate the next generation of liquid biopsies. We bridge the gaps between healthcare, patients, and disease. -- **Spam Alert** Please be aware of potential phishing scams imitating FYR Diagnostics. Individuals posing as FYR have created multiple spam domains and contacted individuals, asking for personal and sensitive information to apply for fake job positions. All authentic communications from FYR will be from the fyrdiagnostics.com domain. Future job postings can be verified by visiting our website at: fyrdiagnostics.com Please note that our team will not ask anyone for sensitive or personal information (e.g., credit card details). All correspondence from the FYR team will come directly from a fyrdiagnostics.com email address. Please remain vigilant and report any suspicious activity immediately. Stay safe!

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

We offer advanced diagnostic test solutions that GO BEYOND the limits of detection for low-abundance flea and tick-borne infections, such as bartonellosis and Lyme borreliosis. Our recently launched Nanotrap Urine test is a more sensitive direct detection test method for confirming Lyme disease diagnoses. Learn more on our website.

GenBody is a diversified manufacturer of diagnostic tests for over 78 human diseases. With more than 20 years combined experience in the diagnostic industry and through its vast network between several key institutes, universities and hospitals, our core strength is in R&D. GenBody specializes in developing monoclonal antibodies and recombinant antigens in-house at our facility in South Korea. Recently, the US FDA granted Emergency Use Authorization to GenBody's COVID-19 Ag point-of-care antigen test for SARS-CoV-2 infection. The immunochromatographic rapid diagnostic test is designed for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal swab specimens. The test can be performed by a healthcare professional and an at-home test is in development for future use. Earlier this year, GenBody received a US National Institutes of Health contract for the US production of a visually read, single lateral flow rapid test system for SARS-CoV-2. Located in Jurupa Valley, California, the US factory is expected to be complete in Q3 2021. GenBody is rapidly expanding its footprint in the US and expects to increase its headcount in regulatory, product development and sales. For inquires regarding opportunities join our team, please call 949-561-0664 or jobs@genbodyamerica.com. For partnership opportunities, call 949-561-0664 or email partnerships@genbodyamerica.com.

Gene Bio Medical is dedicated to the research & development, manufacturing, and commercialization of high-precision, low-cost, and effective diagnostic technologies that improve human health and enable the response capabilities towards a variety of diseases. We have a vision to revolutionize the healthcare industry and innovate for the greatness of our community. Founded by a group of talented research scientists, practitioners, and business experts, Gene Bio Medical has rapidly developed into an industry leader in molecular diagnostics technologies. The company manufactures and markets its own products, develops new innovative products, and collaborates with the healthcare ecosystem to bring innovations to people.

Detecting Pathogens Takes Too Long Our patented CAPTURE (Confirm Active Pathogens Through Unamplified RNA Expression) technology solves this problem, and we are now developing a portable instrument to screen for hundreds of pathogens within an hour for less than $20. GeneCapture's unique approach to disease diagnostics uses rapid RNA-based technology to bring infection detection to the Point of Care; whether that's a hospital bed, an airport, a cruise ship, or a battlefield.

GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perou's laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSP™) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP™ was licensed to and independently developed by Laboratory Corporation of America® Holdings ("LabCorp") and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentric's second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.

Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy's lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.

Genetesis is a rapidly growing medical imaging company leveraging data science and biomagnetism in the fight against cardiovascular disease.

Geneticure optimizes prescription drug therapy by using patients’ DNA to guide their blood pressure treatment with a new, actionable tool, supported by clinical evidence to help you provide even better care for your hypertension patients.

A premier research institution providing global genomic profiling and molecular diagnostics services to academic centers, pharmaceutical and biotech industry, oncologists, and pathologists with innovative diagnostic, prognostic, predictive, and personalized testing. Genome Explorations, a Tesis Biosciences company, is a state of the art CLIA certified GLP compliant Lab providing NextGen sequencing, Genotyping, Gene Expression and microRNA profiling services. Our Clients range from Fortune 500 Pharmaceutical and Biotech to Individual Investigators at Academic institutes and are located worldwide. Our experienced scientists work one-on-one with researchers and clinicians to provide a ‘Complete Solution' for all their Research and Clinical needs, from experimental design to in-depth data analysis and advanced bioinformatics. Genome Explorations also offers ‘Complete Solutions' for challenging specimens, such as whole blood and FFPE tissues.

Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression's OneRNA™ test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA's to approved therapies and clinical trials.

Gestalt transforms pathology through an intelligent, configurable, and vendor-neutral, AI-driven, digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. This platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing their invaluable experience where it matters most. *Research Use Only (RUO) unless following CAP guidelines for LDT.

GestVision Inc. is a biotechnology company that is committed to securing safer pregnancies by fearlessly challenging the status quo for women's health. We promise to deliver confidence to healthcare providers to make sound clinical decisions. Our aim is to address the unmet medical needs in women's health by bringing forth premium products based upon robust scientific discoveries.

At Glucotrack, we are pioneers in diabetes technology, dedicated to transforming the way diabetes is managed. Our mission is to develop innovative, long-term solutions that prioritize accuracy and ease of use. With a commitment to reducing the daily burden of diabetes management, we create cutting-edge technologies designed to enhance the lives of those we serve. Join us in our journey towards a future where managing diabetes is simpler, more effective, and empowering.

Glycominds, a commercial stage diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease biomarkers with a distinctive focus on the Inflammatory Bowel Disease (IBD).

Glycotest is Creating the New Clinical Standard for Early Diagnosis and Surveillance of Liver Cancer

Grace Bio-Labs manufactures products for life science research and molecular diagnostics. Our chambers and seals offer rapid setup for containment of samples for staining, imaging, incubation, hybridization, and enzymatic reactions. Sealed chambers of various dimensions offer significant advantages over standard coverslip incubation, and can minimize precious reagent use during assays. Applications for these chambers include proteomic, genomic, tissue and cell analysis. Our portfolio of protein microarray products, including ONCYTE® nitrocellulose film slides and complemenatry reagents for protein microarrays , are designed to work together to provide the highest sensitivity and quantification for protein diagnostics and proteomic studies.

GrapheneDx is designing adevice that willput the power of the highest performing diagnostics in the palm of your hand and the comfort of your home.

We are an advocate for physicians and patients, supporting them with unsurpassed integrity, regulatory compliance, and clinical expertise. Our pledge to deliver the highest professional operating standards in the laboratory service industry coupled with ongoing research and support exemplifies our commitment to being provider engaged and patient focused.

GRIP Molecular is developing a novel, patent-protected, chip-based electronic biosensor that will provide lab-grade diagnostic results in minutes using a mobile device at the point of need. Unlike existing diagnostic technologies, it has the capability to simultaneously detect various diseases and characterize their state of infection (infectious to immune) with a single test. GRIP uses a combination of novel nanomaterials and patented 3D printing to deliver accurate results in minutes without the burden of complex chemistry. The appearance of COVID-19 as a global health threat has increased the urgency to transform diagnostics, which the GRIP team was well into even before this threat emerged. The ability to quickly, easily and cost-effectively test for active infection and immunity at the point of need has become the new baseline for what we should expect for early detection of all kinds of disease, but particularly when fighting a pandemic level enemy. GRIP is committed to confirm the science and commercialize a new approach with a number of specific panels/products that address our most challenging diseases and chronic conditions.

GT Molecular develops ultrasensitive Molecular Assays, Digital PCR and qPCR Tests End-to-End solutions for cancer detection and waterborne pathogens including SARS-CoV-2. Detect as little as 1-3 molecules of target DNA

Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, we're transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext®, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal® for early-stage cancer patients. The Guardant Health screening portfolio, including the FDA-approved Shield™ test, aims to address the needs of individuals eligible for cancer screening. Important Note for Job Applicants: Guardant Health is aware of recruiting scams where unauthorized individuals use the company's name in fraudulent emails, job postings, and social media messages. Please note that Guardant Health will never ask for money or credit card information during the job application process, nor does the company communicate with candidates via online chatrooms or personal email accounts such as Gmail or Hotmail.

Guided is a Georgia-based medical technology company that develops and commercializes non-invasive medical devices for early detection of cancer.

At Harbinger Health, our mission is to change the cancer paradigm by taking a proactive approach to cancer detection and prevention. We envision a future where cancer is no longer a life-altering event, but a routine health problem that can be addressed with early intervention. To achieve this, we have developed proprietary solutions for cancer pre-emption, starting with blood-based tests that can detect cancer before it even becomes visible. By identifying biological programs that are the root cause of cancer, we can enable early-stage and pre-disease identification, leading to truly personalized and effective cancer care for everyone. With Harbinger Health leading the way, we believe that a cancer-free future is not only possible but within reach, for everyone.

Hardy Diagnostics offers products and services related to microbiology. The company's products are used in pharmaceutical microbiology, food and beverage microbiology, and clinical microbiology.

Healgen Scientific is a leading global IVD developer and manufacturer focused on delivering life-changing diagnostic products for patients worldwide. For over 17 years, we have strived to provide world-class products and services across multiple healthcare sectors, such as Infectious Diseases, Toxicology, Fertility & Women's Health, Oncology, Cardiovascular, Metabolism, and more. As a highly trusted healthcare partner for over 140 facilities, we develop state-of-the-art devices that exceed industry standards and redefine healthcare, and our portfolio spans multiple testing platforms.

Molecular Diagnostics

Helena Laboratories is a clinical laboratory instrument and reagent manufacturer. Our clients include major medical centers, small hospitals, large reference laboratories and small private doctor's laboratories. Corporate headquarters, located in Beaumont, Texas (a major port city 80 miles east of Houston) is comprised of over a quarter million square feet of research, manufacturing, inventory, engineering and administrative facilities. Approximately 75 field specialists are located in major cities throughout the United States. Helena has been awarded the U.S. Secretary of Commerce "E"​ Award for excellence in contribution to the American economy through export operations. With hundreds of laboratory products and more than 40 registered patents, Helena continues to be a market leader in the development of new diagnostic tests.

Heligenics is a life sciences company that has developed proprietary technology, which shows the impact of genetic mutations to revolutionize genetic testing and drug development for major diseases. We are the first company to develop High Content Screening for Biologic Drugs, previously the mainstay for the development of small compound drugs. As the effect of most mutations on gene function is largely unknown, Heligenics comprehensively measures the functional significance of mutations in the human genome through a massively parallel in-vitro process called the GigaAssay, measuring the impact of all potential amino acid substitutions in the functional target protein, doing in a few months what would take many years to do if at all. For cancer diagnostics companies, our functional data enables improved genetic test interpretation, and for pharmaceutical companies, we empower the conversion of generic drugs into targeted precision medicines or can rescue a failed drug candidate through the identification of variants for a redesigned genetically stratified clinical trial. Explore more! Email: mschiller@heligenics.com Website: Heligenics.com LinkedIn: linkedin.com/company/heligenics-inc/ Twitter: twitter.com/heligenics

HelixBind is working to revolutionize care for invasive infections such as sepsis. Our novel diagnostic platform provides faster, more accurate, and more informative microbiology results direct from blood, assisting clinicians in identifying bloodstream infections and developing personalized antimicrobial interventions.. Our approach can improve outcomes, save lives, and reduce the spread of antimicrobial resistance.

Hememics uniquely uses graphene-based sensors with our patented bio preservatives to bring handheld, lab-quality testing performance to wherever needed – whether it is a farm, emergency room or battlefield. Our rugged, low-cost platform consists of a portable, easy-to-use reader utilizing a single-use biochip with 32 sensors. Our sensors can be individually programmed to detect molecular, antigen and antibody targets. We put a whole lab in your hand so you can make decisions when and wherever necessary – simplifying workflows with results within minutes.

Hemex Health focuses on commercializing proven research into cost-effective, intuitive devices optimized to make diagnostics more accessible at the front lines of healthcare. Our products are designed to be easy to use and provide benefit quickly and effectively for the healthcare worker and patient on the ground, at the point-of-need. The company's leaders, with backgrounds in international business and biomedical engineering, have decades of success in developing and delivering more than 60 products that have made a difference in people's lives. We leverage our experience in building successful medical products to solve major needs in global health. Our low-cost technologies are targeted for the developing world and can impact millions by identifying diseases which can be affordably treated. Hemex is developing a diagnostic platform (utilizing technology which received a 2016 Patents for Humanity Award) that can quickly and easily diagnose hemoglobin disorders, such as sickle cell disease and beta thalassemia, from a drop of blood. The solution provides point-of-care access to diagnostic information faster, more cost-effectively, and more accurately than any solution on the market today. Hemex is an equal opportunity employer. All employment-related decisions are based solely upon one's individual merit and qualifications directly related to professional competence, and without regard to race, color, religion, national origin, pregnancy status, sex (gender}, age, marital status, mental or physical disability, sexual orientation, gender identity, military or veteran status, genetic history, or any other characteristic or classification protected by applicable law. We will also attempt to reasonably accommodate an individual based on his/her physical or mental limitation or because of the individual's sincerely held religious beliefs.

HemoSonics is breaking new ground in point-of-care Viscoelastic #hemostasis testing. When time is critical, the Quantra® QPlus® System offers rapid, accurate, and easy to understand results that enable clinicians to make more informed #transfusion decisions, more quickly. This novel, cartridge-based POC VET system now has De Novo marketing authorization in the USA and is intended to assess the coagulation status of perioperative patients at the point of care. Follow us at @HemoSonics

Hera Biotech is developing and commercializing a non-surgical test for endometriosis diagnosis and staging.

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

Histologics has developed a series of Tissue-Based Technology™ products that leverage the benefits of our patented Kylon™ medical material. Kylon™ medical material incorporates hundreds of "micro-curettes" which are incorporated into single-use, disposable devices used for biopsy as well as wound care and debridement. Kylon™ is common to all Histologics single-use, disposable devices and offers distinct benefits over legacy "metal" devices and procedures. Within the Gyn field, Kylon™ is rapidly expanding use in epithelial curettage and colposcopy procedures, where Kylon™ yields tissue samples that rival more traditional, invasive techniques using antiquated metal cutting tools, whose use and success are subject to sharpening, sterilization, and general management (cost of use). Kylon™ is designed with the patient, physician, and pathologist in mind. Our devices are minimally invasive, yet yield tissue samples that statistically compare to your current methodologies. The use of Kylon™ devices is also rapidly evolving in the field of wound care and debridement. Kylon™ devices enable debriding with more control and less trauma than a scalpel or curettage techniques. Kylon™ also provides another key benefit to impart agitation to the underlying tissue. This agitation through micro-punctation of the wound site, along with the associated friction which produces small amounts of heat, works to stimulate new tissue development, which may lead to faster more comprehensive healing in less time (and less patient trauma when compared to scalpel-based procedures). Visit www.Histologics.com (GYN) or www.HistologicsWC.com for more information. Watch our videos (below). Fill out our sample request form today! Dr. Neal Lonky, MD MPH is nationally recognized for his work in female health, where he specializes in early cancer detection.

We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives. None of this would be possible without the talent, skills and aspirations of our employees. Their expertise and dedication to developing and sharing more robust, science-based certainty drives our increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families and communities. What powers our growth across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market access. Our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses. We work toward this goal every day, always aware that in an increasingly complex and competitive global environment, we must continually earn the trust of our customers and their patients. By focusing on women’s health while still delivering health benefits to everyone, we are setting a new standard of excellence that is strengthened by purpose, driven by passion and brought to life by our promise of more certain early detection and better health outcomes. To view our community guidelines, visit: www.hologic.com/social-media

Human Longevity, Inc. ™ (HLI) is the genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries from these data to generate personalized health insights. Our goal is to extend healthy human life by revolutionizing human health and transforming the practice of medicine. Our DNA determines so much about each of us, but other factors can also influence our health. HLI is focused on compiling and analyzing more genotypic and phenotypic data because the combination of both enables us —to generate unprecedented insights and accelerate our understanding into what makes us who we are and what we can change for a life better lived.

Founded in 1981, HYCOR Biomedical is a global manufacturer and marketer of in vitro diagnostic products. Since its founding, HYCOR has served the allergy diagnostic testing needs of clinical laboratories, hospitals and doctors'​ offices worldwide. The recently launched NOVEOS™ builds upon 40 years of experience in specific IgE testing, and supplements the Company’s existing line of HYTEC® products. The company is focused on delivering NOVEOS, a new generation of fully-automated allergy system that solves the shortcomings of today's technology, with 1/10th the sample requirement and negligible interference issues. For more information, please visit www.HYCORbiomedical.com.

Hygiena delivers rapid microbial detection, monitoring, and identification solutions to a wide range of industries, including food and beverage, healthcare, hospitality, pharmaceuticals, and personal care. Utilizing advanced technologies and patented designs, Hygiena provides industry-leading ATP monitoring systems, PCR-based pathogen detection and characterization systems, allergen tests, environmental collection devices, and more. Hygiena is committed to the mission of providing customers with high-quality innovative technologies that are easy-to-use and reliable, backed by excellent customer service and support. Headquartered in Camarillo, California with multiple offices around the world including Wilmington, Delaware, United Kingdom, Spain, Canada, Mexico, Australia, Brazil and China, and over 180 distributors in more than 100 countries worldwide, Hygiena branded products span the globe.

The Swoop® system brings MR brain imaging within reach. Our mission is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world's first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020. It is a portable ultra-low field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

At iCAD, we believe that is possible to create a world where cancer can't hide. Leveraging the power of artificial intellegence (AI), we empower healthcare providers to more accurately, reliably, and quickly detect disease and improve outcomes. The ProFound Breast Health Suite offers a comprehensive portfolio of clinically proven AI technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation providing certainty and peace of mind - Optimizing every patient's opportunity to live better, longer lives! To learn more, visit www.icadmed.com.

Rapid Syndromic Testing for All Labs The mission of iCubate® is to provide rapid, accurate and affordable syndromic testing to all laboratories to ensure care providers have the right tools to improve care and outcomes for their patients. The iCubate® team has developed the iC System™, a low-cost, fully automated, molecular diagnostic platform using armPCR technology, along with a suite of syndromic infectious diseases panels, including sepsis/positive blood cultures, upper / lower respiratory tract infections, GI, mycobacteria, and more. Why iCubate for your lab? • Rapid syndromic testing for infectious diseases for better care, sooner • Affordable system increasing accessibility for large and small labs • Multiplex assay with high target specificity and sensitivity for actionable results • 3 minutes of hands-on time with routine lab processes Twitter: @iCubate FDA Cleared Products iC-System™ (iCubate’s platform) iC-GPC Assay™ for Gram positive cocci Anticipated clearance 2019 iC-GN Assay™ for Gram negative rods Robust Assay Pipeline GI, Respiratory, Mycobacterium

Welcome to the cutting edge of spatial biology and translational research! We're a specialized Contract Research Organization (CRO) and a CLIA High Complexity-certified, CAP-accredited clinical diagnostic laboratory, dedicated to empowering your scientific pursuits! Our focus lies in the field of spatial biology, spatial phenotyping, tumor micro-environment mapping, multiplex immunofluorescence (mIF), IHC, histology, digital pathology, digital and quantitative PCR (dPCR and qPCR), as well as next-generation sequencing (NGS). We use cutting-edge equipment to provide next-generation tissue pathology services, including high-resolution imaging and comprehensive analysis of tissue samples. Our collaborators include scientific teams across the drug development pipeline. Whether you're trying to identify predictive biomarkers or stratify patients, we can help you study the intricate interplay between cells and their surroundings, unlock insights into disease mechanisms, and uncover novel targets. Our team of experts can provide you with end-to-end support including method development and validation, sample testing, regulatory compliance, and clinical trial logistics.

IGENOMIX USA is a biotechnology company that specializes in genetic testing services for reproductive health and fertility.

Ikonopedia is a next-generation breast radiology reporting and patient tracking system. Our closed-loop system is automated to track and monitor patients to full resolution of all clinical concerns. Clinical reports are clear, consistent, and 100% compliant with the ACR BI-RADS® Atlas 5th Edition. Ikonopedia is MQSA-compliant and offers screening and diagnostic modalities that will improve patient safety and save valuable time for the radiologist and staff.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

Imagion Biosystems is dedicated to providing tools to find and eliminate cancer. We are a multidisciplinary team with expertise in the physics of magnetic fields and nanotechnology and the medical application of these fields. Our focus is in the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Our technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention. Our proprietary technologies and methods employ magnetic nanoparticles targeted towards cells associated with cancer and other diseases and provide the ability to detect these cells using highly sensitive magnetic sensors. These methods have numerous preclinical and clinical applications. Preclinical research projects have focused on the early detection of breast cancer, ovarian cancer, and prostate cancer.

Immucor is a Georgia-based healthcare technology company that develops transfusion and transplantation diagnostic equipment for hospitals and clinical laboratories.

Since 1976, Immunalysis Corporation has focused on identifying and meeting the demands of the toxicology marketplace. With an expansive line of ELISA and Homogeneous Enzyme (HEIA™) assays, plus Quantisal™ – Immunalysis' proprietary oral fluid collection device, as well as automation tools and confirmation support, Immunalysis provides forensic toxicologists with powerful, comprehensive drug testing solutions.

immunArray is a molecular diagnostics company that is engaged in developing novel blood-based tests to support the diagnosis and management of autoimmune diseases.

Immune IQ has developed, in collaboration with Honeywell, the Immune Reveal platform. It reads disease information from a patient's immune system in 5 minutes to rapidly identify critical diseases, many not detectable today. Our powerful diagnostic approach has a much lower cost-per-test, a greater range of disease identification, and a shorter time to results than other cellular- and mRNA-based approaches. Immune IQ's initial focus is sepsis, one of the world's greatest healthcare challenges.

Quality is our Heritage - Service is our Passion Immuno Concepts is a privately hold company that specialises in the manufacturing of in vitro diagnostics for Autoimmune Diseases since 1980. Our product portfolio comprises reagents and instrumentation such as a unique automatic microscope scanning system for immunofluorescent slide tests. Hospital labs all over the globe and major lab chains trust in our quality and service.

Aristo Vojdani, PHD, MSC, CEO Immunosciences Lab. Inc. located in Los Angeles is part of the Medical and Diagnostic Laboratories Industry.

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, we focus on critical life threatening diseases such as COVID-19, HIV/AIDs, lung cancer, breast cancer, bladder cancer, HPV/cervical cancer, head and neck cancer, ovarian cancer, hepatitis, and organ transplant infections. Our proprietary diagnostic method provides specific molecular details about each and every cell. This technology now made available through IncellDx, is capable of revolutionizing the field of molecular diagnostics, one cell at a time.

Indica Labs is a digital pathology company that specializes in advanced software solutions for medical imaging and analysis in the field of healthcare technology.

Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology. The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. *Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Inform Diagnostics, a Fulgent Genetics Company, is a leading pathology laboratory trusted by clinicians throughout the U.S. We provide timely, accurate and definitive patient diagnoses in the fields of dermatopathology, gastrointestinal pathology, hematopathology, neuropathology, breast pathology, molecular diagnostics (Covid-19 testing), and genitourinary pathology. Working for Inform Diagnostics means you will contribute alongside top multidisciplinary talent in an environment with cutting-edge tools and breakthrough technologies. It is a place where people are passionate in their belief that every patient deserves the right answer. Driven by an unwavering dedication to quality, Inform Diagnostics profoundly impacts patient care, one diagnosis at a time. The company has state-of-the-art laboratories in Boston, Dallas, New York City, and Phoenix. Visit us at informdx.com.  

InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. InfraScan Inc.'s patented NIR technology for diagnosing brain hematomas enables neurosurgeons to effectively, conveniently, and accurately detect intracranial bleeding in patients with Head Trauma.

Ingenio Diagnostics (ID), a Genesis Drug Discovery and Development (GD3) Member Company, combines experience in Pharmaceutical, Biotechnology, and CRO services with a clinical diagnostic laboratory's licensure and accreditation. We deliver clinical diagnostic laboratory services and specialty testing with the additional benefit of dedicated quality assurance & quality control division. Our highly-skilled team of scientists, clinical, and operations personnel have extensive experience analyzing a wide variety of patient specimen types, spanning multiple analytical platforms in many therapeutic areas.

The OcuCheck is a point-of-care device that uses a specialized electrical chemical sensor with proprietary coatings to measure specific biomarkers in the tear film Currently, the OcuCheck is the only device that can simultaneously measure MMP-9 and tear film osmolarity in one device. It is also one of the most accurate devices for quantitative measurement of MMP-9.

Insight Genetics provides advanced diagnostic solutions that enable personalized cancer care and improve patient outcomes. We have a portfolio of assays that detect specific cancer biomarkers and an innovative platform technology for assay development. Our products and services have application in translational research, clinical diagnostics and drug discovery.

Integrity Laboratories is a leading healthcare technology organization with a passion for precision medicine through molecular diagnostics. Our singular purpose is to enable clinicians, through advanced technologies, to improve patient outcomes while lowering total costs of healthcare delivery. We partner with the most trusted providers, healthcare systems, and payer networks to improve healthcare for all through high complexity, rapid clinical diagnostics.

Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery. Integro Theranostics was born out of a collaboration between Kingdom Capital (values based private investment company) and Washington University School of Medicine. We are combining the clinical infrastructure of a top research medical center, the technology of a world renowned scientist, and the resources of Kingdom Capital to commercialize this transformative technology and improve surgical outcomes for cancer patients.

Interpace Biosciences develops molecular diagnostic tests under the brand Interpace Diagnostics, and provides clincal trial services under the brand Interpace PharaSolutions.

InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.

Intrinsic LifeSciences LLC provides superior, innovative & patent-protected research test kits and certified diagnostics & clinical research CLIA services for hepcidin and erythroferrone (ERFE), the key indicators of anemia, inflammation and pregnancy disorders. Our CAP accredited clinical lab, IntrinsicDx™, offers the Intrinsic Hepcidin IDx™ Test service. We also provide RUO immunoassay testing for other related biomarkers. To learn more visit www.intrinsicdx.com, www.intrinsiclifesciences.com.

Invivoscribe® is a global leader dedicated to Improving Lives with Precision Diagnostics®, advancing the quality of healthcare by providing innovative products and clinical services for oncology. Our Streamlined CDx® (companion diagnostic) model accelerates the development of novel therapeutics, enabling personalized approaches to patient care. With products manufactured in our state-of-the-art cGMP facility, we provide a comprehensive range of platform agnostic assays, reagents, controls and software for clonal gene rearrangements, translocations, gene mutation testing, and measurable residual disease (MRD). Invivoscribe’s products consistently surpass industry and regulatory standards and play a crucial role in identifying, stratifying and monitoring hematologic cancers, enabling scientific advancements and empowering clinicians to make informed treatment decisions. Our subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM®), offers extensive clinical diagnostic and biopharma services for the detection and monitoring of myelo- and lymphoproliferative disorders. The LabPMM network performs globally standardized flow cytometry and molecular testing services for pharmaceutical and healthcare organizations, providing results that are critically important for patient care in the U.S., Europe, and Asia. Join us in our mission to revolutionize oncology diagnostics and improve patient outcomes worldwide. Visit our website to discover how Invivoscribe’s ecosystem is driving advancements in precision medicine.

Ionetix is a Michigan-based medical device firm that designs and develops cyclotron technology-based radioisotope equipment for cancer diagnosis and therapeutic applications.

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.

Ipsum Diagnostics is a nationally acclaimed molecular diagnostics laboratory, renowned for its expertise in identifying infectious disease pathogens and antibiotic resistance genes. Our molecular panels leverage the power of polymerase chain reaction (PCR) technology and provide fast results for more effective treatment that leads to improved patient outcomes. Located in Atlanta, GA, our state-of-the-art laboratory specializes in molecular and anatomical pathology. We accommodate workflow needs by providing services such as customized reports, statistical analysis of patients with different treatment plans, and meaningful data to assess overall treatment performance amongst patient populations. Our comprehensive and succinct patient reports can be made available via EMR integration, portal access, fax, or our easy to use mobile or tablet app. Ipsum's software capabilities allow for a superior customized experience, with the highest quality standards that will have your reports completed promptly and efficiently. Ipsum Diagnostics creates a true partnership environment between Provider, Patient, and Laboratory. For locations needing a UPS pickup please follow the below instructions: 1. Call (800) PICKUPS 2. When prompted reply "Schedule a pick"​ 3. You will be asked for your phone number 4. Be prepared to have tracking number ready to provide 5. Provide address of pick up with a time frame UPS Phone Center Shortcuts: https://www.ups.com/us/en/contact/ivr-Popup.page?

Isabl integrates the whole genome and transcriptome to inform cancer care

JAJ International, Inc is a worldwide leading company in the rapid one-step diagnostic industry. Founded in 1998, our scientists have developed extraordinary lines of products, many of which hold unique patents. JAJ International develops, manufactures, and markets a wide array of one-step diagnostic test kit, including Cardio markers, Infectious diseases, Drug abuse, Sexually transmitted diseases, Pregnancy and Fertility etc. Pioneered in technological breakthroughs, JAJ is the first, and in many cases the only, company who can achieve rapid tests of equal or better quality than the equivalence in Elisa tests. After many years of Research and Development and many technological breakthroughs, JAJ International is poised to take a leadership position in the Rapid Diagnostic Market.

JBS Science is a biotechnology company that specializes in developing circulating cell-free DNA (cfDNA) in urine technology for improved cancer screening and management through liquid biopsy.

Baylor College of Medicine is a health sciences university that creates knowledge and applies science and discoveries to further education, healthcare and community service locally and globally. Located in the Texas Medical Center, Baylor College of Medicine has affiliations with eight teaching hospitals, each known for medical excellence. The college has total research support of over $400 million annually, and more than 90 research and patient-care centers and units. Currently, Baylor College of Medicine trains more than 3,000 medical, graduate, nurse anesthesia, physician assistant, orthotics and prosthetics and genetic counseling students, as well as residents and post-doctoral fellows.

✨ Journey Biosciences is on a mission to shift the future of care. 🧬 Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass™, to offer up to 12 years of advanced diabetes-related kidney disease (DKD) detection, plus tailored intervention strategies to slow or prevent progression. 🎯 This approach improves patient outcomes, optimizes resource allocation, and reduces costs. 🔍 Discover more about our transformative approach at journeybio.life.

JuneBrain is an early start-up company based in the Washington, DC area. Our mission is to develop a telehealth eye-scanning system that allows clinicians to monitor patients with eye and brain disease outside of the traditional clinical setting, leading to earlier detection of new disease and improved monitoring of treatment efficacy. Though our mission begins in the eye care community, our long-term goal is to extend the use of our device into the broader neurological disease population, thus creating a pathway towards more frequent, widely accessible monitoring of eye and brain health.

Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to your lifestyle.

Kansas State University, often referred to as K-State, is an institution of higher learning located in Manhattan, Kansas, in the United States. A branch campus, including the College of Technology and Aviation, is located in Salina, Kansas. A third campus, K-State Olathe, officially opened on April 26, 2011 and will be the academic research presence within the Kansas Bioscience Park. Kansas State has nearly 24,000 students from all 50 states and more than 100 countries. Social Media User Policy at https://www.k-state.edu/social.

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

K.C. Pharmaceuticals, Inc. is committed in meeting the requirements of the Current Good Manufacturing Practices (CGMP) laid out in the Code of Federal Regulations (CFR) issued by the US Food and Drug Administration (FDA). We are devoted in producing finished pharmaceuticals and medical devices that uphold high quality standards in today's consumer market. As part of our ongoing efforts in maintaining compliance, we have been keen in implementing many systems and procedures designed to improve product quality and ensure customer satisfaction. Since our manufacturing paradigm is "Building Quality Into Products," we have various internal quality control and quality assurance checkpoints through audits, inspections, reviews, and tests to guarantee that all quality requirements have been met.

KDx Diagnostics Inc. pioneers the revolutionary URO17®bladder cancer test, poised to redefine non-invasive detection. As the co-inventor and exclusive licensee of this groundbreaking technology, KDx Diagnostics Inc. has garnered FDA Breakthrough Device Designation, CE-IVD certification, and MHRA approvals for the URO17® test. With extensive testing on thousands of samples and validation through respected peer-reviewed journals, URO17® demonstrates improved sensitivity and specificity as compared to other diagnostic tests and procedures. The URO17® urine test presents a compelling alternative to invasive diagnostics and costly imaging techniques for routine monitoring in the US, while diagnosis and monitoring for outside USA of bladder cancer, potentially setting a new gold standard in bladder cancer diagnosis and monitoring.

Kephera Diagnostics is a startup that aims to address the public health challenges of global infectious diseases with point of care assay technology.

Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and the NCI. We are conducting robust clinical trials to fully demonstrate the power of our approach and earn widespread adoption for a broad portfolio of products predicting response to today’s and tomorrow’s therapies. www.kiyatec.com

Know Labs is transforming non-invasive medical diagnostics. The proprietary technology platform uses radiofrequency (RF) dielectric spectroscopy and can be integrated into a variety of wearable, mobile, or bench-top form factors. The first application is a non-invasive continuous blood glucose monitoring device that will provide the user with real-time information on their blood glucose levels, assisting billions of people with diabetes and prediabetes to manage this medical condition. Know Labs is a public company whose shares trade under the stock symbol KNW (NYSE American).

Koios DS™ is a Smart Ultrasound™ solution for radiologists diagnosing cancer. Using AI algorithms trained on tens of thousands of images combined with data from pathology results, Koios DS™ is clinical decision support for a new era of diagnostic excellence. Smart Ultrasound™ redefines what radiology professionals can discern in the radiology suite. Our proprietary technology and patented methods provide an invaluable “second opinion” that is already being adopted by leading healthcare institutions to improve diagnostic accuracy, speed clinical decision making, and elevate the quality of care. Our software is FDA cleared for use in the USA. Koios DS. We put the AI in ultrasound.

KromaTiD, Inc. provides products and services for mutation detection and disease diagnosis. KromaTiD’s patented dGH™ chromosome imaging platform enables detection of all types of chromosomal rearrangements including previously undetectable cryptic inversions.

Kryptos Biotechnologies is a Life Science startup based in the San Francisco Bay Area. The company uses light to generate heat and control temperature, and provides innovative life science systems that reveal the complexity of biology for clinicians and scientists.

Proprietary applications in diagnostics and therapeutics. International technology development. Translational medicine impacting Immunology, Oncology and Genomics.

Kurin® is a privately held, certified minority owned business dedicated to engineering better healthcare through innovative, cost-effective, clinician-approved technologies. Building on the successful invention, clinical adoption, and corporate acquisition of Curos™ disinfecting port protectors, Kurin is focusing its depth of experience in medical device engineering, marketing, sales and service, to tackle the persistent and costly fallout of false positive blood cultures. With agile development capabilities and intense customer focus, we have seen the Kurin Lock® with Flash Technology quickly gain caregiver acceptance, sideline skin contaminants during blood culture collection, and become the blood culture collection standard of care in hospitals. Curos™ is a registered trademark of 3M Corporation.

Kwokman Diagnostics was founded and developed to help the fast paced sports broadcast industry return to work through accurate and quick results COVID19 testing. Through the initial journey and scope, we realized that a variety of companies would benefit from rapid turnaround results. Therefore we partnered with a number of labs, healthcare workers and logistics companies to ensure an end to end solution for any industry.

L2 is a biotechnology company based in New Haven, Connecticut, USA with focus on new small molecule therapeutics, vaccines, and diagnostics

L7 Informatics provides a unified data and process platform (L7|ESP™) to streamline and optimize manufacturing, laboratory, and business processes across life sciences and healthcare value chains. The L7 Informatics' Unified Platform L7|ESP, with its Workflow Orchestration and Data Contextualization, meets the organizational needs of any life science organization digitalizing their data and laboratory processes, of which the result is maximized total ROI (return of investment), increased utilization and efficiency, and decreased overall cost. L7|ESP captures routine information in smaller labs, while also driving sophisticated wet and dry laboratory processes across an enterprise organization which requires data and analytics strategies that support LotF (lab of the future). The L7|ESP platform integrates all common data information management systems, including LIMS, Notebooks, and MES, but also other resources such as instrument connectors, sample registration, location, receipt accessioning, logistics, scheduling, inventory, environment monitoring, stability testing, custody of chain, and data analytics. L7|ESP is built by scientists for the life sciences community - relentlessly focusing on serving our customers in research, pharma, and diagnostics with the overall goal of better patient outcome. L7 Informatics is supporting customers around the globe that are tackling some of the most challenging and exciting opportunities in healthcare.

Lab Genomics, LLC (LG) is focused on delivering individualized medical care through molecular and genetic diagnostics.

Laguna Diagnostics, LLC, develops proprietary blood-based, molecular biomarker diagnostic tests for accurate diagnosis of mental disorders and neurodegenerative diseases.

Leica Biosystems is proud to be part of Danaher. Danaher's science and technology leadership puts Leica Biosystems' solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. -- Leica Biosystems Privacy Policy can be found at: https://www.leicabiosystems.com/about/privacy-policy/ The collection, storage, use, disclosure, retention and destruction of data on this page, including any personal data, are all subject, as applicable, to Leica Biosystems' Terms of Use and Privacy Policy. We do not endorse or approve user generated content to promote any other use of our products and will remove any comments or references to such off-label use. We reserve the right to remove a topic or comment at our discretion. By accessing the content, you expressly acknowledge and agree: (1) the content is provided only as a convenience to you and you are accessing the content for your personal educational purposes only; (2) the content may be from a variety of sources over which Leica Biosystems has no control, and should therefore not be interpreted as representing the opinions of, or an endorsement by, Leica Biosystems or its associates; (3) the content is provided to you AS IS, and you release Leica Biosystems of any responsibility or damages you may suffer as a result of the content, including without limitation, any damages resulting from the inaccuracy or unsuitability of the content.

LetsGetChecked is a virtual care company that allows customers to manage their health from home, providing direct access to telehealth services, pharmacy, and laboratory tests with at-home sample collection kits for a wide range of health conditions including Sexual Health, Cholesterol, Diabetes, Thyroid, Coronavirus (COVID-19), and more. Founded in 2015, the company empowers people with the care they need to live longer, happier lives. Today, LetsGetChecked is a leader in healthcare innovation with an end-to-end model including manufacturing, logistics, lab analysis, affiliated physician support, and prescription fulfillment, which provides a seamless user experience and a convenient, reliable and secure healthcare experience. LetsGetChecked is available nationwide in the United States and most EU countries. It is co-headquartered in Dublin and New York, with teammates all over the world. To learn more visit www.letsgetchecked.com.

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

LEVY Health's clinical decision support software empowers OB-GYNs to swiftly identify endocrine disorders and aids fertility clinics in streamlining complex work-ups. This reduces the time to diagnoses from years to mere weeks, ensuring a more efficient and effective path to parenthood

Life-saving therapies. Critical diagnostics. Breakthrough clinical trials. Life Couriers places hope in the hands of patients everywhere by being the world's most trusted logistics partner for crucial pharmaceutical and medical products. We are the worldwide market leader for radiopharmaceutical and stem cell logistics. We have taken this experience with the most time-critical shipments in the world to expand our services to biopharmaceuticals, cell and gene therapies, lab specimens, clinical trials, organ transplant, medical devices, and more. We understand a fundamental reality - that missing a delivery can mean losing a life. That is why we have intentionally curated our culture to be solely focused on patient outcomes. Our people care more and they are deeply committed to enhancing, enriching, and saving lives through the power of logistics. We are Life Couriers. Logistics for Life.

LifeLens was founded in 2014 by Dr. Robert Schwartz, Landy Toth, David Robins, and Dr. Robert Van Tassel. Its mission is to create simple, commercially viable technologies for high fidelity physiologic monitoring.

Lifetime Sciences (formerly MyGenetx) is a CLIA-certified and CAP accredited lab focused on molecular and advanced diagnostic testing. Lifetime Sciences is the primary resource for transitioning and implementing precision guided medicine. Our medical team consists of experts in research and clinical product development for genetics. MyPGt™ A pharmacogenetic panel to determine how you metabolize your medication(s). Traditional "one size fits all"​ dosing strategies can cause adverse drug reactions or drug inefficacy. MyHap2™ A proprietary genetic test to determine heart attack risk in patients with diabetes.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com.

Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Our program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.

Lipella Pharmaceuticals, Inc. is a biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis. They are a clinical-stage pharmaceutical company with expertise in drug delivery and the treatment of urologic conditions.

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class. The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2. Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis .

Longhorn Vaccines and Diagnostics, LLC is a research company Headquartered out of 7272 Wisconsin Avenue Bethesda, MD 20814 United States. The R&D facility is at 19 Firstfield Rd Gaithersburg, MD 20878.

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications. The company aims to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind.

Lumos Diagnostics, a California-based Full Service point-of-care diagnostic development company and previous spinoff from Australia-based Planet Innovation, and RPS Diagnostics, a Florida-based commercial diagnostic developer, manufacturer, and marketer of POC diagnostic tests, announced today that they have merged. The combined company will be called Lumos Diagnostics.

Machaon Diagnostics is a clinical reference laboratory and contract research organization (CRO), specializing in the diagnosis, treatment and monitoring of hemostatic and thrombotic conditions, complement-mediated disorders and rare genetic diseases. Machaon Diagnostics has a mission to save more lives with lab tests. Started as a collaboration of four laboratory scientists, we have rapidly grown into a dedicated group of clinicians, scientists, consultants and technologists. Collectively, the Machaon Diagnostics team brings over 400+ years of expertise to the field of laboratory testing. Our esoteric and routine testing menu applies to a wide variety of disorders and clinical trials and therefore draws attention from both a national and an international clientele. Our clients include community hospitals, university medical centers, clinics, commercial laboratories and research laboratories, as well as biotechnology, pharmaceutical and medical device companies. Machaon brings custom solutions to hospitals, laboratories and trial sponsors. Our primary goal is to provide quality testing (CAP/CLIA, GLP, GCP) at industry-leading speed.

Magnetic Insight is developing solutions in Magnetic Particle Imaging (MPI), a new imaging modality that directly detects iron oxide nanoparticle tracers using time-varying magnetic fields. Because the tracer is not normally found in the body, MPI images have exceptional contrast and high sensitivity.

Medical Diagnostic Laboratories, L.L.C. (MDL), founded in 1997, serves primarily as a reference laboratory for Polymerase Chain Reaction (PCR) based testing to physicians, laboratories and hospitals worldwide. MDL is a CLIA certified infectious disease laboratory with multiple state licenses specializing in PCR technology. Molecular diagnostic techniques, such as the PCR method, are considered to be the most sensitive and specific for the laboratory diagnosis of infectious diseases. MDL offers unique, non-invasive, highly stable specimen collection and transport platforms, such as the OneSwab®, UroSwab® and NasoSwab®. These platforms enable MDL to offer a variety of PCR based tests from a single swab with high sensitivity and specificity. MDL specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses. By using molecular techniques, MDL is able to provide clinicians from many different specialties valuable tailored diagnostic information to assist in the detection, diagnosis, evaluation, and treatment of viral, fungal, and bacterial infections. For example, the unique testing MDL offers for the specialties of Urology and Gynecology enables the detection of multiple pathogens as well as certain drug resistance profiles from a single swab by PCR. MDL's primary focus is in the field of infectious disease testing for Urology, Obstetrics and Gynecology, Respiratory Infectious diseases, Vector-borne diseases, Mycology and Pharmacogenomics. MDL is comprised of experts in the fields of Molecular Biology, Immunology, Virology, Microbiology, Mycology, Pharmacogenomics, Antimicrobial Resistance and Oncology. In addition to developing and validating new clinical diagnostic tests, the Research and Development Department also publishes research projects in peer-reviewed journals, presents scientific information at international symposia, and performs contractual research work for major commercial, governmental, and academic organizations.

Mammogen is a liquid biopsy company on a mission to unlock the quality-of-life preservation that exists at the earliest stages of diseases that affect women's health, starting with breast cancer.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.

Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes.

MatMaCorp is a company dedicated to developing rapid, portable, and easy to use molecular testing solutions. This has been achieved by combining engineering, life science, and information technology to create easy-to-use and affordable suite of inter-connected products. As a result, MatMaCorp has provided users the power to evaluate genetic conditions, pathogen detection and disease surveillance in applications ranging from food production, animal health and human health. It is now possible to eliminate the need for laboratory equipment like refrigerators, centrifuges, and pipettes. MatMaCorp's products are geared towards making molecular biology and molecular diagnostic tools accessible to anyone, anywhere and at any time.

Matter Bio is a longevity holding company focused on preserving genome integrity As we age, our genome is constantly being damaged by exogenous and endogenous sources. Occasionally errors are missed and incorporated into the DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss. At Matter, we have assembled a world-class team of scientists and executives to help counter this critical information loss in the genome. To achieve this, we are focusing on a number of assets that address key stages in the genomic information loss continuum.

𝘐𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘏𝘦𝘢𝘭𝘵𝘩 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘴. MaximBio's comprehensive in-house capabilities provide you a world-class experience and confidence in our ability to keep costs down and deliver your products in time. At MaximBio, our team of dedicated professionals with over 25 years of expertise work to create a custom-fit, full service program in state-of-the-art facilities to meet all your needs and specifications: • FDA cGMP Registered for manufacture and distribution of medical devices • Compliant with 21 CFR Part 820 for medical devices • ISO 13485:2016 Certified for manufacturing and packaging of medical devices

Mdxhealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

MedCognetics provides an advanced AI software platform which integrates into the radiology workflow. The AI platform is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating more predictable medical outcomes and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com.

Restech offers minimally invasive tools to multiple specialties in order to accurately diagnose and manage reflux, and will continue to create solutions related to the complexity gastric related diseases. Restech’s tools are helping evolve the standard of care for patients with reflux, and fecal incontinence, providing physicians with the necessary data to transform the algorithm of care for tens of millions of patients.

Emergo provides quality and regulatory compliance consulting to medical device and IVD companies. We assist with medical device registration/approval, regulatory strategy, ISO 13485 and QMS compliance, local in-country representation and post market surveillance in 20+ markets worldwide. Offices in North America, South America, Europe, Asia, Australia and the Middle East.

Over 100 million Americans have either a pre-chronic illness, or a disease and the majority don’t even know it. Early detection, intervention and timely personal monitoring matters; but, improving wellbeing requires consumer interactions to be easy, convenient and fit naturally into their daily “life flow.” Medic.Life is a unique biotech startup focused on blending miniaturized assay systems, medical IoT, AI and mobile into a waste analyzer platform – a smart toilet – resolving pain points for everyday users and providers. Within 2 years, our technology will be found in clinics, senior care, primary care, pharmacies, retail outlets, and homes, while generating mountains of personal health data. As such, Medic is really a data company with a sophisticated user interface that captures, analyzes and trends vital health indicators every time our toilets are used and notifies users when anomalies are detected. It’s like having a Medic at your disposal. Medic.Life has a strong IP position with 60 patents granted and more than 90 pending so far. We are working with over 20 partners for our onboard science center (microfluidics, lab on chip, proprietary sensors) and seek to double that number in the 2020-21 timeframe. If you have miniaturized technology to analyze urine, feces, vitals, body composition and circulation, then please contact us.

Meditrina is an innovative start up Company located in San Jose, CA, and founded in 2016 developed the Aveta™ hysteroscopy suite which was designed to provide physicians with the best care in their diagnosis and treatment of endometrial polyps and uterine fibroids. The system seamlessly integrates into any operating, procedure, or exam room. This new hysteroscopy system is an all-in-one platform which includes the single-use Aveta™ Pearl Hysteroscope for myomectomy, and the single-use Aveta™ Coral Hysteroscope for polypectomy procedures with integrated tissue resection and fluid management capability. The Aveta™ Pearl Hysteroscope is the first single-use hysteroscope to include full physician control providing proprietary fluid management and video control function directly on the hysteroscope handle.

Melio is developing a clinically actionable fast and comprehensive test for all common infections

MeMed is a leading med tech and bio-convergence company, having developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders – at the right place and the right time.

Menssana Research is the leading developer of advanced new breath tests for detection of disease. We are now performing clinical studies with the BCA and with BreathLink (TM), mostly funded by the National Institutes of Health and BARDA, to evaluate breath testing in several diseases including lung cancer, breast cancer, heart transplant rejection, radiation exposure, and tuberculosis. The Food and Drug Administration has approved the Heartsbreath test for heart transplant rejection for clinical use. For more information, please visit menssanaresearch.com.

Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages. 

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian's products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers, and agri-bio companies in more than 70 countries around the world. Meridian's website address is www.meridianbioscience.com.

Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.

Mestastop Solutions is a biotechnology startup based in India, focused on addressing cancer metastasis. The company aims to develop innovative solutions to combat the spread of tumors, which significantly contributes to cancer-related deaths worldwide. Mestastop has gained global recognition for its research, presenting its work at major international conferences such as the American Association of Cancer Research Annual Conference and the European Association of Cancer Research. The company is involved in diagnostics and discovery related to cancer metastasis, with a focus on small molecule drugs to tackle distant metastasis. Mestastop's approach includes unraveling the biology of metastasis to create targeted treatments. The company has been vetted by the scientific outsourcing platform Science Exchange and is recognized as an authorized service provider, underscoring its credibility in the field.

Metabiomics has developed a new type of microbiome diagnostic test for early detection and monitoring of polymicrobial and immunological diseases such as inflammatory bowel disease, colon cancer, HIV infection, alcoholic liver disease, and others that are non-invasive, lower cost, more sensitive and accurate than currently available diagnostic procedures. For the past 10 years, Metabiomics has been a pioneer in human microbiome research specializing in functional metagenomics and systems biology applied to advances in microbial DNA sequencing methods, clinical research, and in vitro diagnostics. Our on-going clinical research is unraveling some of the secret relationships between human microbial communities, immunology, and health. Our research collaborations with Diversigen, the Harvard Chan School of Medicine, Penn State University and George Mason University Microbiome Analysis Center and several medical research institutions are focusing on microbial biomarkers and immunological responses in intestinal dysbiosis, colon disease and cancer, liver disease, and other immunological diseases.

Metabolic Solutions is the world leader in the application of Stable Isotopes Biomarkers in drug development. For over 30 years, the pharmaceutical industry has turned to our technology to unlock the mechanisms and efficacy of their potential therapeutics. We have a well-earned reputation for personalized service, fast turnaround time and competitive pricing. We provide complete solutions for your clinical study including protocol design consultation, custom kit manufacturing, validated assays, GCLP measurements and data analysis. Our full-service approach makes these powerful tools accessible and provides clear answers that are accurate, precise, and reliable. Additionally, we provide medical breath testing kits and measurement services for small intestinal bacterial overgrowth (SIBO), lactose intolerance and fructose malabsorption. Our CLIA and GLP-compliant laboratory stands ready to provide answers to your most challenging questions. To see our assay list and the services we offer, please visit our website at https://www.metsol.com/ .

Almost every factor that affects health – from genetics and the microbiome to disease and lifestyle – exerts its influence by altering metabolite levels in the body or other biological system. By producing the most accurate and comprehensive picture of the collection of metabolites, known as the metabolome, from a single biological sample, Metabolon can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of disease, medical intervention, diet or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers some of biology’s most difficult questions. Metabolon's unrivaled capability to look deep into the metabolome has enabled us to build the world’s largest library of compounds that currently includes 5,200+ total known molecules. Our proprietary Precision Metabolomics™ platform, combined with the world's most experienced metabolomics scientists, delivers biologic insights and identification of novel commercial opportunities for drug discovery and development, through clinical trials and life cycle management. Metabolon’s expertise is also accelerating research and product development for clients in academia, population health, consumer products, and nutrition industries. Founded in 2000 and based in Research Triangle Park, North Carolina, Metabolon has conducted more than 10,000 independent and collaborative studies, resulting in 2,000+ publications in leading peer-reviewed journals. For more information about our technology, products and services, please visit www.metabolon.com.

A NEW Test to Determine Breast Cancer Risk....A Breakthrough!!!! Women with lumps in their breasts have to make a difficult decision whether or not to undergo treatment. For these women, a NEW TEST can help in the assessment of their cancer risk and hugely facilitate their decision-making process. We have studied a protein (called hOPN-c), which serves this purpose. The presence of hOPN-c in a lump indicates an elevated risk for breast cancer down the road, and the more of it is detected the more substantive is the risk. A pathologist can simply apply this test to a biopsy

mFluiDx is a UC Berkeley spinout startup that develops innovative technology to enable rapid, low-cost molecular DNA/RNA diagnostics at point-of-care.

MiCareo believes in a future where medicine can offer the right treatment for the right patient at the right time. To get us to that future, we must find crucial information that is hidden away deep inside rare cells that circulate in our body. Our mission is to unlock the secrets of these rare cells and offer a way forward for research and drug development in the pursuit of precision medicine. We invite you to join us towards these goals. We strive to deliver solutions for the fundamental unmet needs in rare cell processing for personalized medicine, clinical diagnostics, drug development, and biomarker discovery. Our proven robust technology is founded on research started in 2005. We integrated disposable microfluidics with a fully automated sample processing, laser sorting, and fluorescence imaging system, to provide the simplest tools to answer your complex rare cell questions. We provide innovative tools for the analysis of rare cells for Liquid Biopsy, Circulating Tumors Cells, Immune Cells, and Other Rare Cells. Our circulating tumor cell platform does rare cell isolation and analysis for cancer prognosis and treatment development and efficacy evaluation. We have Collaboration Service Centers in Taiwan and Seattle WA, USA, where we can process your samples and give a detailed introduction to our products and services. We also work with distributors throughout the world to offer our products globally. Contact us to get started with your rare cell analysis.

Microarrays is a biotechnology company that offers array products for biological research, detection, and diagnostics, focusing on advancing array-based technologies.

MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX's work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions.  MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.

Whether it is partnering with clients to help with design for manufacturing on new programs or to support existing applications, Micron Products, Inc. is prepared to commit all resources necessary to find a solution. As a Full Service Supplier, each member of our manufacturing, product design, research and quality teams stand ready to work in collaboration with clients to meet any challenge. Micron Products, Inc. has been supplying the medical industry with world class quality medical components since 1978. Micron Products, Inc. is a wholly owned subsidiary of Micron Solutions Inc. (NYSE: MKT: MICR)

Milagen is a privately held, late-stage, pre-commercial diagnostic company focused on commercializing easy-to-use, non-invasive, in vitro diagnostic (IVD) products designed to fulfill unmet clinical needs in the prevention, detection, diagnosis, and management of major cancers. We are making the transition to commercialize our novel, proprietary antibody-based blood serum assays for detection of Breast and Colon cancer recurrence in a CLIA setting while we are preparing for a major clinical study to support an intended use for the early detection of major cancers.

Focus on women's heatlh

Mindera Health™ is commercializing scalable extraction technology and data analysis to report a patient’s individual transcriptomic data. Mindera’s technology creates Dermal Intelligence™, actionable information for payers, providers and patients. The company’s flagship test, Mind.Px, uses both a dermal biomarker patch and Machine Learning to determine a patient’s receptivity to very expensive psoriasis biologics. This information is valuable to payers, who can save thousands of dollars per biologic patient using Mind.Px at the outset of prescription. Mind.Px is the first test in a large planned product pipeline, including psoriatic arthritis and eczema biologic receptivity.

MindX Sciences, Inc. is the future of mental health management by providing the only mental health solution that gives providers the confidence of the correct diagnosis and proper treatment choice. We bring objectivity and precision to mental health management. Our unique and proprietary RNA blood tests assess disease state and disease risk and help with diagnosis and tracking of response to treatment. Additionally, our tests also match patients to medications and nutraceuticals based on their biology, in a precise and personalized way. Reach out to us at info@mindxsciences.com

MiraDX was founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to improve personalized cancer treatment. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do. Through worldwide collaborations MiraDX has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDX.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.

Diagnostics We build innovative diagnostic and monitoring tools that empower people to make better decisions about their health. Drug Discovery We translate early-stage research into customized RNAi and CRISPR Cas9 animal and cell models to accelerate drug development. Therapeutics We identify and validate new drug targets, unleashing the commercial potential of RNAi to benefit people on a global scale. Established in 2010 to harness the power of RNAi and genetic engineering technologies developed by our founders in the labs of the world's leading experts at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Harvard Medical School, Mirimus creates innovative research and clinical technologies to address health issues on a global scale. Today, Mirimus markets multiple unique and high-value drug discovery and diagnostic products and services, and is advancing a pipeline of therapeutic candidates in partnership with leading biopharma companies to create novel high-impact health care solutions that benefits society on a global scale. Mirimus' ability to leverage its cutting-edge science and proprietary technology platforms to rapidly create new, affordable technology and products at scale is core to the way we work. We embrace diversity and creativity and have a proven track record of innovative problem solving—which led to our recognition as a $1M grand prize winner of the XPRIZE competition by developing a radically affordable, rapid, non-invasive methodology for mass COVID-19 testing—driving us to make better drugs and detect disease earlier. At Mirimus, our ingenuity, respect for our colleagues' ideas and creativity, executional agility, and a commitment to global health equity combine to create a unique culture of innovation that delivers measurable progress.

Mitera is a maternal-fetal medicine (MFM) telehealth company. We help inform and educate our patients about their pregnancy-related risks and options through obstetrical screenings and at-home genetic testing kits, empowering them along their family-forming journey.

We are a tech-centered, animal diagnostics company on a mission to help veterinarians lengthen the lives of their patients by applying deep learning to the diagnostics they use daily.

Molecular Testing Labs is a mission-driven, innovative health sciences company specializing in precision laboratory diagnostics. Molecular is committed to revolutionizing accessibility to testing via proprietary technology systems, advanced logistics, and cutting-edge research and development. We are pioneering and innovating distinctive distribution and specimen collection methods that open access to medical testing where geographic, financial, and stigma barriers once created gaps in the healthcare industry. We provide accessible and innovative laboratory solutions through collaborative partnerships with payors, private healthcare institutions, universities, commercial partners, and public health organizations. Molecular Testing Labs is a CLIA-certified and CAP-accredited, state-of-the-art, esoteric and reference laboratory. We specialize in high-complexity, molecular testing with an extensive portfolio of services including infectious disease, toxicology, targeted sequencing, single nucleotide polymorphism (SNP) genotyping, and Next-Generation Sequencing (NGS), and high-resolution immune profiling. Molecular Testing Labs offers a variety of clinical trial services comprising of assay development, trial site training, investigator support, and customized reporting. We apply the maximum level of control to obtain the most consistent and highest quality results. Molecular Testing Labs is founded on three guiding principles – Compliance, Innovation and Partnership. For more information, please visit our corporate website – www.moleculartestinglabs.com.

Moleculera Biosciences offers advanced testing services in a fully-accredited CLIA/COLA clinical laboratory specializing in autoimmune neurobiology. As pioneers focusing on neuropsychiatric disorders caused by molecular mimicry, we offer the Autoimmune Brain Panel™, an aid to a physician's diagnosis of autoimmune-based neuropsychiatric disorders. The Autoimmune Brain Panel™ helps identify whether an individual's neurologic/psychiatric symptoms, such as obsessive compulsive behaviors, tics, anxiety, attention deficit hyperactivity disorder, and sometimes behaviors associated with Autism Spectrum Disorders, could be caused by a treatable autoimmune condition triggered by common infections.

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements. Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

More Diagnostics controls are stable, convenient, reliable, thus ensuring accurate results in your lab. We are a trusted business partner providing exceptional support in the industry and understanding of the clinical diagnostic laboratory division.

The Biosound® Therapy System The Biosound Therapy System integrates Biofeedback, Sound Frequency Healing, Music Therapy and Guided Imagery. The Biosound Therapy System consists of a vibrational platform constructed with...

myBiometry is a platform to remotely monitor and manage patients with chronic conditions using software and biomarker data generated from proprietary sensors. Our initial focus is asthma.

Myolex is disrupting how to measure muscle wasting (and treatment), caused by obesity drugs, aging, and sport injuries. Myolex® EIM is a patented device technology and SaaS data analytics platform that is built to disrupt skeletal muscle measurement by becoming the clinical and wellness standard to aid in the diagnosis and treatment of obesity drug and age-related muscle wasting. Myolex has developed the 1st quantitative, sensitive, painless, portable for home use muscle quality assessment device that is specifically designed to non-invasively, comprehensibly, and precisely detect and monitor single muscle wasting.

At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies. We are always interested to hear from smart, passionate people with a background in bio stats, data science, and ML. Connect with us!

Nanopath Inc. is a molecular diagnostics company enabling high-quality molecular testing in minutes. The company is commercializing a first-in-class molecular diagnostic platform to enable scalable, point-of-care disease diagnosis.

Developing a technology platform that includes proprietary antibody-conjugated nanoparticles that are specifically adapted to antigen peptides that are only present in the bloodstream when the targeted disease is active.

Nanoscope Technologies was founded in 2009 with an objective to develop new methods and devices for scientific, industrial and biomedical applications. Nanoscope has developed a range of biomedical technologies which include diagnostics and therapeutic devices and molecules. These have already generated interest from several clinicians, industries and leaders. We strive to translate the technology to market and bedside.

NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret, and visualize complex and highly sensitive information, we enable customers in healthcare, life sciences, logistics, telecommunications and other industries to automate, understand and act on data while keeping it secure and scalable. Our product portfolio comprises the latest technology in payer-provider collaboration platforms for real-time coverage decision support, and data solutions that provide multi-data analysis, reporting and professional services offerings.

NantOmics employs a comprehensive, integrated panomic approach to detect molecular alterations in individual tumors and inform personalized treatment options for patients with cancer. Whole genome sequencing of a patient’s matched tumor sample and normal sample pinpoints tumor-specific alterations at the DNA level, RNA sequencing confirms and gives relevance to mutations in DNA, quantitative proteomics measures the levels of clinically important proteins, and integrative analysis identifies disrupted pathways that are specific to the patient’s tumor.

Nashville Biosciences is leveragingresources and proprietary analytical methods to help improve the prevention, diagnosis and treatment of a wide range of diseases.

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women's health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.  Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients. #TeamNatera includes clinicians, scientists, biostatisticians, researchers, and laboratory professionals from around the world. Our diverse teams blend a passion for patients with deep clinical, scientific, and technological roots. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Interested in joining us on our mission to change the management of disease worldwide? Visit https://www.natera.com/careers-at-natera to learn how you can become a part of our talented team. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. Please be advised that Natera will reach out to candidates with an @natera.com email domain ONLY. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes. https://www.natera.com/privacy/

Naveris has developed blood tests for cancers to enable early diagnosis in the general asymptomatic population, real time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission.

Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases, with an initial focus on personalized Rheumatoid Arthritis diagnostics. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

Neogen®'s Solutions Can Be Found at Every Step of the Food Chain. Neogen provides a comprehensive range of solutions and services for the food processing, animal protein and agriculture industries, not only helping to protect the world's food supply, but also enabling our customers to produce more efficiently and effectively than they could before. We are also proud to serve the companion and performance animal industries, as well as the fields of life sciences and toxicology.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.

Electrodiagnostics

NeuroDex is developing a suite of blood-based biomarkers that can identify patients with synucleinopathies even in the context of different forms of dementia. This technology relies on NeuroDex’s recent advances in isolatingcell-specific extracellular vesicles (exosomes) from plasma and detecting protein markers of disease in the contents or on the surface of NDEs. Extracellular vesicles/exosomes are nano-sized (30-200nm) membrane vesicles released from all cell types in the body. While the biogenesis and biological function of extracellular vesicles are complex, it is clear that they carry protein, RNA, and lipids that reflect their cell of origin and thus can serve as a rich source of biomarkers.

Neurotron is a medical devices company that specializes in Neurometer CPT electrodiagnostic sensory nerve conduction threshold (sNCT) testing equipment.

Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.

At NextGen Jane, we believe in enriching your Quality of Life, expanding your Agency, and enabling your Pursuit of Data. All good revolutions are anchored in coherent philosophies championed by an impassioned base. This is our revolution, to empower women with the information needed to make smart decisions and take true health ownership. Armed with our SmartTampon platform that serves as a sentinel system for your reproductive health, we hope to impact how you manage your health, from menarche to post-menopause. If you dig it, join us. It is hard to create new ways of engaging with our health in rigid systems within a complex care system, but not impossible. Help us re-engineer our future, in our image.

Nexus Dx is a global provider of Near Patient Testing systems and advanced diagnostic solutions. The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most. Company Highlights: Primary focus on expansion of assay systems in the Near Patient Testing industry Multi-product revenue generating business Proprietary technologies and content Highly experienced management team Nexus Dx Inc.

Nielsen BioSciences, Inc. is a private, San Diego-based biotechnology company focused on offering medical professionals trusted and valued biological products with wide-ranging applications of cell-mediated immune responses. We are building on a solid foundation of over 40 years developing and delivering antigen-based products. Our research and development leverages heterogeneous antigenic profiles to enlist cell-mediated immunity in the evaluation, treatment, or prevention of diseases. Antigenic diversity enables us to effectively address conditions missed by narrowly targeted strategies

Nonagen Bioscience is a biotechnology company that specializes in developing first-in-class diagnostics for early detection and prediction of human cancers.

Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry: – Focusing on high-purity controlled substances – Leveraging intellectual property to devise the most efficient routes to APIs – Providing analytical data, chemical and physical properties, stability studies and regulatory assistance – Formulation friendly particle size grades and extended technical packages – Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply – Supporting world-class supply security of controlled-substances, from schedule I to schedule III

At NorthStar Medical Radioisotopes, our mission is to provide patients global access to game-changing radiopharmaceuticals. We are a growing, commercial-stage company focused on advancing patient care by providing therapeutic radioisotopes and novel radiopharmaceuticals to detect and treat cancer, and customized radiopharmaceutical development services. Radiopharmaceutical therapy is increasingly important for cancer treatment, and NorthStar is expanding our industry-leading position in developing commercial-scale production technologies to meet this important healthcare need. We routinely produce the therapeutic radioisotope copper-67 (Cu-67) and are poised to be one of the first commercial-scale producers of non-carrier-added (n.c.a.) actinium-225 (Ac-225), using first-in-kind and environmentally preferable electron accelerator technology. NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CMDO/CMO) unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. At NorthStar, we prioritize professional growth of our employees. Working with our cutting-edge technology offers a stimulating and rewarding environment for talented individuals who want to be part of our exciting and growing business. We are committed to providing our employees with fulfilling work experiences and valuable career development opportunities.

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable's proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product's medical impact and commercial value faster, higher, and more likely than traditional drug development.

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) develops and sells scientifically created and clinically proven eyecare and wound care products. Manufactured in the U.S., Avenova Antimicrobial Lid & Lash Solution is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited. NovaBay's leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is available directly to consumers through online distribution channels such as Amazon.com. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. NovaBay offers a full portfolio of scientifically developed products for each step of the standard dry eye treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. The Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in the United States. For more information, please visit www.novabay.com.

Lab-quality, Clinically Actionable Results in Minutes Anywhere! Novel Dx detects the genetic material of pathogens using Nucleic Acid Amplification techniques. These are the same methods that are utilized in large reference laboratories Novel Dx delivers lab-quality results in under 30 minutes so patients can be tested and treated in the same visit

Novir is a cutting-edge biotechnology company revolutionizing the way the world perceives and approaches healthcare. At Novir, we challenge the conventional care model by placing our focus on proactive measures rather than waiting for diagnoses. We firmly believe that care shouldn't start at diagnosis, but rather in the early stages of prevention. Our mission is to empower individuals to take charge of their health through innovative services and technologies that enable a pre-care pathway for anyone, anywhere, anytime.

Novodiax is a biotech startup dedicated to advancing cancer and autoimmunity diagnostics through innovative rapid immunoassays. Our revolutionary ihcDirect® assays are listed for in vitro diagnostic (IVD) use and provide immunohistochemistry (IHC) results in as little as 10 minutes on frozen tissues! They also provide workflow benefits for formalin-fixed, paraffin-embedded (FFPE) tissues, helping reduce assay time by up to 40-60 minutes. ihcDirect works by directly conjugating primary antibodies to our proprietary and sensitive polymerized horseradish peroxidase (polyHRP) detection system, thus delivering immunoassays for histology and cytology (2020) that: - Are lightning fast (~10 minutes) - Require minimal lab space and no specialized equipment - Can be performed at room temperature - Are simple to perform like H&E tests, yet provide the sensitivity and specificity of immunoassays Our assays are also perfect for helping you advance your research (see our ihcPrime™ and Q-Stain® products and custom services), develop cutting edge companion diagnostics (CDx), and more. Let's partner together to make that happen! Visit our website or contact us to learn more. www.novodiax.com sales@novodiax.com

NOWDiagnostics (NOWDx) develops and manufactures over-the-counter (OTC) and point-of-care (POC) diagnostic tests. Its patented approach enables virtually any immunological assay to be accurately performed onsite in one step using a small amount of capillary blood, yielding results in minutes. With over 75 patents issued and pending, NOWDx's First To Know® and ADEXUSDx® product lines are available in markets worldwide. Founded in 2013, with headquarters and manufacturing in Springdale, Arkansas, NOWDx envisions a world where people have greater access to in-home testing with results in minutes. The company’s investors include Kompass Kapital Management, DigitalDx Ventures and the Labcorp Venture Fund. NOWDx is committed to changing healthcare by providing accessible, affordable, and accurate testing for all.

Sample prep engineered for liquid biopsy. nRichDX, based in Irvine, CA is an emerging leader in the liquid biopsy sample prep market, delivering significantly more analyte (cfDNA, ctDNA, cfTNA, cfRNA) than existing sample prep systems for molecular testing. The nRichDX liquid biopsy sample prep platform is the result of an intensive technology development effort that commenced in 2016. Being introduced in late 2018, the nRichDX system is a 510K-exempt, highly differentiated, universal sample prep system for the multi-billion dollar liquid biopsy and precision medicine markets. nRichDX solves one of precision medicine’s greatest problems - - inaccurate diagnostic results for up to 50% of liquid biopsy-based molecular diagnostic tests (NGS, PCR, Micro Array, etc.) due to a lack of target material. The nRichDX platform improves workflow, greatly enhances test sensitivity and produces consistently reliable test results while increasing revenue and reducing operational costs and complexity.

Nuclein, LLC was founded in 2017 by experienced biotechnology entrepreneurs Alan Blake and Dr. Richard Crockett. The company's mission is to create a hand-held, disposable, all-in-one, self-test for infectious disease testing, which delivers battery-powered, sample-to-answer results within one hour, without the need to mail in a sample. The company is headquartered in Austin, Texas.

Develops a diagnostics platform.

The NuProbe team has pioneered the development of a unique and novel PCR-based enrichment method called Blocker Displacement Amplification (BDA). The BDA technology enables the selective amplification of low abundant sequence variants (SNV and indels) in a background of wildtype DNA.

NuView Life Sciences is a clinical stage precision oncology company. The Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor is over-expressed on the surface of a wide range of cancer types at the onset of oncogenesis. NuView's NV-VPAC1 small molecule binding agent designed to identify and bind to the VPAC receptors has been utilized in clinical trials for binary in vitro and in vivo of confirmation of cancer. The NV-VPAC1 agent can be utilized to deliver existing therapeutics and new alpha and beta emitters. NuView will pair existing imaging and therapeutic radionuclides with NuViews proprietary agent and provide a Theranostics solution for patients and clinicians.

Leverage nVector's advanced Adeno-Associated Virus platform to quick-launch your gene therapy strategy or accelerate existing initiatives. We enhance testing and trials with superior diagnostic biomarkers.

nView medical, based in Salt Lake City, UT, is a startup whose mission is to make surgery safer, faster, and consistently accurate. nView develops imaging technology — bringing breakthrough AI solutions for image creation, image processing, and image visualization to surgery and interventional radiology. nView medical backers include the National Science Foundation (NSF), the National Institutes of Health (NIH), the State Of Utah, the National Capital Consortium for Pediatric Device Innovation, MedTech Innovator, HealthTech Arkansas, Dr. Kevin Foley, M.D., and Fusion Fund (Palo Alto, CA). Its founder, Cristian Atria, has had a progressive career with GE Healthcare in positions that range from development engineer to general manager with P&L responsibility. He has successfully assisted start-up and public companies with technology transfers, licensing, product development, regulatory approvals, and commercialization.

NX PharmaGen develops blood-based molecular diagnostic testing products.

Welcome to the Oasis Diagnostics® LinkedIn Company Page! We're so glad you found us. Oasis Diagnostics® Corporation was founded in 2002 to address a growing need for non-invasive saliva based technology for rapid testing, sample collection, and molecular diagnostics [DNA, RNA and proteins] in the Life Sciences area. The Company is dedicated to meeting the need for more effective screening tools, which may be applied to the early detection of diseases and medical disorders, utilizing non-invasive test specimens, particularly oral fluids (saliva). The Company’s range of collection and [future] diagnostic tools are covered by a portfolio of issued US, EU and International patents. Recognizing that early diagnosis is the key to disease prevention on a global basis, the Company directs its research efforts towards the development of oral based rapid, point-of-care, laboratory-based and molecular products, which fit into a Corporate objective of improving the quality of healthcare for our global customers.

Octagos Health is a dynamic and rapidly growing healthcare technology company dedicated to improving patient outcomes through AI-driven solutions. Octagos provides a cloud-based platform that aggregates remote and in-person device interrogations for all cardiac rhythm management (CRM) manufacturers, wearables (Holter, MCT, etc.) and remote physiologic monitoring (RPM).

OKRA Care is highly committed to providing hospital-grade glucose monitoring test kits to help patients manage diabetes effectively

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

Oncobox is transforming cancer care with precision medicine by leveraging the power of artificial intelligence and systems biology. Through the integration of deep molecular profiling—which includes analysis of not only DNA mutations (exome) but also RNA gene expression (transcriptome)—and comprehensive data analytics, we achieve unmatched precision in identifying the most effective treatment strategies, markedly improving outcomes for patients battling late-stage cancers. The effectiveness of Oncobox's technology is backed by both prospective and retrospective studies. This approach has shown remarkable success, leading to a twofold decrease in disease progression and a significant increase in progression-free survival (PFS). Oncobox's innovative use of deep molecular profiling is setting new standards in the precision and efficacy of cancer treatment.

Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions. They are focused on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

OncoTAb, Inc., a North Carolina based biotechnology company, was founded by Mayo Clinic alumna Dr. Pinku Mukherjee, with a mission to improve the quality of cancer care by addressing unmet cancer diagnostic and therapeutic needs. The company has just launched its first product: Agkura™ Personal Score – a simple, non-invasive blood test that aids breast cancer detection in women with dense breast tissue. Roughly half of the women in the US have dense breast tissue and mammograms miss 50% of the breast cancers in these women, resulting in late stage diagnosis and mortality. Agkura™ Personal Score measures the biomarker tumor-associated MUC1 (tMUC1) and shows a trend of increasing value from benign disease through breast cancer stages 1 to 4. Women can monitor their personal score in conjunction with annual mammograms. A score above the normal range or an increase greater than normal variation will trigger a recommendation for diagnostic imaging (ultrasound or MRI), resulting in earlier stage diagnosis of breast cancer. The company is also working on developing treatments for breast and pancreatic cancers.

OneOme, co-founded by Mayo Clinic, is working to help providers incorporate pharmacogenomics into patient care by offering the RightMed Test and associated tools. The RightMed Test may help providers optimize medication selection for their patients by analyzing and reporting on 27 genes. OneOme is privately held, based in Minneapolis, MN. For more information, visit www.oneome.com and follow us here for updates.

OnsiteGene Inc. is a biomedical technology company developing on-site genetic testing based on a new sample prep and qPCR process.

Mission We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship. About Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics to help combat infectious disease. Our innovative approaches to infectious disease diagnostics consist of highly multiplexed syndromic molecular panels to address the global threat of antimicrobial resistance (AMR), improve antibiotic stewardship, and decrease the spread of multidrug-resistant microorganisms (MDROs). Together we improve patient care and fight AMR through cutting edge molecular microbiology.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test. The company's Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase IIb trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

As a global leader in digital pathology, OptraSCAN is dedicated to revolutionizing diagnostics and patient care through advanced technology. We specialize in providing cutting-edge digital pathology solutions, including state-of-the-art digital pathology scanners and whole slide imaging scanners, designed to enhance the accuracy and efficiency of diagnostic processes. Our extensive range of digital slide scanners includes brightfield slide scanners, histology slide scanners, and fluorescence slide scanners, enabling healthcare institutions to transition seamlessly from traditional microscopy to sophisticated digital pathology systems. Our whole slide scanners and digital pathology slide scanners offer high-resolution imaging that improves precision, streamlines workflows, and provides cost-effective results. OptraSCAN leads the way in digital histopathology with innovative solutions that integrate advanced artificial intelligence (AI). Our AI-powered pathology scanners and digital pathology artificial intelligence technologies are designed to boost diagnostic accuracy and efficiency. We offer comprehensive solutions including whole slide imaging scanners and computer-aided region detection systems. We are committed to making digital pathology accessible to all, providing compact and advanced scanning systems that overcome barriers to modern diagnostic methods. Our digital pathology solutions include cloud-based LIMS (CLOUDPath), image analysis tools (OptraASSAYS), and up to 10 TB of complimentary cloud storage. By choosing OptraSCAN, you partner with a leading digital pathology company that is shaping the future of diagnostics with high-quality digital pathology scanners and integrated whole slide imaging solutions. Our goal is to ensure that healthcare systems worldwide can seamlessly adopt and benefit from our transformative digital pathology technologies.

OraSure Technologies developd, manufactured and distributed of point-of-care diagnostic tests, molecular collection devices. These include rapid tests for the detection of antibodies to HIV and Hepatitis C (HCV) on the OraQuick® platform; sample self-collection and stabilization products for molecular applications; and oral fluid laboratory tests for detecting various drugs of abuse. Orasure's wholly-owned subsidiaries include DNA Genotek, CoreBiome, and Novosanis.COVID-19: BARDA funded the development of a rapid coronavirus test that can be self-administered at home.

Orbit Genomics is transforming complex disease diagnosis, treatment and prevention through early warning genomics. Our patent pending OrbiSeq™ platform analyzes novel genomic markers which uniquely reflect not only inherited predisposition to disease, but also risk acquired from lifestyle and environmental exposures. OrbiSeq can be applied to diagnose, treat and help prevent complex diseases including cancer, heart disease and neurological diseases. Our first product is an aid to diagnosis for lung cancer, the world’s deadliest cancer and the only major one without a routine screening test. Diagnosis often requires an expensive and invasive biopsy. Our simple blood test will eliminate unnecessary biopsies.

Ortho Clinical Diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testingVitros Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Calibrators - EUA 4/2020

Health tech startup developing artificial intelligence tools for ear exams.

OTraces has developed a blood-based disease testing platform that uses math- and physics-based noise suppression techniques never before employed in human disease testing, and has thereby achieved 90%+ accuracy in the detection of cancer tumors as measured by predictive power.

Overjet is the world-leader in dental AI. Founded by experts from MIT and Harvard University, Overjet builds artificial intelligence that helps dental organizations give patients the highest quality of care. Our FDA-cleared technology is the first objective standard for making oral health decisions — so that dentists can detect pathologies with precision and educate patients with confidence.

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

PAI Life Sciences is a biotechnology company located in Seattle, WA, specialized in the developmental and translational research necessary to bring products from the laboratory to bedside. Its mission is to address neglected diseases throughout the world with the idea of “serving the underserved.” The company has developed novel protein biotherapeutics and has a pipeline of products ranging from infectious disease vaccines and adjuvants to therapeutics for cancer.

microbial, bacterial, microbiology, clinical medicine, laboratory medicine, BACLIB

PATH is a global team of innovators working to accelerate health equity so all people and communities can thrive.

Founded in 1965, PathGroup is a premier provider of anatomic, clinical and molecular pathology services, as well as one of the largest providers of women’s health services in the United States. Privately held and physician-centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service.. More information about PathGroup can be found at www.pathgroup.com The PathGroup social media sites are produced and maintained as a public forum by PathGroup, Nashville, Tennessee. Links to other Internet sites should not be construed as an endorsement of the views contained therein. We respect our followers'​ rights and it is inappropriate to post any patient related information or requests. Should such posts be published, they will be immediately deleted.

Pattern Ag uses predictive analytics to help farmers with input decisions such as crop protection, seed selection, and fertility needs. Pattern envisions a future where conventional agricultural inputs are enhanced and eventually replaced by precision microbiome engineering, improving farm productivity and sustainability.

Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics. The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information. The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.

PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.

The WHO estimates that by 2020, depression will be the leading cause of disability worldwide. Pax Neuroscience, Inc. is a clinical diagnostics company focused on development and commercialization of blood tests for depression diagnosis and for antidepressant response. These tests are based on novel protein biomarkers derived from hypothesis-driven data sets and early clinical results are promising.

For 85 years, PerkinElmer has pushed the boundaries of science in our food, industrial, life science and environmental markets. In addition to innovative laboratory technologies, our OneSource services division delivers a highly trained, experienced, and collaborative team of service engineers with solutions scalable and customizable to serve laboratory needs. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate better, and create better. PerkinElmer is a leading, global provider of technology and service solutions that help customers measure, quantify, detect, and report in ways that help ensure the quality, safety, and satisfaction of their products. Science with Purpose. Learn more at www.perkinelmer.com.

Perosphere Technologies is focused on bringing forth new, Point-of-Care (PoC) solutions that make diagnosis, treatment, and prevention a matter of actionable data. We bring the clarity and confidence needed to transform an incomplete clinical picture and drive the way decisions are made in coagulation.

Personal Genome Diagnostics (PGDx) is empowering the fight against cancer by unlocking actionable information from the genome. We are committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.Our expertise in advanced cancer genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. We specialize in high-throughput next-generation sequencing, proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive approaches in cancer.

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.

PharmaNest is an image analysis and contract research company focused in the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.

Disrupting research enzyme/protein production, we are the first to introduce a Taq Polymerase free from background DNA contamination. We are now proud to introduce our new RNA extraction free EF1 SARS-CoV-2 Detection Kit, CE marked for in vitro diagnostics! Find out how we plan to have the gold standard of testing available with results in less time it takes to explain your job to grandma!

PHASE Scientific is a high-growth biotech company with a mission to inspire a new state of health. Headquartered in Hong Kong with locations in Southern California and China's Greater Bay Area, we provide novel diagnostic tools and services for cancer and infectious diseases with our proprietary technologies. REVOLUTIONIZING HEALTHCARE THROUGH BETTER INSIGHT Better treatment starts with more timely and more precise detection, at the very beginning. Our proprietary technology, PHASIFY™, redefines the gold standard of diagnostics by making target molecules quicker and easier to detect. The technology, with the ability to concentrate target molecules by 10-100x, can help track down hidden conditions that are otherwise neglected, making diagnostics test more affordable, accessible, faster, easier, and more accurate. PHASIFY™ has a huge potential to be used in a wide range of applications. We are committed to further strengthening the research and development efforts to develop best-in-class screening and diagnostic tools and services in cancer and infectious diseases. Our aspiration is to support people in every step of their integrated healthcare journey, from early screening, diagnostics, treatment to ongoing monitoring, so as to make everyone healthier. PRODUCTS AND SERVICES INDICAID™ | At-home rapid tests that can be used anytime, anywhere PHASE lab | Medical lab for cancer and infectious diseases, powered by PHASIFY™

Phenomix Sciences is a precision medicine obesity biotechnology company on a mission to conquer obesity globally through the use of proprietary testing and personalized lifestyle guidance. The company offers the MyPhenome™ test, exclusively licensed from Mayo Clinic, which measures DNA and metabolites related to obesity to improve weight-loss effectiveness. Phenomix Sciences is committed to advancing the understanding of obesity treatment through precision medicine and believes in the power of knowledge and accurate diagnosis.

A specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:

Phi Life Sciences is a Molecular Diagnostic and Laboratory Service company that aims to help patients by reducing disease mortality and adverse drug reactions through affordable, state of the art screening and diagnostic technologies. Phi Life Sciences is the bridge between scientists with innovative technologies and the patients and doctors whom they can benefit. We build this bridge through products developed in laboratory services and offered to patients and doctors through clinical services. Phi Life sciences aims to improve the efficiency, delivery, accessibility, and utility of molecular testing services through innovative technologies, licensed products, and clinically actionable result that empower physicians to deliver precision treatments and diagnoses by incorporating molecular tests that will improve their patients' health. Phi Life Sciences aims to improve patient health through the use of cutting edge molecular diagnostic tools. We exist to achieve the human potential.

Photon Biosciences' core technology is a new ultrasensitive detection platform that combines bioengineered proteins with a uniquein vivobiomineralization process that results in a number of different genetically expressible luminescent bionanoparticles that are non-bleaching and non-blinking with luminescence intensities that rivals and surpasses many fluorescent organic molecules. The excitation and emission wavelengths of these expressible bionanoparticles can be tuned with the composition of the mineralization process and span much of the visible and near infrared regions of the electromagnetic spectrum. Because of its unique photophysical properties, PBS® has been developed into new ultrasensitive probes for biomolecular research, detection technologies, and cellular imaging.The company is developing a test to detect contamination in donated platelets.

PinkDx is an early-stage company whose vision is to positively impact the health of women throughout their life journey. We focus on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and provide answers that have an immediate, positive impact on their lives. Our first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. Led by a team of diagnostics industry veterans, PinkDx is privately held, with funding from prominent biotechnology investors, including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital and Mayo Clinic.

PLD is a leading supplier of over-the-counter solid and liquid dose remedies in the Analgesic, Cough/Cold, Allergy, Sleep/Awake/Motion, Digestive, Nutritional, First Aid, Electrolyte and Epsom Salt categories. We pride ourselves on delivering the highest quality product in the most cost-efficient manner possible. This includes adhering to cGMP and stringent FDA regulations, so every product we manufacture meets and even exceeds the industry's rigorous standards. Since we began in 1988, it is our unwavering commitment to excellence that has enabled us to grow to serve every major retailer in the U.S. and many around the globe. Today we remain at the forefront of the consumer healthcare industry with 1,000+ dedicated employees and more than 1,000,000 sq. ft. of state-of-the-art facilities across New York, California, Florida and South Carolina. Our Mission To provide high quality and affordable healthcare products that help people feel well through services that cultivate trust and confidence. We foster an environment where people are passionate about their work and the wellbeing of their communities. Our Vision To be the most respected, efficient, and reliable partner delivering healthcare products and services that improve People's Lives Daily. Interested in a career at PLD? Please visit: http://www.pldevelopments.com/careers/

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision's CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

The scope of experience of Polaris’s executive team spans nine decades & several fields, including military service, medicine, & federal research & development. These experiences have allowed the team to cultivate timely knowledge of pandemic-era mental health needs, & develop deeply unique qualifications to address these needs. The team has garnered numerous awards, ranks, titles, & accomplishments, ranging from captain to engineer, Purple Heart recipient to medical doctor, virologist & immunologist, 9/11 responder to Iraq War veteran, & PhD to Homeland Security Public Health Officer amid the threats of SARS & anthrax. In 2017, inspired by their work at the Defense & Veterans Brain Injury Center & the US Department of Veterans Affairs, a veteran & a scientist coalesced their visions seeded in service around the urgent need for 21st-century innovation in behavioral healthcare. Drawing upon decades of experience in biomedical technology, public health, & molecular biology, they founded a company to take aim at the mental health crisis that results in 22 veteran suicides each day. Partnering with the Illumina Accelerator & scientists from Mount Sinai & the Max Planck Institute of Psychiatry, the team developed the first-to-market, patented genomic biomarker assay to identify PTSD risk in 2018. As a veteran-owned business, our roots remain in our founding mission to improve the lives of US military service members & veterans living with behavioral health conditions, such as post-traumatic stress disorder (PTSD). In 2020, global public health events & an evolving behavioral health landscape revealed that the number of people standing to benefit from advances in diagnostics & treatment is broadening by the day. Guided by a calling to serve, we expanded our mission to encompass: - Veterans & active-duty US military service members, - First responders, frontline workers, & individuals in high-risk occupations, & - Trauma-exposed communities at large.

We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we're working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that's precise to the biology of their disease.

Since its inception in 2011, Precipio’s (NASDAQ: PRPO) vision is to battle the problem of cancer misdiagnosis, by developing innovative technologies that improve diagnostic accuracy and laboratory workflow, delivering better results to patients and their physicians. In addition to robust R&D and commercial departments developing and bringing to market its proprietary products, Precipio also operates a clinical laboratory that serves as a testing ground for company products from its development phase to full utilization within the clinical setting. Precipio’s Products Division develops, produces, and sells proprietary diagnostic products to laboratories. Precipio also has a Clinical Diagnostics Division which operates the company’s CLIA/CAP laboratory, servicing oncologist practices and hospitals to provide comprehensive diagnostic services, while utilizing the same technologies developed by the Products Division.

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

Precision Image Analysis (PIA) is an innovative, cloud-based image post-processing service delivering analysis, reports and expertise at lower cost with improved consistency through standardization and greater efficiencies in workflow. "The cost and value of PIA services is consistently better than that of purchasing and maintaining specialized software especially when considering the need to train staff to effectively and efficiently interact with that software."​ ~ Dr Michael Wheat Attending Physician, Cardiologist Porter Hospital PIA offers CT and MRI post-processing services to the healthcare and research communities with specific expertise in Cardiac, Vascular and Neuro. Advanced medical imaging often needs time-consuming post-processing by experienced experts. This requires costly software, hardware and extensive training for personnel. PIA provides advanced medical imaging post-processing as a service. Why Outsource Image Post-Processing? --Immediate Access to Advanced Imaging Analysis, Reports & Experts -- PIA specializes in CT & MRI post-processing with specific expertise in Cardiac, Vascular and Neuro post processing. --No Capital Costs - Hospitals and diagnostic imaging centers are under continued pressure to bring down capital expenditures. --No Hardware, Maintenance or Upgrade Costs - High value post-processing WITHOUT costly ongoing fees & overhead also associated with employee retention, training and certification. --It's a service - PIA provides image post-processing as a service to hospitals, diagnostic imaging centers and researchers with no training required. --We never go on vacation. When planning for your medical image post-processing needs, think of PIA as your outsourced expert. Let us show you how we can improve your WORKFLOW and CASHFLOW. Visit www.piamedical.com or contact us at (425) 822-8199 | info@piamedical.com.

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.

Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.

The convergence of unbiased spatial analytics and explainable AI ushers in a new era of precision pathology. The novel insights from our platforms reveal the existence of intermediate cell types and their functional states as well as communications between cells. Our solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. info@predxbio.com

Prevencio is Revolutionizing Blood Tests For Cardiovascular Disease || Powered by Artificial Intelligence (AI) || Preventative Medicine for Heart Health Prevencio's purpose is to prevent the preventable. 80% of cardiovascular disease, including heart disease and stroke, are preventable (CDC). Prevencio's personalized blood tests provide earlier detection and prevention which can diminish unnecessary procedures and related side effects, as well as improve patient outcomes. Published in top-tier cardiology journals and presented at leading cardiovascular meetings, Prevencio's patented, proprietary technology has been used to create seven life-saving cardiovascular tests, with more in development.   Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. To learn more visit us at: www.prevenciomed.com

Previse is on a mission to save lives through the earlier detection and prevention of cancer, starting with esophageal cancer. They are actively working to get patients and healthcare providers the answers they need sooner by understanding and unlocking the power of biomarkers on cancer development and severity. Previse's technology was made possible by grants from the National Institutes of Health ("NIH") and developed after decades of research by the GI Early Detection Biomarker Lab at the Johns Hopkins University School of Medicine. An esophageal cancer diagnosis is something that nobody wants to hear. Today, this cancer takes 16,000 lives in the United States each year. The primary reason - the current detection method, upper endoscopy, is both invasive and expensive, so it's often not used until symptoms arise. In over 75% of cases, this is after the cancer has already spread and treatment options are limited, leading to esophageal cancer being the 3rd most lethal cancer in the United States (behind only pancreatic and lung cancer). Previse's early-detection system combines a simple routine test given as part of routine care with our patented DNA biomarkers that accurately test for disease. Our system is convenient, inexpensive, and accurate, so it can be given to those at risk before cancer symptoms, empowering patients to know earlier, receive necessary treatments, and live a healthier, longer life.

Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Prime leverages multiple patented advanced technologies in microbial diagnostics including RT-LAMP, Rapid PCR, and mNGS (Next generation sequencing) to enable samples to result in under 1 hour with minimal lab infrastructure and technical expertise. Prime's products are best in class for Covid, Influenza, Sexually Transmitted Infections and new drug resistant microbes. All of Prime's assays are locally developed in the United States and can serve millions of people. Founded in NYC in 2017, Prime's scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and Esther Dyson. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar, BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others.

At Primex Clinical Laboratories, we're dedicated to enhancing health with precision and passion. Since 1996, our presence in clinical diagnostics has been unwavering, serving diverse clients across Central and Southern California, Nevada, and American Samoa. We're more than a testing facility, our laboratory is a center of innovation and reliability. We pride ourselves on delivering personalized customer service, and high-quality testing with quick and accurate results, contributing to our community's health and well-being. Understanding the vital role of diagnostics in healthcare, we aim to be your most trusted lab partner. Our focus extends beyond recognition; we strive to gain your trust through personalized service, precise testing, and innovative solutions. We dedicate ourselves daily to advancing healthcare with meticulous care and a personal touch, shaping a healthier future. Learn more at Primexlab.com.

Princeton BioMeditech Corporation develops rapid, point-of-care diagnostics. Utilizing its patented technologies, PBM has developed and introduced an extensive menu of over 70 different one-step/rapid tests.COVID-19: EUA (02/2021)

Harnessing the Power of Cytokine Monitoring and Host-Response Understanding to Transform Healthcare Cytokines, pivotal biomarkers of inflammation, are essential in tracking the progression of infections, helping physicians tailor more effective treatments. Annually, over 10 million patients in the U.S. are diagnosed with infections, and the post-COVID-19 era has highlighted the value of cytokine monitoring. However, the current methodologies are costly and slow, undermining its potential. Our solution introduces point-of-care cytokine testing that matches central lab accuracy, completed in just 5-10 minutes, and at a significantly lower cost. This enables continuous, real-time monitoring, offering timely, actionable insights to both physicians and patients exactly when needed. Proactive Diagnostics is transforming how infections are assessed and managed, to improve care in several critical areas: - Enhancing clinical outcomes - Minimizing unnecessary antibiotic use - Shortening hospital stays - Reducing patient readmissions Our AI-driven, cloud-connected platform leverages unique data collection capabilities to deepen our understanding of individual host responses to various inflammatory stimuli. Such capabilities can also play a critical role in other important clinical areas such as the treatment of Autoimmune Diseases, where monitoring host response can inform therapy adjustments and drastically improve lives; or in the treatment of Cancer, where Cytokine levels can help optimize the administration of groundbreaking immunotherapies and adjust treatments to harness the immune system's power more effectively against tumor cells. This transformation in cytokine monitoring could be the key to a new era of personalized, predictive, and preventative medicine, where each patient's treatment is as unique as their response to disease.

ProciseDx is helping patients leave appointments with answers instead of just another appointment. Our point-of-care diagnostic solutions are enabling faster decisions for patients and physicians.

PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment. Powerful, Untapped Disease Insights Built on a Proteomics Foundation: Until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next generation tools that can elucidate complex proteomics at scale. Complementary Molecular Information: Genomic data has made clear contributions to researchers' abilities to understand and more precisely treat disease, but it is has shown limited impact on early-stage disease detection. Proteomics provides direct information on the biological state of a cell, including disease at its earliest state, but proteomics data has been technically difficult to generate – until now. By complementing the new sources of proteomics data with genomics and other data, such as metabolomics, we now have the tools to generate powerful multi-omics data that will be the key to unlock the detection and treatment of disease at its earliest stages, when these diseases are most likely to be cured. Unlocking Disease Detection and Treatment with Multi-omics Data: We designed our proprietary multi-omics platform around the most robust approaches to generating proteomic, genomic and metabolomics data at scale, including the use of the Proteograph technology platform from the life science tools company Seer (NASDAQ: SEER) whom PrognomiQ spun out of in 2020.

There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis – increasing the risk of bleeding – or less intensive therapy – reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death. Prolocor's precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' experiences and outcomes. The Promaxo MRI system is designed for image-guided interventions including live MRI guided biopsies, treatment planning, robotic surgeries, and radiation.

Propeller Health is a precision digital health company on a mission to uplift every person living with chronic disease so they can take control of their health and live a better life. We power motivating, care-connected patient journeys and unify value for all stakeholders – providers, payers, pharma, and other healthcare and life sciences organizations. The Propeller Platform includes FDA-cleared and CE-marked medical devices, consumer apps, support and coaching, and secure access to clinical data for provider monitoring. Our precision approach is designed to motivate behavior change and track patient adherence with the goals of enabling medication optimization and helping predict costly exacerbations. In more than 150 peer-reviewed abstracts and publications, our digital-first chronic respiratory care platform has demonstrated improved quality of life and clinical outcomes while lowering healthcare costs. As a wholly owned subsidiary of ResMed, Propeller brings broad respiratory care expertise, digital therapeutic coverage, and scale globally.

ProPhase Labs Inc. (Nasdaq: PRPH) ("ProPhase") is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach.

Proxim Diagnostics - Next-generation point-of-care solution. COVID-19 antigen test.

We are the makers of the CardioChek and A1CNow point-of-care test systems. Our aim is to help healthcare providers close gaps in care with fast, accurate testing for cardiovascular disease and diabetes risk factors. CardioChek Plus provides full lipid panel and glucose results in as little as 90 seconds. A1CNow provides A1C results in 5 minutes. Both systems are portable and easy to use, making them ideal for nearly any healthcare setting. The company’s name represents the three pillars upon which it has built its success: People, Technology, and Service.

The QTI team has been on an incredible journey, starting with a shared mission to create disruptive innovation to expand access to medical imaging while ensuring superior patient experience and improving health outcomes. We anchor our efforts in medical imaging because when the body can be scanned often and without harm, health conditions can be detected before symptoms appear. Chief among the new advancements in medical imaging is 3D body imaging. Today QTI focuses on our breast imaging technology, which is native 3D, high resolution, and generates reproducible image quality regardless of operator or breast size or tissue type. Current breast imaging paradigm leads to unnecessary concern and cost. ▪️Unlike mammography, QTI technology is effective in screening women with dense breasts, or 40% of women in US. ▪️35% of women aged 40-70 do not get screened. Of the 65% of women who get screened, 15% suffer unnecessary callbacks for ultrasounds, MRI, or biopsies. 80% of biopsies are benign. ▪️QTI’s technology can be a much-needed alternative for high risk women under 40, as cancers in younger women are usually aggressive and survival outcomes are poor. Our QT Imaging Breast Acoustic CT™ Scanner is the only true 3D imaging device, FDA cleared for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. There is no ionizing radiation or compression like in mammography or contrast dyes injections like in MRIs. The technology uniquely quantifies breast density. Surface-to-volume ratios and volumetric doubling time growth rate can be calculated to determine significance of lesions and improve specificity. This breast scanning system gives women the choice they deserve to ensure their breast health over time; for healthcare providers, a technology that is accessible, affordable, and accurately visualizes internal structures of the breast; and, for investors, a market segment extension and a purposeful investment opportunity.

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson's disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S. In September 2020, The Clarifi COVID-19 Test Kit obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis fo SARS-CoV-2.

QuantuMDx is dedicated to improving and democratising global health by providing transformative diagnostics to overburdened healthcare systems, empowering frontline healthworkers with intuitive, rapid, accurate and low cost decentralised testing solutions. COVID-19: CE Mark (06/2020)

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

QuidelOrtho develops and manufactures intelligent solutions that are transforming data into understanding and action for more people in more places every day, helping spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence. Together, we are advancing diagnostics to power a healthier future.

QuidelOrtho develops and manufactures intelligent solutions that are transforming data into understanding and action for more people in more places every day, helping spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence. Together, we are advancing diagnostics to power a healthier future.

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radio-pharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radio-pharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radio-labeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology. RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

A healthcare software company developing artificial intelligence (AI)-powered solutions, RADLogics provides machine learning image analysis solutions to improve radiologists' productivity while enhancing patient outcomes. Based in New York, NY, US, and Tel Aviv, Israel, RADLogics is one of the pioneers in using AI & machine learning image analysis and advanced big data analytics to search and analyze imaging data from CTs, MRIs, PET scans, and X-rays to help reduce diagnostics turnaround time from hours to minutes by automating detection and report generation functions. The company's patented AI medical image analysis platform enables rapid development of AI algorithms, and provides seamless integration into existing radiology workflow.

Rarecells develops and commercializes the ISET technology to isolate Circulating Cancer Cells for early cancer diagnosis and medical research. Rarecells® Diagnostics was created in 2010 by Patrizia Paterlini Brechot, Professor of Cell Biology and Oncology, in order to make the scientific and technological advances developed by her team available to research teams and patients. Rarecells® Diagnostics’ core product is the patented ISET® (Isolation by SizE of Tumor cells) Technology. Rarecells® Diagnostics has the exclusive license of patents belonging to the French Public Institutions University Paris Descartes, Assistance Publique Hôpitaux de Paris and INSERM protecting the Rarecells® Device and its consumables, as well as the analyses performed on cells isolated using the Rarecells® System. Rarecells® Diagnostics is a science-driven company. We are scientists working for scientists and patients. We care about bringing benefits to the patients.The team delivers customer satisfaction by manufacturing high quality products and providing high-level scientific assistance. Rarecells® and ISET® are registered trademarks of Rarecells SAS.

Leaders across Research, Translational Medicine and the Clinic rely on RareCyte as a one-stop resource for Spatial Biology and Liquid Biopsy solutions. Headquartered in Seattle, WA, RareCyte is an innovative precision biology company that has developed technologies and end-to-end integrated platforms enabling advances in oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. Our highly multiplexed fluorescent imaging systems, reagents and contract services empower investigators to unlock spatial context for key biomarkers and develop therapeutics and companion diagnostics through rare cell analysis.

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Ravata Solutions is a fertility and reproduction company that specializes in hardware and diagnostics to transform the IVF laboratory with automated assisted reproductive technologies (AART) and enhance human disease model development for pre-clinical studies.

The CLIA-certified Razor Genomics Molecular Prognostic Assay is helping with precision management of the world’s deadliest cancer

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

The company uses biology-guided radiotherapy to detect and respond to signals emitted from cancer cells, and use them to guide treatment.

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.COVID-19: Renalytix has entered into a joint venture with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), Kantaro Biosciences, LLC (“Kantaro”), to develop and scale production of COVID-19 antibody test kits.

We Put The Needs Of Healthcare Providers At The Center Of Everything We Do. We understand the unprecedented challenges faced by providers today. We have made it our mission to create single-source solutions that help you navigate today's turbulent regulatory, medical and market environments while protecting your patients, your employees and your profitability. Our Unified Approach Is Driving New Ideas Rennova Health is reimagining the traditional channels of healthcare services with an expansive suite of diverse products and brands. These interoperable solutions work in unison to drive better treatment outcomes, more cost-effective patient care, and optimized revenue streams. We support each of our solutions with unprecedented service excellence, while continuing to build on the best medical science and technologies available. We also maintain the highest standards of corporate transparency, fiduciary responsibility, accountability, and regulatory compliance. Rennova Health encompasses an ever-expanding group of remarkable products, services and resources. By incorporating diverse brands underneath a single company, we create more empowering, efficient and innovative solutions to address your most pressing challenges, including: Industry-leading diagnostic testing solutions for precision medicine. Streamlined EHRs, a proprietary lab ordering and reporting application, and other progressive software services. Comprehensive medical billing and financial services for enhanced revenue cycle management. Rennova Health's Brands: Medytox Diagnostics Advantage ClinLab CollabRx Medical Mime Medical Billing Choices Platinum Financial Services

RetiVue LLC is focused on providing novel, high definition retinal imaging technology with a wider field of view to help document early eye disease to help needless blindness. The RetiVue WF Desktop and RetiVue WF Portable are the first affordable non-mydriatic widefield retina cameras for everyone from babies to adults. Our revolutionary design allows you to image up to ten times more of the retina than competing devices. Point and shoot automatic image capture gives you perfect images of the eye every time, regardless of level of expertise. Our company strives to become the de-facto standard equipment used for eye screening, capturing higher quality images, while simultaneously maintaining device affordability and simplifying ease of use.

We develop immunologic therapeutics and diagnostics designed to make the world a healthier place. $6.2 Million Public Offering on February 5, 2024.

Microfluidics for Molecular DiagnosticsCOVID-19: (12/2020) EUA for COVID-19™ MDx Assay

In 2017, IEH Laboratories and Consulting Group acquired the Atlas technology from Roka Bioscience. The IEH Laboratories and Consulting Group family of companies continues to grow. IEH now employs more than 1,800 employees in eight countries (Australia, Austria, Canada, China, England, Germany, Mexico, and the USA). We also recently completed the acquisitions of: Sample6, Unitech, Toximet, Biomerx Laboratorium GmbH, VIL Institut fur Lebensmittelsicherheit, Labor Iben GmbH, and Iben Mikro Stop GmbH. In addition, we have expanded our expertise by welcoming new experts to the IEH family for consulting services including former FDA, USDA and industry senior leaders to further assist the food industry. The Roka and Sample6 acquisitions have allowed us to expand our capabilities in rapid pathogen detection and automation. We have now validated both systems for the detection of Listeria in food samples after only 10-15 hours of enrichment, and same day results are available for environmental samples

RT MicroDx is reshaping the healthcare landscape by developing accurate, affordable, at-home molecular testing solutions that empower individuals, alleviate financial distress, and contribute to healthier communities worldwide. Our readerless RT LAMP reaction, utilizing saliva samples, empowers individuals and families to take control of their health journey from the comfort of their homes. Leveraging our scalable testing platform, we are currently developing the first over-the-counter, molecular-based, at-home test for strep, the “RST,” offering a simplistic yet robust and inexpensive testing solution that only requires a saliva sample rather than a painful and invasive throat swab. With accuracy levels reaching 97% specificity and 99% sensitivity, our solutions transcend traditional at-home testing barriers, offering timely and reliable results.

Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. The company's mission is to fast-track the early stage of drug discovery using predictive models of the human brain for therapeutic success.

Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.

Salimetrics supports thousands of salivary researchers in more than 20 countries around the world. Our assays have been used in more saliva-related published papers than any other assay in the field. We believe Salimetrics is a unique company. We combine uncompromising scientific process with human passion to deliver what we hope are superior products and services for saliva testing and collection. We provide consultation, assistance with study design, advice for funding, and support for all things saliva testing-related, because we believe saliva testing can help researchers learn and discover things that will translate to cures, treatments and understanding around the world. If you have a ground-breaking study, ideas for innovative saliva testing products, or simply need advice, please don't hesitate to contact us. We work with a diverse network of saliva researchers around the world. This network extends the salivary research community by providing credible, data driven results that advance the scientific field of salivary research. Together, we can make a difference. To place an order, request a quote, or have your questions answered please visit our website. https://salimetrics.com/contact/ We are always ready to assist you!

SandboxAQ is harnessing the exponential power of AI + Quantum (AQ) technology. The inspiration for SandboxAQ and some of the team originated at Alphabet Inc., becoming an independent entity in 2022. Our mission is to develop commercial products for financial services, healthcare, telecommunications, public sector, and other computationally-intensive industries. Our team's unique approach enables cross-pollination across a diverse range of fields, from physics, computer science, neuroscience, mathematics, cryptography, natural sciences, and more! Our success comes from coalescing diverse talent to create an environment where experimental thinking and collaboration yield breakthrough physics + AI solutions. Join a culture where thought leadership, diverse talent, employee engagement, and technological impact will create the next tech uproar. We are deeply committed to education as a means to advance quantum solutions and computing initiatives. We invest in future talent through internship programs, research papers, developer tools, textbooks, educational talks/events, and partnerships with universities/talent hubs to attract multi-disciplinary talent. Our hope is to inspire people from all walks of life to be prepared for the quantum era and encourage a path in STEM.

SANO Diagnostics is pioneering a disposable, cost-effective point-of-care diagnostic platform with initial focus on human chronic wounds, such as diabetic foot ulcers and pressure ulcers. Measuring wound protease-related biochemistry to provide clinicians with more information on their patients'​ current wound status and progression, Sano's lead diagnostic is designed to help personalize treatment, promoting faster healing and significantly reducing treatment costs. The company is also in early stage development of a diagnostic for use in the equine market. Sano has won several awards/recognitions, including 1st place - Harvard Business School Boston Club – 1st place (judged by VC, angel, legal/service professionals), 1st place - Mass Medical Device Development Center (judged by Smith & Nephew, UMass Medical, legal/service professionals), Finalist - Harvard Business School New Venture Competition (judged by HBS alumni), 1st place Venture Forum 5 Minute Pitch, and 2015 Finalist, $50K Gold Award, MassChallenge (judged by investors, serial entrepreneurs, academic and for-profit execs).

Sapere Bio is a longevity technology company. SapereX, a blood-based measure of cellular senescence and immune function, captures fundamental mechanisms of aging. SapereX allows clinicians and scientists to see early aging and monitor how interventions aimed to increase healthspan are working in individual patients. We are changing the way aging is measured and imagined, for longer healthspan and better lives. Sapere Bio was co-founded by Dr. Norman Sharpless, former Director of the NCI, and Dr Natalia Mitin, current CEO of Sapere Bio.

We are biotech company located in the Boston area, with a mission to revolutionize non-invasive diagnostics. The systems we are developing allow monitoring cancer patients'​ progress, as well as looking very early into pregnancy to gain a complete genetic picture of the fetus, all with a simple blood test.

Scanogen is a molecular diagnostic company developing systems to read the biomolecular information of body fluids with the goal of improving health care. The Company has developed Single MOLecule Tethering (SMOLT), a proprietary technology for rapid and ultra-sensitive detection of biomolecules. The Company is using this technology to develop a simple-to-use and sample-to-answer diagnostic platform. Scanogen has received NIH grants totaling $9.5 million to develop its diagnostic assays and it is currently focused on two areas: Point-of-care diagnosis and bloodstream infection detection.

In vitro diagnostic company, specializing in the production of antibodies, controls, blockers including HBR. - Clean Rooms - Filling - Finishing - Packaging - Sub-Assembly - Inventory Space - Kit Manufacturing - Lyophilization - Antibody Production - Medical Device Manufacturing

SCIMEDX is a diagnostic manufacturer with over 30 years of proven experience. Best known for its range of autoimmune and infectious disease testing products. Scimedx extends it's platforms for disease testing. The first was ImmuoCyt+ an FDA cleared & patented assay for bladder cancer. From there Scimedx expanded it's IFA and Latex Infectious assays by acquiring PANBIO for HHV, Dengue, West Nile. Scimedx then went on to acquire Parasitology serology assays from IVD Research. Continuing it's growth, Scimedx has finalized it's rapid testing platform. Scimedx is the de-facto manufacturer of IFA, ELISA, Agglutination tests, delivering solutions for disease testing worldwide.

Scipher Medicine is building the future of patient treatment. Most patients who are prescribed blockbuster therapies today don’t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher's platform identifies which drug will work based on the patient's fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.

ScyTek Laboratories, Inc. a Utah, USA corporation involved in the manufacture of diagnostic reagents Special Stains, Antibodies, Hematology, Microbiology, Hematoxlyn

Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and based in Portland Oregon. Our commitment is to become a leader in three areas intended to advance global access to care as reflected by our: (1) expertise in rapid point of care diagnostic assays, especially alternative fluid (e.g. oral, urine, etc) assays, (2) scientific and market leadership in novel HIV epidemiological disease incidence assays and other public health tools and (3) novel clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of researchers, scientists and business people that share our common mission and develops, manufactures and licenses these technology and products to improve access to medical care around the world.

Seno Medical is leading commercialization efforts in opto-acoustic imaging of breast cancer. Seno's opto-acoustic technology combines both laser optics and conventional ultrasound technology to provide fused functional and anatomical imaging in real time. The result is an imaging device that delivers additional functional information regarding breast masses and increases confidence in making a breast biopsy decision. For more information or to answer any questions call 210-615-6501 or email digitalmarketing@senomedical.com. Seno's Imagio® Breast Imaging System (9005) received the CE Mark (April 2014) and has completed a post-market surveillance and clinical follow-up study in Europe. The newest version (9100) is approved by the FDA for commercial distribution in the U.S.

SeQure Dx, Inc. is applying genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their GUIDE-seq and ONE-seq technologies enable identification of all potential off-target sites prior to initiating therapy, to allow comprehensive confirmation of actual edits.

Seraph Biosciences, Inc. is a biomedical device company headquartered in Detroit, Michigan. The company was founded in 2014 with the primary purpose of commercializing its groundbreaking, diagnostic technology known as Seraspec®. Seraph's team consists of seasoned academic physicians, biomedical engineers, artificial intelligence experts, and device commercialization professionals tasked with combatting the major public health crises of our time. By leveraging the principles of Raman Spectroscopy, Seraspec® represents a paradigm shift away from current methods for screening and identification of dangerous bacterial, viral and fungal pathogens. Seraspec's® patented technology and method of detection effectively eliminates the need for time-consuming and costly laboratory-based methods of specimen collection, processing and pathogen identification. Safety, efficiency, accuracy and profitability are simultaneously enhanced through a portable, point-of-need technology for real-time pathogen detection and identification. A higher power just got involved in the fight against infection.

Sera Prognostics is a leading proteomic and bioinformatics company dedicated to improving the lives of women and babies through precision biomarker-based tests designed to enhance pregnancy care. Our vision is to deliver pivotal information to physicians early in pregnancy to help them to improve the health of their patients and reduce costs of healthcare delivery. The PreTRM® Test reports to a physician the individualized risk of premature birth, enabling earlier proactive interventions in patients with higher risk. We're also developing a robust pipeline of innovative tests focused on other complications of pregnancy, including preeclampsia, gestational diabetes, growth restriction, and others. Learn more about our values, culture, and open positions on our website.

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.

SHINE Technologies accelerates a practical, incremental four-phase pathway to clean, abundant fusion energy, starting with using fusion technology to solve today's problems in medicine, manufacturing, energy, and beyond. #SHINETogether #FusionTechnology

Siemens Healthineersenables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare.COVID-19: CE mark for its molecular Fast Track Diagnostics (FTD)SARS-CoV-2 Assay.

Silver Lake Research Corporation is a biotechnology company based in Monrovia, California, founded in 1992. The company specializes in the development and manufacturing of diagnostic test kits, focusing on rapid point-of-care diagnostics. Their proprietary EAP™-derived monoclonal antibodies ensure high accuracy and sensitivity, comparable to laboratory assays. The company offers a range of diagnostic test kits, including those for water quality, air contaminants, and urine analysis. Their Watersafe® line features a highly sensitive water lead test and comprehensive bacterial detection. Additionally, Silver Lake supplies bio-engineered proteins for therapeutic drugs and diagnostic components to other companies. They operate one of the largest independent automated production facilities for lateral flow tests in the U.S. Silver Lake Research emphasizes consumer safety, targeting concerns related to waterborne pathogens and carcinogens. They also provide white-label components for third-party diagnostic kits, indicating strong partnerships within the industry. The company operates from two locations, with general operations in Monrovia and administrative functions in Irwindale.

SISCAPA technology is the smart shortcut to sensitive quantitation of protein biomarkers and targets. SISCAPA assays combine the precision of MRM mass spectrometry with the power of affinity enrichment to deliver a superior alternative to conventional immunoassays for protein quantitation. The SISCAPA workflow is highly automated and exploits familiar LC-MS/MS platforms widely used for drug and metabolite quantitation. At SAT we believe quantitation of proteins in biologic samples provides an actionable measure of the state of health, disease and treatment. We provide services and products for sequence-specific protein quantitation and robust generation of data in an automated, multiplexed and high throughput manner. Analysis is carried out using a generic workflow, allowing for validation and industrialization of processes for such applications as biomarker validation, protein bioanalysis, pathway research for therapeutic development and monitoring and for use in laboratory-developed tests. SISCAPA assays enable multiplexed quantitation of proteins over many orders of magnitude dynamic range. The generic, automated workflow ensures robust results with high throughput and precision. SISCAPA services include complete Assay Reagent Development or specialized Assay Implementation to maximize your up-time and help you quantitate proteins with unmatched precision. Our pipeline has generated reagents for SISCAPA quantitation of more than 250 different proteins to date, providing an unparalleled experience base.

SiteOne Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of hypersensitivity disorders such as pain, itch, and cough. The company is advancing a novel class of highly selective small molecule inhibitors to target Nav1.7, Nav1.8, and Nav1.9 sodium ion channels. SiteOne Therapeutics is dedicated to the development of novel therapeutics to safely and effectively treat pain and other hypersensitivity disorders.

SmartHealth Dx develops precision diagnostics that address unmet clinical needs in pathology and vascular inflammation for advancing today's standard.

info@smlgenetree.com | www.smlgenetree.com | SML Genetree is recognized as a premier partner in developing technology and on-time delivery, providing both basic research of molecular biology and applied research in molecular diagnosis. SML Genetree is an affiliate of Samkwang Medical Laboratories (SML), one of the largest diagnostic commercial labs in South Korea in 1985.

Our vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With our robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value radiopharmaceutical intellectual property, we are poised to deliver on the promise of radiopharmaceuticals. www.sofie.com www.twitter.com/sofiebio www.instagram.com/sofiebio

Solaris Diagnostics is a CLIA certified, CAP certified, and HIPAA compliant lab providing both contemporary and cutting-edge molecular diagnostics testing. At Solaris, we look forward to assisting in the care of your patients by providing both contemporary laboratory testing and cutting-edge molecular diagnostics. Our scientists are trained in a variety of essential disciplines, including molecular genetics, microbiology, cytogenetics, biochemistry, and pharmacology. Our mission is to deliver industry leading laboratory services, backed by ongoing research, and resulting in improved patient care and outcomes.

SomaGenics is a privately held biotech company with offices and laboratories located in Santa Cruz, CA. We specialize in small RNA technologies, including innovative RNAi-based therapeutics using sshRNA molecules, and diagnostics/biomarker detection (NGS, quantitative PCR) of small or fragmented RNA, including microRNA.

The SomaScan® Platform is the only proteomics platform on the market that scales with precision.

Sonavex, Inc. is a Baltimore-based medical device company originally spun out of Johns Hopkins focused on Empowered Patient Care. The company has developed a portfolio of novel ultrasound solutions that empower patient care by delivering critical visual and quantitative data to improve outcomes and reduce costs. EchoMark is a bioresorbable and highly echogenic (visible under ultrasound) implant used to mark at-risk blood vessels such that the site can be easily assessed for future complications. EchoSure is a deep-learning enabled 3D automated ultrasound device designed to be used by healthcare providers without ultrasound training to assess blood flow and morphology of vessels marked by the implanted EchoMark device. For more information, please visit http://www.sonavex.com

Sonde Health is a health technology company with a voice-enabled symptom detection and monitoring platform for chronic and mental health conditions. Our products are based on patented and proprietary, best-in-class technology developed by amazing people with advanced audio signal processing, speech science and machine learning backgrounds. We analyze over 4,000 vocal features that reflect changes in your voice caused by the changing physiology of your body due to symptoms of disease. Sonde's platform is designed with people's privacy in mind, and work on most smartphones people already own, preventing you from having to wear something new or add anything to your busy life.

Sonivate Medical develops and manufactures technologies to reduce healthcare costs and expand access to diagnostic imaging.

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Spear Bio, founded in 2021, is a well-funded and rapidly growing start-up headquartered in Woburn, Massachusetts. Spear Bio’s proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar levels from sub-microliter sample volumes, enabling unprecedented sensitivity. We are dedicated to revolutionizing early disease diagnosis and monitoring, empowering clinicians and researchers to improve patient outcomes, and advance global health. For more information, please visit www.spear.bio or email info@spear.bio.

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by "Seeing the Unknown®" with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of changing the current standard of care in the future, DeepView® is expected to provide faster and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.

Spectral Medical is a Phase 3 company advancing the fight against endotoxic septic shock through an innovative theranostic approach. This unique strategy combines the EAA™ Endotoxin Activity Assay, the only FDA-cleared diagnostic for the risk of developing sepsis, with targeted rapid therapy using Toraymyxin™ (PMX). PMX is a Polymyxin B extracorporeal direct hemoadsorption column which is highly effective in removing endotoxin in the bloodstream. Already approved in Japan and Europe (1994 and 2002 respectively), PMX has been safely used on over 340,000 patients. Spectral holds exclusive U.S. development and commercialization rights for PMX since 2009, with a distribution agreement for Canada since 2010. In July 2022, the FDA granted Breakthrough Device Designation to PMX for treating endotoxic septic shock, a condition that affects around 330,000 people in North America annually. Spectral is currently conducting the Tigris Trial, a confirmatory study evaluating PMX combined with standard care vs. standard care alone in a 2:1 randomized trial of 150 patients, utilizing Bayesian statistics to assess its effectiveness. The trial methods are detailed in the Critical Care publication “Bayesian methods: a potential path forward for sepsis trials." https://doi.org/10.1186/s13054-023-04717-x

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

SPECTRONRx provides therapeutic and diagnostic Isotopes for clinical and research use. They specialize in providing you flexible and efficient Contract Manufacturing and Contract Research services.COVID-19: EUA (O5/2020) Hymon SARS-CoV-2 Test Kit.

STAGE, developed by SpinTech, is an advanced MRI imaging software platform that reduces brain scan time by 30%. The software provides enhanced visualization and quantification of scan images. STAGE automatically detects biomarkers critical to proper diagnosis of neurological conditions that cannot be seen with current MRI techniques (i.e. traumatic brain injury, dementia, Parkinson's, Multiple Sclerosis, and stroke). We're committed to bringing the future of imaging technology to every patient suffering from neurological disease with a cost effective, workflow-efficient software platform that improves patient outcomes and maximizes costly imaging equipment ROI. STAGE software is compatible with most manufacturers' existing equipment. Visit our website to learn more and set up a demo!

SpotitEarly is revolutionizing cancer pre-screening with an innovative AI-based test that can detect multiple cancer types from a single breath sample. This simple solution allows for easy, at-home sample collection in minutes, without any healthcare professional assistance. Our off-the-shelf test is affordable and available everywhere, at everyone’s convenience, removing the barriers that keep about half of the people from getting tested on time. With an impressive 94% accuracy (sensitivity and specificity), our technology has been shown to be effective even in early-stage cancer detection, which can significantly increase treatment options and survival rates. By harnessing the science of scent, SpotitEarly identifies cancerous VOCs in exhaled breath. This smart technology enables more frequent testing of wider audiences at a fraction of the cost, ultimately saving lives and improving clinical outcomes globally. We envision a world where hassle-free pre-screening is the norm. Join us in our mission to make cancer prevention easy, effective, and universally accessible, bringing enhanced quality of life and peace of mind for all.

Advancing cerebrovascular care through groundbreaking neuro intravascular imaging and AI technologies.

Read the eBook on Navigating R&D: https://www.starlims.com/navigating-research-and-development-guide/ **One partner, powerful informatics solutions.** STARLIMS is a recognized leader in enterprise laboratory informatics, providing customers around the world with digital solutions for R&D and quality labs. With nearly four decades as in informatics, STARLIMS is in the business of delivering results. 🌐 2,000+ Labs Worldwide 👥 1,100+ Customers 🌍 85+ Countries 🔬 LIMS, SDMS, LES, and Advanced Analytics 🏆 Leader on G2 💡 With the intuitive cloud Labstep Electronic Lab Notebook (ELN) STARLIMS is your one true partner in lab informatics from R&D through to commercialization 🌟 Industry Solutions: 🧪 Life Sciences 🏭 Contract Development Manufacturing Organizations (CDMOs) 🍔 Food & Beverage ⚗️ Chemical 🍃 Agrochemical ⛽ Oil & Gas 🛍️ Consumer Goods 📝 Contract Testing, 🏥 Public Health 🩺 Clinical Diagnostics We're committed to providing quality products and services that help our customers reach their goals. Whether your mission is to discover a breakthrough drug, protect the health of the population, or get safe toys to market, we're here to support you.

At Starling is building a first-of-its-kind at home urology remote patient monitoring platform that seamlessly integrates into anyone's bathroom routine. By monitoring changes in urine over time, we aim to bring the hospitalization reduction benefits of remote monitoring to a new range of chronic conditions such as recurrent UTIs, BPH, and chronic kidney disease.

Streck is an industry leader in the development and manufacturing of laboratory products. We make products that clinical laboratories use to ensure their instruments are accurately reporting patient results. In fact, Streck invented the first hematology reference controls and has developed many more firsts for the clinical laboratory. At the heart of the growth experienced by Streck during the past four decades is a healthcare industry constantly striving to provide better care to more people. Streck is at the center of helping clinical laboratories keep pace with the changes to which they must adapt. Hospitals, physician offices and research laboratories in every corner of the globe rely on Streck controls. The innovation and desire that drives Streck translates into unprecedented opportunity for every member of the Streck team – a team with a shared vision of quality and service.

StrokeDx provides portable, rapid, and non-invasive stroke diagnostic and imaging tools.

Subtle, Inc., is a medical imaging software company. Our goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. We use the state-of-art proprietary deep learning AI algorithms to renovate the radiology workflow to deliver faster, safer and smarter solutions for imaging exams.

Summit Biomedical Imaging, LLC., a spin-off company from Memorial Sloan Kettering Cancer Center (MSK, New York City), was founded by Thomas Reiner and Christian Brand in 2016. Recently, Summit Biomedical Imaging was awarded a federal grant through NIH's Small Business Innovation Research (SBIR) program, also known as America's Seed Fund, to support the strong potential of commercialization of their innovative biomedical technology. This early-stage funding from the National Cancer Institute (NCI) allowed them to open their Research and Development facilities in the heart of New York City to develop novel targeted cancer diagnostics.

Sunbird Bio is a leader in protein-based diagnostic tests, becoming the first company to overcome the challenge of accurately detecting and differentiating the specific proteins that aggregate, and therefore signal the presence of Alzheimer’s disease, with a simple blood draw. We are addressing the tremendous, growing need for more reliable and sensitive diagnostic tests to accelerate drug development and enhance patient care. Our pipeline of innovative, non-invasive technologies, such as our APEX technology, will empower researchers and clinicians with unparalleled insights not available from current tests.

Sunrise Medical Laboratories. We put people first. For over 40 years, we at Sunrise Medical Laboratories have consistently provided our member physicians and their patients with the most accurate and diagnostically meaningful results possible. Our success stems from our commitment to three essential principles. Courtesy Whether you're a physician or a patient, your needs are our top priority. We are committed to providing prompt service, timely notice of appointments and results, and empowering our employees with the answers to any questions you may have. Compassion We know that medical testing can sometimes be worrisome or stressful. For this reason, we train our staff to provide information, care and comfort whenever needed. Whether it's distracting a child during a blood draw or explaining a complex test, we're glad to go the extra mile for each and every patient. Professional Expertise We continually invest in the most advanced technologies so that we can provide the highest quality medical laboratory services available. We are fully licensed and accredited by The College of American Pathologists (CAP), New York State Department of Health, the Center for Medicare and Medicaid Services (CLIA), U.S. Department of Health and Human Services (Medicare), and the Pennsylvania Department of Health. Because your well-being, comfort and peace-of-mind are utmost to our success, we are proud to say, "We take it personally".

Superfluid Dx is a biotechnology company focused on developing accurate diagnostics for neuro-degenerative diseases by harnessing the power of cell-free mRNA. They are also working on novel blood-based early detection methods.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements.

To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions that matter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond.

Co-founded by MIT scientists in 2017 and headquartered in Cambridge, MA, Synlife's team is innovating new therapeutic and diagnostic platforms through bottom-up engineering of synthetic cells.

Sysmex Inostics is a medical diagnostics company that specializes in cancer testing through liquid biopsy technology, catering to precision medicine.

SYSTAAQ Diagnostic Products is one of the leaders in molecular diagnostics, offering a wide range of products and services in the field of molecular testing. We have a unique capacity in people and technology to provide innovative, cost-effective, timely and reliable solutions in biomedical research and laboratory diagnostics.

T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.

Founded with a purpose to bring the full power of a lab to those providing care, Talis Bio is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. While timely diagnosis of infectious diseases is critically important to enable effective treatment, testing is primarily performed in centralized laboratories, which require specimens to be shipped for processing, delaying the return of results by days. Point-of-care testing solves this problem by empowering healthcare providers to generate lab quality results without the wait. From the doctor's office to remote care settings, we are re-defining the treatment of infectious diseases. The Talis One™ point-of-care system is designed to deliver fast, accurate, lab-quality molecular diagnostic testing in a variety of health care settings. Talis Bio strives to deliver results from sample to answer in less than 30 minutes. To achieve our purpose, we focus on three things: 1. Putting customers and patients first 2. Making Talis Bio a great place to work 3. Living our values to Dream Big, Share Our Screens, Serve Others, Bring Our "A" Game, and Build Trust

Target Discovery is a company that specializes in innovative testing strategies using analytical instrumentation, surface chemistry, microfluidics, nanotechnology, signal processing, and machine learning to provide affordable and accurate results.

Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenient diagnostic tests to their patients. Tasso was originally founded to find a better way to collect blood instead of a painful fingerstick or time-consuming venous draw. Since then, our products have been used in pharmaceutical clinical trials, by Olympians as part of a new virtual anti-doping program, and broadly by hospital systems across the US.

TECHLAB, Inc. is a leading developer and manufacturer of infectious disease diagnostics products worldwide. Since 1989, the company has offered a quality portfolio of diagnostic tests which now includes assays for C. difficile, respiratory pathogens, H. pylori, Campylobacter, Shiga toxin producing E. coli, protozoan parasites, and biomarkers of intestinal inflammation. TECHLAB is headquartered in Blacksburg, VA and manufactures its diagnostic tests in the United States at its state-of-the-art manufacturing facility in Radford, VA.

TellBio Inc. is a development stage biotechnology company with the goal to revolutionize the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology and complementary therapeutics platform,

Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It's About Time. For more information, visit tempus.com and follow us on Twitter (@TempusLabs).

Tesis Biosciences’ unique integrated medical platform is revolutionizing targeted genetic sequencing. Precision-based medicine to help treat major chronic diseases. Our mission is to change medicine by providing physicians, hospitals, and researchers with the tools to help patients treat and overcome major chronic conditions such as heart and lung disease, cancer, diabetes, and Alzheimer’s through advanced genetic testing. Through our collaborative efforts utilizing our unique processes, we help medical device and pharmaceutical companies bring to market products that improve the quality of life for patients.

Community Tissue Services is a quality, ethical provider of services to donor families, medical communities, recipients, and community partners through recovery, processing, and distribution of tissue grafts. Community Tissue Services strives to be on the forefront of new graft development and biotechnology to better serve recipients and medical professionals.

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thunder Biotech, Inc. is an immune-oncology company developing patented MOTO-CAR™ technology - genetically engineered CAR macrophages - that help cancer patients' immune cells recognize and attack solid tumors. Traditional cancer treatments— like surgery, radiation, and chemotherapy—are often ineffective, invasive, and difficult to tolerate. Thunder Biotech is designing MOTO-CAR™s to be a more effective and humane therapy. Thunder Biotech's MOTO-CAR™s re-educate Tumor Associated Macrophages and restore their M1 ability to recognize and eliminate tumor cells. In addition, MOTO-CAR™s are armed with tumor specific receptors that directly adhere to the tumor cell surface allowing them to initiate tumor cell destruction and recruit the natural T cell response engaging them to eliminate the tumor. This T cell response will then provide the body with a memory response preventing tumor recurrence.

Emerging diagnostics company.

TopoGEN is a research diagnostics company that provides innovative products and services for researchers working with topoisomerases and engaged in mechanism based drug discovery and development. The company was created by topo research active scientists who understand the needs and the restraints placed on other cancer researchers or those working in areas peripheral to topoisomerases. Top-selling products include: -Drug Screening Kits to identify topoisomerase active drugs for use in cancer chemotherapy and antibacterial applications -Assay Kits for assaying prokaryotic and eukaryotic topoisomerases (type I, II, IV, gyrase), both in vitro and in vivo -A complete line of DNA substrates and DNA cleavage targets, topoisomerase inhibitors, topoisomerase antibodies, and kit replenishment reagents Our contract screening service offers you powerful, mechanism based custom screens developed and conducted entirely in house. Our cell based (in vivo) screens for detecting topoisomerase I and II poisons in the context of the cancer cell represents the new gold standard for identification of novel anti cancer agents. Since the early 1990s TopoGEN has maintained a dedicated clientele around the world. We offer substantial product support, data interpretation and consultation advice. When you become our customer, we become your partner in research. We review your data and offer valuable input. Please contact us for further information about how we can assist your research goals.

At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques. By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process. We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable. Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.

TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Our other preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L1, and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. Until now, targeting biomarkers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets. TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

Transplant Genomics is a biotechnology company that focuses on improving organ transplant outcomes through noninvasive serial monitoring driven by genomics.

Triad Isotopes is a manufacturer and supplier of radiopharmaceutical products.

Trice Medical™ was founded to fundamentally improve orthopedic diagnostics for the patient, physician, and payer by providing instant, eyes-on, answers. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physicians office. Our mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system.

TrimGen is a precision medicine company that specializes in pharmacogenomics for behavioral health and chronic pain.

True Diagnostics (True) designs and develops innovative POC diagnostic tests and devices based on its proprietary TrueDX™ Platform, which utilizes reliable and low-cost lab methods and its own proprietary or partnered biomarkers to offer rapid diagnoses to facilitate treatment decisions in point-of-care, point-of-incidence and remote-of-care settings. The TrueDX Platform's portability and affordability allow it to be easily adopted into emerging markets to provide accurate diagnosis within minutes. For the $21 billion point-of-care market, the power of the TrueDX Platform lies in its simplicity and flexibility. Tests have an 18-month or longer shelf life with no refrigeration required. The platform's flexible design additionally permits it to quickly commercialize a myriad of biomarkers discovered for cancer, autism, Alzheimer's, diabetes, drugs of abuse, infectious diseases, cardiac health, traumatic brain injury, viral and bacterial infections and more.

Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera’s expanding portfolio continues to focus on improving corneal health, both as a primary goal and in preparation for surgery. Get more details and new product announcements at www.trukera.com.

Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera's expanding portfolio continues to focus on improving corneal health, both as a primary goal and in preparation for surgery. Get more details and new product announcements at www.trukera.com.

Truveta is a growing collective of health systems in the US with a mission of Saving Lives with Data. Truveta delivers the most complete, clean, and timely regulatory-grade EHR data for scientifically rigorous research. Truveta is trusted by leading life science, government, health system, academic and research organizations to accelerate adoption of new therapies, improve clinical trials, and enhance patient care.

Truvian is a transformational diagnostic company bringing lab-accurate results to the point-of-action where consumers engage healthcare providers to lead healthier lives. With a focus on making routine blood testing accessible, convenient, and transparent, Truvian is accelerating the transition to a sustainable healthcare ecosystem through its comprehensive benchtop solution that delivers timely, actionable results to help stop disease before it starts.

Tymora Analytical Operations provides new research services, products, and reagents to the life science R&D organizations. Tymora has developed nanoscale platform technologies – with PolyMAC and pIMAGO as the lead products – for unmet needs in analysis of protein phosphorylation that relates to the onset of numerous diseases, most notably cancer

Uh-Oh Labs is a medical technology company that develops diagnostic tests through their Loop-de-Loop platform, offering simplicity, speed, and lower costs for accurate lab-grade results.

Unetixs Vascular Inc. is the leading U.S.-based manufacturer of physiologic vascular instruments. We design and manufacture the country's most in-depth line of technically advanced instrumentation for diagnostic vascular testing, and we offer all our products in international markets. For over 25 years, we have listened to our customers and provided the equipment and training that best meets their needs. We rely on a team of medical professionals to provide recommendations, and we collaborate with education professionals recognized as among the best in the field to provide training. Whatever your noninvasive peripheral vascular testing requirement, you can rely on Unetixs to provide products that not only meet today's needs but can grow to fulfill tomorrow's requirements. From our portable and affordable Revo® 1100 to several MultiLab® peripheral vascular diagnostic systems, all available with our VascuLink® networking and reporting software, we have tailored a range of systems for vascular labs, hospitals, mobile services and the offices of vascular surgeons, cardiologists, primary care physicians, endocrinologists, podiatrists and other specialists.

United Biomedical, Inc (UBI) is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases. Our product pipeline is filled with our new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. Our platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire. UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development.

Universal Diagnostics S.A. (UDX) is a Spanish in-vitro diagnostics company developing minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, prostate, liver, pancreatic lung, breast cancer (>50% of all new cancer cases p.a.) via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX's first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

UroViu Corporation's mission is to revolutionize the cystoscopy platform for improved patient care and efficiency and has operations in California and Washington and production facilities in Asia. UroViu is the developer of the always ready cystoscopy platform, the most portable, self-contained and versatile single-use cystoscopy solution on the market. The intuitive portable platform and product suite are protected by a portfolio of 13 granted and many more pending patents. UroViu's vision is to simplify the scope of patient care.

Variantyx is a technology-driven precision medicine company providing state-of-the-art diagnostic solutions for the rare genetic disorders and reproductive genetics markets, and treatment optimization in oncology. Our unique, comprehensive testing platform uses whole genome sequencing to identify all major genetic changes from a single sample. The results empower patients and providers with information that can rapidly end the challenging diagnostic search, optimize treatment, and improve quality of life. We are a diverse, multinational company that embodies professionalism, transparency, tenacity, and respect. See more with us: www.variantyx.com/.